Page last updated: 2024-11-04

amantadine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2130
CHEMBL ID660
CHEBI ID2618
SCHEMBL ID4098
SCHEMBL ID2619248
SCHEMBL ID15672299
SCHEMBL ID20409394
SCHEMBL ID21309814
SCHEMBL ID21310017
SCHEMBL ID23419027
MeSH IDM0000847

Synonyms (193)

Synonym
BIDD:GT0757
unii-bf4c9z1j53
gocovri
ec 212-201-2
bf4c9z1j53 ,
bdbm50033369
AB00053414-14
AB01275427-01
DIVK1C_000815
KBIO1_000815
NCIOPEN2_001059
1-aminoadamantane
1-adamantamine
pk-merz
nsc-341865
1-adamantylamine
wln: l66 b6 a b- c 1b itj bz
tricyclo[3.3.1.1(sup3,7)]decan-1-amine
SPECTRUM_000030
tricyclo[3.3.1.1(3,7)]decan-1-ylamine
amantadina
CHEBI:2618 ,
tricyclo[3.3.1.1(3,7)]decane-1-amine
amantidine
amantadinum
aminoadamantane
adamantan-1-ylamine
tricyclo[3.3.1.1(3,7)]decan-1-amine
NCGC00015036-01
lopac-a-1260
BSPBIO_001822
NCGC00179597-01
amantadine (inn)
D07441
OPREA1_248648
BSPBIO_001570
PRESTWICK3_000407
BSPBIO_000334
SPECTRUM5_000772
LOPAC0_000004
adamantane,1-amino
amant
adamantan-1-amine
tricyclo[3.3.1.1~3,7~]decan-1-amine
inchi=1/c10h17n/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9h,1-6,11h
symadine
1-adamantanamine
tricyclo[3.3.1.1^3,7]decan-1-amine
nsc341865
AB00514655
STK298781
768-94-5
C06818
amantadine ,
DB00915
1-adamantylamine, 97%
NCGC00162039-02
NCGC00162039-03
tricyclo(3.3.1.13,7)decan-1-amine
hsdb 3202
1-aminotricyclo(3.3.1.1(sup 3,7))decane
einecs 212-201-2
amantadinum [inn-latin]
tricyclo(3.3.1.1(3,7))-decan-1-amine
tricyclo(3.3.1.1(sup 3.7))decan-1-amine
amantadine [inn:ban]
adamantanamine
adamantylamine
brn 2204333
nsc 341865
tricyclo(3.3.1.1(sup 3,7))decan-1-amine
amantadina [inn-spanish]
KBIOSS_000390
KBIOGR_000548
KBIO2_000390
KBIO3_001322
KBIO2_005526
KBIO2_002958
NINDS_000815
SPBIO_000002
PRESTWICK1_000407
SPBIO_002273
SPECTRUM2_000081
SPECTRUM3_000291
PRESTWICK0_000407
SPECTRUM4_000134
BPBIO1_000368
IDI1_000815
PRESTWICK2_000407
NCGC00162039-04
NCGC00162039-01
(3s,5s,7s)-tricyclo[3.3.1.1~3,7~]decan-1-amine
HMS1989O12
NCGC00015036-07
1 aminoadamantane
CHEMBL660 ,
AKOS000113994
TCMDC-125869 ,
L000868
HMS1791O12
NCGC00015036-03
AKOS000119324
A838887
AKOS007930692
tox21_110068
cas-768-94-5
dtxcid502117
dtxsid8022117 ,
CCG-204100
AKOS015935124
NCGC00015036-09
NCGC00015036-02
NCGC00015036-08
NCGC00015036-04
NCGC00015036-05
NCGC00015036-06
adamantamine
amantadine base
BP-13040
FT-0607338
amantadine [inn]
amantadine [mart.]
amantadine [who-dd]
amantadine [hsdb]
amantadine [vandf]
amantadine [mi]
S5499
BRD-K70330367-003-01-2
gtpl4128
AB00053414-16
SCHEMBL4098
tox21_110068_1
NCGC00015036-11
tricyclo[3.3.1.13,7]decan-1-amine
SCHEMBL2619248
1-adamantyl amine
tricyclo[3.3.1.13,7]decane-1-amine
1-adamantaneamine
adamantyl amine
adamant-1-ylamine
1-amino-adamantane
adamantaneamine
adamantane-1-amine
1-adamantanylamine
1-adamantamine(1-aminoadamantane)
SCHEMBL15672299
mantadine (salt/mix)
symmetrel (salt/mix)
exp-105-1 (salt/mix)
1-amantadine
(3r,5s,7s)-adamantan-1-amine
W-104338
J-650234
STR04703
AE-641/01634060
AC-25879
HMS3604O07
AB00053414_17
AB00053414_18
SCHEMBL20409394
mfcd00074732
CS-W008656
SBI-0049993.P004
40933-03-7
F0001-1962
amantadinehcl
Q409761
1-aminoadamantane-d15
AS-14215
ads-5102, exp 105-1
BCP09869
SCHEMBL21309814
SCHEMBL21310017
BRD-K70330367-003-03-8
SDCCGSBI-0049993.P005
NCGC00015036-24
HMS3887I19
Q27453436
1-admantaneamine
SCHEMBL23419027
NCGC00015036-13
768-94-5 (free base)
SY017655
EN300-33893
HY-B0402
1-adamantanamine (purified by sublimation)
amantadine (mart.)
tricyclo(3.3.1.1(3,7))decan-1-amine
tricyclo(3.3.1.1(3,7))decane-1-amine
amantadina (inn-spanish)
tricyclo(3.3.1.1(3,7))decan-1-ylamine
amantadinum (inn-latin)
1-aminotricyclo

Research Excerpts

Overview

Amantadine hydrochloride is a risky drug for triggering delirium in dialysis patients; however, it is often administered casually. It is an N-methyl-d-aspartate receptor agonist with secondary dopaminergic activity that is used to treat Parkinson's disease-related dyskinesia and to treat fatigue in multiple sclerosis.

ExcerptReferenceRelevance
"Amantadine is an old, antiviral compound, which moderately improves motor behavior in Parkinson's disease. "( GOCOVRI
Müller, T, 2022
)
2.16
"Amantadine hydrochloride is a risky drug for triggering delirium in dialysis patients; however, it is often administered casually. "( Amantadine-associated delirium in patients with maintenance dialysis: Insomnia-associated recovery and uneven seasonal distribution.
Chao, J; He, J; Li, J; Si, B, 2023
)
3.8
"Amantadine is an N-methyl-d-aspartate receptor agonist with secondary dopaminergic activity that is used to treat Parkinson's disease-related dyskinesia and to treat fatigue in multiple sclerosis. "( Amantadine toxicity causing visual hallucinations.
Barbara, JM; Pace, A, 2023
)
3.8
"Amantadine acts as a nicotinic receptor antagonist, dopamine receptor agonist and non-competitive N-Methyl-D-aspartate receptor antagonist."( Amantadine for NeuroenhaNcement in acutE patients Study - a protocol for a prospective pilot proof of concept phase IIb study in intensive and intermediate care unit patients (ANNES).
Adeyemi, K; Blum, C; Bösel, R; Brendel, B; Feil, K; Häberle, HA; Haug, I; Hofmann, A; Martus, P; Mengel, A; Rattay, TW; Riessen, R; Schwarz, P; Single, C; Siokas, V; Zago, M; Ziemann, U, 2023
)
3.07
"Amantadine is an antiviral drug available in oral and intravenous forms. "( Effect of Repeated Intravenous Amantadine Infusions in Patients with Parkinson's Disease: An Open-Label Pilot Study.
Djaldetti, R; Khlebtovsky, A; Steiner, I; Treves, T, 2019
)
2.24
"Amantadine is a glutamatergic antagonist that works by inhibiting the NMDA receptor. "( Amantadine exerts anxiolytic like effect in mice: Evidences for the involvement of nitrergic and GABAergic signaling pathways.
Garg, C; Garg, M; Walia, V, 2020
)
3.44
"Amantadine is an evidence-based pharmacologic strategy for treating drug-induced parkinsonism and might be an alternative treatment for other DIMDs in select patients. "( Revisiting amantadine as a treatment for drug-induced movement disorders.
Caroff, SN; Jain, R; Morley, JF, 2020
)
2.39
"Amantadine appears to be an option for the symptomatic treatment of osteoarthritis in cats."( Owner evaluation of quality of life and mobility in osteoarthritic cats treated with amantadine or placebo.
Allweiler, S; Almeida, D; Baldo, C; Flynn, K; Guedes, A; Shipley, H; Tucker, L; Wendt-Hornickle, E, 2021
)
1.57
"Amantadine is a drug that can help in the prevention of SARS-CoV-2 symptomatology, as has been demonstrated in observational clinical studies."( Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2.
Aranda-Abreu, GE; Cortés-Borra, A, 2021
)
3.51
"Amantadine is a drug that can be prescribed as a prophylactic that prevents symptomatology caused by SARS-CoV-2 coronavirus."( Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2.
Aranda-Abreu, GE; Cortés-Borra, A, 2021
)
3.51
"Amantadine is an antiparkinsonian medication scarcely associated with PHS. "( Parkinsonism-hyperpyrexia Syndrome After Amantadine Withdrawal: Case Report and Review of the Literature.
Dos Santos, DT; Imthon, AK; Pille, A; Schumacher-Schuh, AF; Strelow, MZ, 2021
)
2.33
"Amantadine (AMD) is a prohibitive veterinary medicine in the entire world. "( Development of a competitive immunochromatographic assay for the sensitive detection of amantadine in chicken muscle.
Guo, Q; Hu, L; Lai, W; Liu, D; Luo, K; Wu, S; Xia, J; Xu, G; Zhu, F, 2017
)
2.12
"Amantadine is an interesting candidate as new antidepressant drug for the treatment of depression."( Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials.
Andreatini, R; Galduróz, JC; Raupp-Barcaro, IF; Vital, MA,
)
1.85
"Amantadine is an old antiviral compound, which moderately improves impaired motor behaviour."( Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia.
Möhr, JD; Müller, T, 2019
)
1.24
"Amantadine is an antiviral and antiparkinsonian drug that has been evaluated in combination therapies against hepatitis C virus (HCV) infection. "( Protective role of amantadine in mitochondrial dysfunction and oxidative stress mediated by hepatitis C virus protein expression.
Agriesti, F; Capitanio, N; Moradpour, D; Piccoli, C; Quarato, G; Ripoli, M; Scrima, R, 2014
)
2.17
"Amantadine hydrochloride is an antiviral agent that is also effective in the treatment of Parkinson's disease. "( Right ventricular outflow tract tachycardia after an initial dose of amantadine.
Çetinkal, G; Doğan, SM; Kocaş, C; Türkmen, Y, 2015
)
2.09
"Amantadine is an established dopamine agonist that supports neurological function."( Amantadine to Treat Cognitive Dysfunction in Moderate to Severe Traumatic Brain Injury.
Meyers, T; Stelmaschuk, S; Will, MC,
)
2.3
"Amantadine is a tricyclic symmetric amine that can effectively protect against the hepatitis C virus."( Amantadine inhibits cellular proliferation and induces the apoptosis of hepatocellular cancer cells in vitro.
Chong, Z; Fang, D; Feng, D; Lan, Z; Liu, C; Zang, W; Zhou, J, 2015
)
2.58
"Amantadine hydrochloride is an antiviral medication used as therapy for parkinsonism and as a cognitive enhancer. "( Cardiotoxicity after massive amantadine overdose.
Kazzi, Z; Morgan, B; Patel, M; Schwartz, M, 2008
)
2.08
"As amantadine is a frequently employed drug in brain injury rehabilitation, with known effects on fatigue and motor processing speed, this study examined the effect of amantadine on the sleep-wake behaviour of patients with brain injury undergoing rehabilitation."( Effect of amantadine on the sleep-wake cycle of an inpatient with brain injury.
Al-Adawi, S; Burke, DT; Dorvlo, AS; Hoaglin, H; Vesali, F, 2009
)
1.27
"Amantadine (AMA) is an uncompetitive antagonist of the N-methyl-d-aspartate receptor, with clinical application, acting on treatment of influenza A virus and Parkinson's disease. "( DNA damage in brain cells and behavioral deficits in mice after treatment with high doses of amantadine.
Gianesini, J; Kaefer, V; Ledur Kist, TB; Pereira, P; Picada, JN; Semedo, JG; Silva Kahl, VF; Von Borowsky, RG, 2010
)
2.02
"Amantadine is a tricyclic symmetric amine that inhibits the replication of many DNA and RNA viruses."( Inhibitory effects on HAV IRES-mediated translation and replication by a combination of amantadine and interferon-alpha.
Fujiwara, K; Gauss-Müller, V; Imazeki, F; Ishii, K; Kanda, T; Kiyohara, T; Wakita, T; Yang, L; Yokosuka, O, 2010
)
1.3
"Amantadine is an established antiparkinsonian drug with a still unclear molecular site of action. "( The noradrenaline transporter as site of action for the anti-Parkinson drug amantadine.
Nanoff, C; Pifl, C; Rebernik, P; Reither, H; Sommerauer, C, 2012
)
2.05
"Amantadine is a well-tolerated and effective treatment for motor symptoms in ataxia telangiectasia."( Movement disorder in ataxia-telangiectasia: treatment with amantadine sulfate.
Ben-Zeev, B; Hassin-Baer, S; Lerman, SF; Levi, YB; Nissenkorn, A; Tzadok, M, 2013
)
1.35
"Amantadine, is a non competitive NMDA receptors antagonist that has been proved beneficial in Parkinson's disease. "( New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET - [(11)C]raclopride study.
Carpinelli, A; Fazio, F; Franceschi, M; Galli, L; Gobbo, C; Messa, C; Moresco, RM; Panzacchi, A; Rizzo, G; Volonte, MA, 2002
)
2.02
"Amantadine is an antiviral agent that may have activity against hepatitis C virus."( Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin.
Maygers, J; Pande, H; Thuluvath, PJ, 2003
)
1.28
"Amantadine is an antiviral drug with activity against influenza A viruses, but not influenza B viruses."( Emergence of amantadine-resistant influenza A viruses: epidemiological study.
Masuda, H; Oshitani, H; Saito, R; Sato, I; Sato, M; Suzuki, H, 2003
)
1.41
"Amantadine is known to be a noncompetitive N-methyl-D-aspartate receptor antagonist and may be useful in preventing postoperative central sensitization, acute opioid tolerance, and opioid-induced hyperalgesia, thereby decreasing pain and analgesic requirements. "( Effects of perioperative oral amantadine on postoperative pain and morphine consumption in patients after radical prostatectomy: results of a preliminary study.
Katz, J; Koren, G; Snijdelaar, DG, 2004
)
2.05
"Amantadine is a noncompetitive N-methyl d-aspartate receptor antagonist. "( Amantadine in the akinetic-rigid variant of Huntington's disease.
Bonelli, RM; Kapfhammer, HP; Magnet, MK,
)
3.02
"Amantadine is a well tolerated medication when it is used in pediatric patients with traumatic brain injury. "( Amantadine in pediatric patients with traumatic brain injury: a retrospective, case-controlled study.
Green, LB; Hornyak, JE; Hurvitz, EA, 2004
)
3.21
"Amantadine is a reasonable option for improving cognition and reducing agitation following a TBI but confirmatory evidence of the efficacy the drug is necessary."( Amantadine for traumatic brain injury: does it improve cognition and reduce agitation?
Leone, H; Polsonetti, BW, 2005
)
3.21
"Amantadine is a well-known medication involved in drug-induced livedo reticularis (LR), yet remains under-reported in the English literature."( Amantadine-induced livedo reticularis: a report of two cases.
Cook-Norris, RH; Hayes, BB; Miller, JL; Rodriguez, A; Zic, JA, 2006
)
2.5
"Amantadine is an antiviral agent, which is utilized primarily in the treatment of influenza, but also, occasionally in the treatment of hepatitis C."( Interferon signal transduction of biphenyl dimethyl dicarboxylate/amantadine and anti-HBV activity in HepG2 2.2.15.
Hwang, KW; Joo, SS; Kim, MJ; Lee, DI; Won, TJ, 2006
)
1.29
"Amantadine is an effective drug for treatment of both, Parkinson's disease and viral infections. "( Stimulation of suicidal erythrocyte death by amantadine.
Föller, M; Geiger, C; Lang, F; Mahmud, H; Nicolay, J, 2008
)
2.05
"Amantadine toxicity is a particular problem in patients with renal insufficiency because 90% of an oral dose is excreted unchanged in the urine."( Amantadine-induced coma.
Ito, V; Macchio, GJ; Sahgal, V, 1993
)
2.45
"Amantadine is a monoprotic weak base that inhibits intraerythrocytic growth in in vitro cultures of Plasmodium falciparum, specifically chloroquine-resistant strains. "( Effect of pH on in vitro potency of amantadine against Plasmodium falciparum.
Evans, SG; Havlik, I, 1996
)
2.01
"Amantadine is an antiviral agent effective against influenza A viruses. "( Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse.
Blouin, RA; Chambers, TM; Fenger, C; Harkins, JD; Holland, RE; Lu, M; Rees, WA; Tobin, T; Woods, WE, 1997
)
3.18
"Amantadine is an antiviral agent that was unexpectedly found to cause symptomatic improvement in patients with Parkinsonism, although its mechanism of action remains to be elucidated. "( Amantadine increases aromatic L-amino acid decarboxylase mRNA in PC12 cells.
Boulton, AA; Juorio, AV; Li, XM; Qi, J, 1998
)
3.19
"Amantadine is a drug with a primary amino group, and consequently a likely candidate for metabolism by acetylation. "( Amantadine acetylation may be effected by acetyltransferases other than NAT1 or NAT2.
Aoki, FY; Bras, AP; Hoff, HR; Sitar, DS,
)
3.02
"Amantadine is an uncompetitive NMDA receptor antagonist, which has been in clinical use for many years."( The N-methyl-D-aspartate receptor channel blocker amantadine does not cause histopathological alterations in human brain tissue.
Jellinger, K; Kornhuber, J; Leblhuber, F; Riederer, P; Wiltfang, J, 1999
)
1.28
"Amantadinesulfate is a well known substance which has proven useful in the treatment and prophylaxis of viral infections, in treating symptoms of Parkinson's disease, cocaine dependence, and apathy in multiple sclerosis. "( Amantadine revisited: an open trial of amantadinesulfate treatment in chronically depressed patients with Borna disease virus infection.
Beelitz, G; Berghöfer, A; Bode, L; Brodhun, B; Ferszt, R; Kühl, KP; Ludwig, H; Müller-Oerlinghausen, B; Severus, EW; Winzer, B, 1999
)
3.19
"Amantadine hydrochloride is an accepted and well studied selective inhibitor of influenza virus reproduction."( Combined antiinfluenza virus activity of Flos verbasci infusion and amantadine derivatives.
Serkedjieva, J, 2000
)
1.26
"Amantadine is a putative dopaminergic compound known to be therapeutically effective in idiopathic and postencephalitic Parkinson's disease. "( Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism.
Fann, WE; Lake, CR, 1976
)
3.14
"Amantadine hydrochloride is a well-known antiviral agent that has been used for the prevention of influenza A2, the treatment of Parkinson disease, and, more recently, multiple sclerosis. "( Fetal outcome following intrauterine amantadine exposure.
Koren, G; Levy, M; Pastuszak, A, 1991
)
2
"Amantadine hydrochloride is a commonly prescribed drug with a narrow therapeutic-to-toxic range. "( Amantadine toxicity presenting with complex ventricular ectopy and hallucinations.
Hughes, B; Pimentel, L, 1991
)
3.17
"Amantadine is an antiviral agent that is also used in the treatment of parkinsonism and neuroleptic-induced extrapyramidal symptoms. "( Acute psychosis after amantadine overdose.
Bessen, HA; Snoey, ER, 1990
)
2.04
"Amantadine is a drug with diverse uses ranging from prevention of influenza A illness to the treatment of patients with Parkinson's disease. "( Clinical pharmacokinetics of amantadine hydrochloride.
Aoki, FY; Sitar, DS, 1988
)
2.01
"Amantadine proved to be a useful and safe addition to the armamentarium when given in daily doses of 200 mg."( Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study.
Barbeau, A; Botez, MI; Joubert, M; Mars, H, 1971
)
2.41

Effects

Amantadine has a growing body of evidence for the treatment of aggressive behavior in patients with traumatic brain injury, autism spectrum disorder, and developmental disability.

Amantadine-sulfate has been used for several decades to treat acute influenza A, Parkinson's disease (PD), and acute or chronic drug-induced dyskinesia. It has been shown to displace [3H]MK 801 from its binding site on the NMDA receptor.

ExcerptReferenceRelevance
"Amantadine has a growing body of evidence for the treatment of aggressive behavior in patients with traumatic brain injury, autism spectrum disorder, and developmental disability. "( Adjunctive Amantadine Treatment for Aggressive Behavior in Children: A Series of Eight Cases.
Loveland, JG; McGrane, IR; Zaluski, HJ, 2016
)
2.27
"Amantadine has a potential anti-inflammatory activity that can be a safe alternative for NR-CHC subjects to combination therapy."( Amantadine in non-responder patients with chronic hepatitis C: a randomized prospective study.
Beyler, AR; Coban, S; Dökmeci, A; Ekiz, F; Erdem, H; Köklü, S; Ormeci, N; Ozkan, H; Palabıyıkoğlu, M, 2012
)
3.26
"Amantadine has not been reported to cause dyskinesia and is rarely implicated in impulse control disorder."( Amantadine Revisited: A Contender for Initial Treatment in Parkinson's Disease?
Feldman, M; Margolesky, J; Marmol, S; Singer, C, 2021
)
2.79
"Amantadine has been suggested as a candidate, and cellular as well as clinical studies have indicated beneficial effects of this drug."( Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2.
B Andreas, L; Becker, S; Bentzen, BH; Giller, K; Jeppesen, MG; Kledal, TN; Kolocouris, A; Mujezinovic, A; Rosenkilde, MM; Toft-Bertelsen, TL; Tzortzini, E; Xue, K, 2021
)
2.79
"Amantadine has complex activity including antiviral, antiinflammatory and dopaminergic effects."( The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design.
Bonek, R; Chełstowski, W; Dąbrowski, P; Dec, M; Fiedor, P; Gala-Błądzińska, A; Goch, A; Grieb, P; Kiciak, S; Król, ZJ; Papuć, E; Rejdak, K; Segiet, A; Zasybska, A; Łukasiak, J, 2022
)
1.83
"Amantadine has been proposed as a treatment for COVID-19 because it shows anti-SARS-CoV-2 activity in vitro. "( Efficacy of oral amantadine among patients hospitalised with COVID-19: A randomised, double-blind, placebo-controlled, multicentre study.
Barczyk, A; Barczyk, M; Boda, Ł; Cofta, S; Czajkowska-Malinowska, M; Duława, J; Dyrbuś, M; Farnik, M; Harat, R; Huk, M; Kotecka, S; Kuna, P; Nahorecki, A; Nasiłowski, J; Naumnik, W; Przybylski, G; Skoczyński, S; Słaboń-Willand, M; Wita, K; Zioło, G, 2023
)
2.69
"Amantadine has been shown to promote the rate of neurologic recovery for patients with traumatic disorders of consciousness when administered between 4 and 16 weeks, as demonstrated by a well-designed randomized control trial."( Pharmacology in Treatment of Patients with Disorders of Consciousness.
Marino, MH, 2024
)
2.16
"Amantadine has been shown to reduce anesthesia and surgery-induced neuroinflammation and cognitive dysfunction. "( Amantadine attenuates sepsis-induced cognitive dysfunction possibly not through inhibiting toll-like receptor 2.
Huang, P; Lu, Y; Xing, W; Zeng, W; Zuo, Z, 2018
)
3.37
"Amantadine has demonstrated significant antidyskinetic effects in animal PD models and in randomized double-blind placebo-controlled trials (RCTs) in patients with PD."( Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.
Perez-Lloret, S; Rascol, O, 2018
)
1.51
"Amantadine ER has potential to supplement levodopa therapy in PD and improve patient therapeutic outcomes."( Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
Dashtipour, K; Lyons, KE; Pahwa, R; Tafreshi, AR, 2019
)
1.57
"Amantadine has a growing body of evidence for the treatment of aggressive behavior in patients with traumatic brain injury, autism spectrum disorder, and developmental disability. "( Adjunctive Amantadine Treatment for Aggressive Behavior in Children: A Series of Eight Cases.
Loveland, JG; McGrane, IR; Zaluski, HJ, 2016
)
2.27
"Amantadine has been used for decades as an inhibitor of the influenza A virus M2 protein (AM2) in the prophylaxis and treatment of influenza A infections, but its clinical use has been limited by its central nervous system (CNS) side effects as well as emerging drug-resistant strains of the virus. "( Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus.
Balannik, V; Cady, SD; DeGrado, WF; Hong, M; Pinto, LH; Wang, J, 2009
)
1.8
"Amantadine has been proposed to improve response rates in addition to standard therapy with peginterferon alpha and ribavirin."( A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients.
Chirino, RA; Chung, RT; Corey, KE; Dehesa-Violante, M; Gorospe, EC; Juarez, JA; Méndez-Navarro, J; Morán, S; Zheng, H, 2010
)
1.32
"Amantadine resistance has become increasingly common among recent seasonal influenza viruses. "( [Drug-resistant influenza viruses: an overview].
Hatakeyama, S, 2010
)
1.8
"Amantadine has over the years fallen out of favor as a drug to address influenza infection; however, it has become part of the arsenal utilized for early symptomatic treatment of PD, as well an option for treating dyskinesia."( Amantadine: the journey from fighting flu to treating Parkinson disease.
Haider, M; Hubsher, G; Okun, MS, 2012
)
3.26
"Amantadine has demonstrated efficacy in small series for absence and myoclonic type seizures. "( Amantadine for the treatment of refractory absence seizures in children.
Bailey, LJ; Hernandez, AW; Kotecha, AC; Malik, SI; Perry, MS, 2012
)
3.26
"Amantadine has a potential anti-inflammatory activity that can be a safe alternative for NR-CHC subjects to combination therapy."( Amantadine in non-responder patients with chronic hepatitis C: a randomized prospective study.
Beyler, AR; Coban, S; Dökmeci, A; Ekiz, F; Erdem, H; Köklü, S; Ormeci, N; Ozkan, H; Palabıyıkoğlu, M, 2012
)
3.26
"Amantadine has been available for 25 years as a treatment and prophylactic against influenza A infection, but has scarcely been used."( The management of influenza in people of working age.
Fleming, DM, 2002
)
1.04
"Amantadine (AMA) has been described as dopamine stimulant and norepineprhine release, capable to block the N-methyl-D aspartate (NMDA) glutamatergic and nicotinic receptors, enhancing the sexual behavior of the male rats and inducing hypersexuality in humans. "( Study of the biodistribution of the amantadine labelled with technetium-99m in Wistar female rats.
Bernardo-Filho, M; Fonseca, AS; Oliveira, MB; Santos, R, 2002
)
2.03
"Amantadine hydrochloride has the additive effects to interferon treatment on the virological responses of serum HCV-RNA during a co-administration, although the combination therapy has not shown a significantly promising effect on the eradication of HCV-RNA in the patients with chronic hepatitis C with a high viral load of genotype 1b virus."( The combination therapy of interferon and amantadine hydrochloride for patients with chronic hepatitis C.
Enomoto, H; Hirotani, T; Ito, H; Kishima, Y; Kuroda, T; Matsuda, M; Nakamura, H; Noguchi, S; Okuda, Y; Terabayashi, M; Uyama, H; Yamamoto, M; Yoshida, K,
)
1.84
"Amantadine has demonstrated both symptomatic benefit and dyskinesia benefit in some patients."( Rationale for current therapies in Parkinson's disease.
Fernandez, HH; Okun, MS; Romrell, J, 2003
)
1.04
"Amantadine has been used for prevention and treatment of influenza A infection. "( [Search of amantadine-resistance in influenza A strains isolated in Santiago, Chile, 2001-2002].
Abarca, K; Fehlmann, E; Ferrés, M; Godoy, P; Le Corre, N; Montecinos, L; Veloz, A, 2005
)
2.16
"Amantadine-sulfate has been used for several decades to treat acute influenza A, Parkinson's disease (PD), and acute or chronic drug-induced dyskinesia. "( Modulation of human motor cortex excitability by single doses of amantadine.
Arndt, T; Heimeroth, A; John, D; Mueller, HH; Oertel, WH; Reis, J; Rosenow, F, 2006
)
2.01
"Amantadine has only been shown to have an effect on type A influenza virus and is only available in tablet form (unsuitable for young children)."( Oseltamivir: new indication. Prevention of influenza in at-risk children: vaccination is best.
, 2007
)
1.06
"Amantadine has been shown to displace [3H]MK 801 from its binding site on the NMDA receptor. "( Locomotor effects of amantadine in the mouse are not those of a typical glutamate antagonist.
Starr, BS; Starr, MS, 1995
)
2.05
"Amantadine has been better studied in this situation, and experience with rimantadine is limited."( Control of influenza outbreaks in the nursing home: guidelines for diagnosis and management.
Arden, NH; Gomolin, IH; Leib, HB; Sherman, FT, 1995
)
1.01
"Amantadine has psychotomimetic properties in patients with Parkinson's disease and normal controls."( Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome.
Kornhuber, J; Weller, M, 1993
)
2.45
"Amantadine has found use primarily as an antiviral agent and in the symptomatic treatment of parkinsonism. "( Amantadine-induced coma.
Ito, V; Macchio, GJ; Sahgal, V, 1993
)
3.17
"Amantadine alone has antimalarial activity."( Plasmodium falciparum: effects of amantadine, an antiviral, on chloroquine-resistant and -sensitive parasites in vitro and its influence on chloroquine activity.
Evans, SG; Havlik, I, 1993
)
1.29
"Amantadine has been used for more than 20 years in the symptomatic treatment of Parkinson's disease (PD). "( Amantadine treatment is an independent predictor of improved survival in Parkinson's disease.
Ahlskog, JE; Basran, P; Ho, MM; Offord, KP; Prasad, M; Rajput, A; Rajput, AH; Schroeder, DR; Uitti, RJ, 1996
)
3.18
"Amantadine has the best ratio of therapeutic effects to side effects when compared with the other anti-parkinsonian drugs currently used."( Twenty-five years of amantadine therapy in Parkinson's disease.
Danielczyk, W, 1995
)
1.33
"Amantadine has similar effects but is more active against rigidity and bradykinesia."( Early idiopathic parkinsonism: initiation and optimization of treatment.
Calne, DB, 1994
)
1.01
"Amantadine has been teratogenic in rats and selegiline has caused neurochemical and behavioral alterations in rats when coadministered with clorgyline."( Pregnancy in Parkinson's disease: a review of the literature and a case report.
Hagell, P; Odin, P; Vinge, E, 1998
)
1.02
"Amantadine has been reported to have the potential to produce viral suppression in patients with hepatitis C."( Treatment of chronic hepatitis C with amantadine.
Goff, JS; Johnson, J; Reveille, RM, 2000
)
1.3
"Amantadine has also revered molindone-induced inhibition of traction response in mice."( Effects of amantadine on modification of dopamine dependent behaviours by molindone.
Balsara, JJ; Chandorkar, AG; Dhaware, BS; Nandal, NV, 2000
)
1.42
"Amantadine, which has been in use for about 30 years, has a relatively good safety profile.* Zanamivir is a costly preparation."( Zanamivir. No noticeable progress against influenza.
, 2000
)
1.03
"Amantadine has been found to have an efficacy of 50 to 90% prevention of illness."( [Anti-influenza A viral drug--amantadine].
Nasu, M; Tokimatsu, I, 2000
)
1.32
"Amantadine has been proved to be beneficial in Parkinson's disease. "( A PET study with [11-C]raclopride in Parkinson's disease: preliminary results on the effect of amantadine on the dopaminergic system.
Carpinelli, A; Comi, G; Fazio, F; Gobbo, C; Messa, C; Moresco, RM; Rizzo, G; Volonté, MA, 2001
)
1.97
"Amantadine, which has been in use for about thirty years, has a relatively good safety profile."( Zanamivir: new preparation. No tangible progress against influenza.
, 2000
)
0.93
"Amantadine has been used since 1969 in the treatment of Parkinson's disease. "( [Circulatory disorders induced by amantidine].
Cloarec, M; Contamin, F; Debray, J; Graisely, B; Mignot, B; Singer, B, 1976
)
1.7
"Amantadine has been shown to be as effective as anticholinergics, but it lacks long-term efficacy."( Initiating treatment of Parkinson's disease.
Koller, WC, 1992
)
1
"Amantadine has been available for many years for prophylaxis and therapy, but there have been concerns about side effects, particularly in the elderly."( Implications of viral resistance to amantadine in control of influenza A.
Arden, NH; Monto, AS, 1992
)
1.28
"Amantadine has been used in Norway to treat Parkinson's disease since 1972."( [Amantadine and rimantadine against influenza A].
Bruu, AL; Orstavik, I, 1992
)
1.92
"Amantadine hydrochloride has been shown in several open studies to benefit children with refractory generalized epilepsy. "( Amantadine hydrochloride for refractory generalized epilepsy in adults.
Denio, LS; Drake, ME; Pakalnis, A; Phillips, B, 1991
)
3.17
"Amantadine has been accepted for both the treatment and prophylaxis of influenza A virus infections. "( Biologic potential of amantadine-resistant influenza A virus in an avian model.
Bean, WJ; Threlkeld, SC; Webster, RG, 1989
)
2.03
"Amantadine hydrochloride has been reported efficacious in the symptomatic management of patients with multiple sclerosis (MS). "( Failure of amantadine hydrochloride to alter immune responses in the experimental allergic encephalomyelitis model of neuroautoimmune disease.
Awerbuch, G; Sandyk, R; Subramanian, G, 1988
)
2.11

Actions

Amantadine can cause endothelial failure and needs to be considered as part of the differential diagnosis of corneal edema. It did not enhance sustained viral response in patients with genotype 1 or high viral load nor did it improve primary non-response, breakthrough or relapse rates.

ExcerptReferenceRelevance
"Amantadine may cause RVOT-VT as well as other cardiac arrhythmias."( Right ventricular outflow tract tachycardia after an initial dose of amantadine.
Çetinkal, G; Doğan, SM; Kocaş, C; Türkmen, Y, 2015
)
1.37
"Amantadine can cause reversible corneal edema but can irreversibly reduce the density of endothelial cells."( Corneal endothelial dysfunction associated with amantadine toxicity.
Chang, KC; Kim, MK; Lee, JH; Wee, WR, 2008
)
2.04
"Amantadine did not enhance sustained viral response in patients with genotype 1 or high viral load nor did it improve primary non-response, breakthrough or relapse rates."( No beneficial effects of amantadine in treatment of chronic hepatitis C patients.
Boland, GJ; de Vries, RA; Drenth, JP; Houben, P; Koek, GH; Lieverse, RJ; Schipper, ME; Siersema, PD; van der Schaar, PJ; van der Sluys Veer, A; van Erpecum, KJ; van Hoek, B; van Ooteghem, NA; van Soest, H; Vrolijk, JM, 2010
)
1.39
"Amantadine can cause endothelial failure and needs to be considered as part of the differential diagnosis of corneal edema."( Bilateral reversible corneal edema associated with amantadine use.
Esquenazi, S, 2009
)
1.33
"Amantadine does not enhance SVR rates in previously treated patients with chronic hepatitis C and cannot be recommended in this setting."( Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Almeida, PR; Cheinquer, H; Lacerda, MA; Lima, MP; Paraná, R; Parise, ER; Pedrosa, SS; Pernambuco, JR; Pessôa, MG; Sette, H; Silva, GF; Tatsch, F; Teixeira, R,
)
1.78
"Amantadine-induced increase in L-DOPA-derived extracellular DA provides the basis for the clinical usefulness of amantadine in combination with L-DOPA."( Amantadine increases L-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats.
Arai, A; Kannari, K; Maeda, T; Matsunaga, M; Shen, H; Suda, T, 2003
)
2.48
"Amantadine can cause corneal decompensation and needs to be considered as part of the differential diagnosis of corneal edema."( Reversible amantadine-induced corneal edema in an adolescent.
Brodsky, MC; Feiz, V; Flynn, SB; Hughes, B, 2004
)
1.43
"Amantadine can cause corneal edema that begins a few months to several years after institution of therapy, and the edema can occur even in a corneal graft. "( Amantadine-associated corneal edema potentially irreversible even after cessation of the medication.
Galor, A; Hollyfield, JG; Jeng, BH; Langston, RH; Lee, MS; McMahon, JT; Meisler, DM; Schoenfield, L, 2008
)
3.23
"Amantadine was found to increase extracellular dopamine concentration in Ca(2+)-dependent manner, but the effect was not abolished by omega-conotoxin."( Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum.
Nakamura, S; Takahashi, T; Yamashita, H; Zhang, YX, 1996
)
1.3
"Amantadine was used to increase the availability of dopamine to the mid-brain region, and the propranolol was used to control the fever, which was believed to be central in origin."( Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury.
Guin-Renfroe, S; Meythaler, JM; Wilkinson, R, 1999
)
1.02
"4. Amantadine did not inhibit p38 MAP kinase and JNK activation induced by tumour necrosis factor-alpha (TNF-alpha) as a non-viral stimulus."( Amantadine inhibits RANTES production by influenzavirus-infected human bronchial epithelial cells.
Asai, Y; Gon, Y; Hashimoto, S; Horie, T; Kujime, K; Mizumura, K; Shimizu, K, 2001
)
2.27
"3. Amantadine did not cause any potentiation of dopamine responses, suggesting that inhibition of amine uptake was not responsible for its effects."( Responses of neurones in the cerebral cortex and caudate nucleus to amantadine, amphetamine and dopamine.
Stone, TW, 1976
)
1
"Amantadine was found to suppress completely the graft-vs.-host reaction in vitro when present at a concentration of 75 microg/ml."( Graft-vs.-host reaction in tissue culture.
Auerbach, R; Shalaby, MR, 1973
)
0.97

Treatment

Amantadine treatment is associated with improved consciousness among patients with different types of non-traumatic brain injury in this observational cohort analysis. Amantadne treatment also reduces the production of NO and metabolism of GABA.

ExcerptReferenceRelevance
"Amantadine treatment yielded a significant decrease in death in-hospital (before PSM: OR 0.143, 95% CI 0.034 to 0.605; after PSM: OR 0.113, 95% CI 0.020 to 0.635) and 3-month mortality (before PSM: OR 0.214, 95% CI 0.077 to 0.598; after PSM: OR 0.176, 95% CI 0.053 to 0.586) in unmatched and matched multivariate analyses."( Early amantadine treatment reduces the risk of death in patients with large hemisphere infarctions:a Chinese hospital-based study.
Li, J; Liu, M; Liu, Y; Wang, C; Wu, S; Yi, X; Zhang, P; Zhang, S, 2021
)
1.82
"Amantadine treatment was associated with improvement of consciousness at day 5 (amantadine: 86.9% vs control: 54.0%; absolute difference: 32.9 (20.0-44.2); adjusted OR (aOR): 5.71 (2.50-13.05), p<0.001)."( Amantadine treatment is associated with improved consciousness in patients with non-traumatic brain injury.
Balk, S; Gerner, ST; Giede-Jeppe, A; Huttner, HB; Jäger, J; Kallmünzer, B; Kuramatsu, JB; Madzar, D; Mueller, T; Rühl, L; Schwab, S; Sembill, JA; Sprügel, MI, 2022
)
2.89
"Amantadine treatment is associated with improved consciousness among patients with different types of non-traumatic brain injury in this observational cohort analysis. "( Amantadine treatment is associated with improved consciousness in patients with non-traumatic brain injury.
Balk, S; Gerner, ST; Giede-Jeppe, A; Huttner, HB; Jäger, J; Kallmünzer, B; Kuramatsu, JB; Madzar, D; Mueller, T; Rühl, L; Schwab, S; Sembill, JA; Sprügel, MI, 2022
)
3.61
"Amantadine treatment also reduces the production of NO and metabolism of GABA."( Amantadine exerts anxiolytic like effect in mice: Evidences for the involvement of nitrergic and GABAergic signaling pathways.
Garg, C; Garg, M; Walia, V, 2020
)
2.72
"Amantadine treatment also reduced Bcl‑2 and increased the Bax protein and mRNA levels."( Amantadine inhibits cellular proliferation and induces the apoptosis of hepatocellular cancer cells in vitro.
Chong, Z; Fang, D; Feng, D; Lan, Z; Liu, C; Zang, W; Zhou, J, 2015
)
2.58
"The amantadine-treated group was divided into 3 subgroups according to the cumulative dose and duration of treatment."( The effect of amantadine on corneal endothelium in subjects with Parkinson's disease.
Chang, KC; Jeon, BS; Jeong, JH; Kim, MK; Lee, JH; Wee, WR, 2010
)
1.2
"Amantadine treatment was not associated with CD81 expression."( Influence of amantadine on CD81 expression on lymphocytes in chronic hepatitis C.
Hartmann, RW; Herrmann, E; Hofmann, WP; Kronenberger, B; Ochs, D; Piiper, A; von Wagner, M; Welker, MW; Zeuzem, S; Zimmer, V, 2010
)
1.45
"Amantadine treatment significantly increased [(11)C-]Raclopride binding (caudate: 10% p = 0.04; putamen 11% p = 0.01)."( New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET - [(11)C]raclopride study.
Carpinelli, A; Fazio, F; Franceschi, M; Galli, L; Gobbo, C; Messa, C; Moresco, RM; Panzacchi, A; Rizzo, G; Volonte, MA, 2002
)
1.3
"Amantadine treatment is overall well tolerated, however its efficacy in reducing fatigue in people with MS is poorly documented and there is insufficient evidence to make recommendations to guide prescribing. "( Amantadine for fatigue in multiple sclerosis.
D'Amico, R; Giuliani, G; Pucci, E; Solari, A; Taus, C, 2003
)
3.2
"Amantadine hydrochloride treatment at doses of 300 mg/d had no effect, on average, for Huntington chorea, although most patients felt subjectively better during the short course of amantadine treatment."( A randomized trial of amantadine in Huntington disease.
Dewey, RB; O'Suilleabhain, P, 2003
)
1.35
"Amantadine treatment was simultaneously provided to 29 ill residents."( Emergence and transmission of amantadine-resistant influenza A in a nursing home.
Cox, N; Drinka, P; Gravenstein, S; Krause, P; Povinelli, L; Schilling, M; Shult, P, 2004
)
1.33
"Amantadine treatment of wild type and chimeric viruses reduced the virus titers by about 50% and 45%, respectively."( A 2a/1b full-length p7 inter-genotypic chimeric genome of hepatitis C virus is infectious in vitro.
Bowden, S; Dong, X; Ewart, G; Gowans, EJ; Haqshenas, G, 2007
)
1.06
"The amantadine-treated patients experienced a significantly more rapid resolution of clinical signs and symptoms when compared with placebo-treated patients."( Therapeutic effects of aerosolized amantadine in naturally acquired infection due to influenza A virus.
Douglas, RG; Hall, WJ; Hayden, FG, 1980
)
1.02
"Amantadine-treated patients showed a significantly greater reduction in fatigue, as measured by the MS-FS, than did patients treated with placebo (p = 0.04). "( Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
Coyle, PK; Cross, AH; Doscher, C; Grimson, R; Halper, J; Jandorf, L; Johnson, B; Krupp, LB; Miller, A; Morgante, L, 1995
)
1.95
"Amantadine-treated patients (n = 250) were similar to the patients not treated with amantadine (n = 586) in terms of age, gender, type of parkinsonism, Hoehn and Yahr stage and dementia status at initial neurological visit."( Amantadine treatment is an independent predictor of improved survival in Parkinson's disease.
Ahlskog, JE; Basran, P; Ho, MM; Offord, KP; Prasad, M; Rajput, A; Rajput, AH; Schroeder, DR; Uitti, RJ, 1996
)
2.46
"Amantadine treatment of Vero cells persistently infected with BDV did not result in reduced viral RNA levels, and application of the drug to persistently infected BALB/c mice had no effect on the concentration of BDV in their brains."( Borna disease virus is not sensitive to amantadine.
Hallensleben, W; Staeheli, P; Zocher, M, 1997
)
1.29
"Amantadine treatment was used as an antidepressant and antiviral compound."( Word recognition memory before and after successful treatment of depression.
Dietrich, DE; Emrich, HM; Hauser, U; Huber, TJ; Johannes, S; Kipp, K; Kleinschmidt, A; Schneider, U; Spannhuth, CW; Wieringa, BM, 2000
)
1.03
"Amantadine-treated participants were retained significantly longer than placebo."( A screening trial of amantadine as a medication for cocaine dependence.
Charuvastra, C; Kintaudi, PC; Ling, W; Shoptaw, S, 2002
)
1.35
"Amantadine treatment of cells infected with H7 strains of influenza A viruses causes an M2 protein-mediated conversion of hemagglutinin (HA) from its native to its low pH conformation. "( Evidence that the amantadine-induced, M2-mediated conversion of influenza A virus hemagglutinin to the low pH conformation occurs in an acidic trans Golgi compartment.
Bayley, PM; Ciampor, F; Hay, AJ; Hirst, EM; Nermut, MV; Sugrue, RJ, 1992
)
2.06
"Amantadine treatment produced a biphasic effect on mouse motility."( Mouse strain-dependent effect of amantadine on motility and brain biogenic amines.
Messiha, FS,
)
1.13
"The amantadine treatment did not alter brain dopamine concentration but increased its immediate acid metabolite, 3,4-dihydroxyphenylacetic acid, in the C57BL/6 mice as contrasted with reduction of the same in the BALB/C mouse strain."( Effect of amantadine on motility of reserpinized mice as a function of brain biogenic amines and mouse strains.
Messiha, FS,
)
1.01
"Pretreatment with amantadine, an inhibitor of clathrin-mediated endocytosis, significantly decreased liposomal uptake in HCAECs treated with or without TNF-α by 77% and 46%, respectively."( Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue.
Lopez-Berestein, G; Rodriguez-Aguayo, C; Sood, AK; Walton, BL; Zhaorigetu, S, 2014
)
0.73
"Treatment with amantadine (AMA), an N-methyl-D-aspartate (NMDA) receptor antagonist and antidepressant drug, increased the antidepressant activity of subsequent drugs in experimental studies and in patients suffering from treatment-resistant depression (TRD). "( Inhibitory effects of amantadine on the production of pro-inflammatory cytokines by stimulated in vitro human blood.
Basta-Kaim, A; Budziszewska, B; Grygier, B; Kubera, M; Lasoń, W; Leśkiewicz, M; Maes, M; Rogóz, Z,
)
0.8
"Treatment with amantadine and therapy with hyperimmunoglobulins seem to be useful."( [Bilateral influenza-triggered panuveitis and subsequent therapy with amantadine and hyperimmunoglobulins].
Cinatl, I; Gümbel, HO; Hattenbach, LO; Lipke, KJ; Schäfer, HG, 2004
)
0.9
"Pretreatment with amantadine (10-40 mg/kg, i.p.) at 30 min or 4 hr before augmented the ambulation-increasing effect of apomorphine (0.5 mg/kg, s.c.), but attenuated that of methamphetamine (2 mg/kg, s.c.)."( [Behavioral effects of amantadine on ambulatory activity and drinking in mice and on continuous and discrete avoidance responses in rats].
Kuribara, H; Tadokoro, S, 1984
)
0.9
"Treatment with amantadine hydrochloride and ribavirin was prescribed, and the patient was discharged after 19 days."( Influenza A pneumonitis following treatment of acute cardiac allograft rejection with murine monoclonal anti-CD3 antibody (OKT3).
Embrey, RP; Geist, LJ, 1995
)
0.63
"Treatment with amantadine should routinely be considered before indicating pallidotomy for levodopa-induced dyskinesias."( [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
Cersósimo, MG; Micheli, FE; Scorticati, MC, 2000
)
1.56
"Pretreatment with amantadine (25--200 mg/kg) prevented these oxotremorine-induced effects in mice."( Amantadine antagonism of oxotremorine effects.
Eshel, Y; Korczyn, AD, 1979
)
2.03
"Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control."( Mouse strain-dependent effect of amantadine on motility and brain biogenic amines.
Messiha, FS,
)
0.75

Toxicity

Amantadine use was associated with a significantly higher incidence of central nervous system adverse events than rimantadne use in this elderly population receiving influenza prophylaxis.

ExcerptReferenceRelevance
"Pharmacokinetic and adverse event profiles of 50- and 100-mg amantadine doses administered daily for up to 21 days for influenza prophylaxis were compared in 82 elderly nursing home residents (mean age 85 yrs, 68% female)."( Comparison of pharmacokinetic and safety profiles of amantadine 50- and 100-mg daily doses in elderly nursing home residents.
Cooper, SL; Degelau, J; Ehresman, D; Guay, DR; Somani, SK; Zaske, D, 1991
)
0.77
" Although no further influenza cases were diagnosed, 22% experienced adverse events."( Occurrence of adverse effects and high amantadine concentrations with influenza prophylaxis in the nursing home.
Cooper, SL; Degelau, J; Irvine, PW; Somani, S, 1990
)
0.55
" The plasma drug concentrations after the first dose correlated significantly with total symptom sources for both amantadine and rimantadine, but the plasma levels of toxic and nontoxic subjects overlapped extensively."( Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics.
Hayden, FG; Hoffman, HE; Spyker, DA, 1983
)
0.76
" Their adverse effects mostly involve bone marrow depression (e."( Adverse effects and drug interactions of clinical importance with antiviral drugs.
Morris, DJ, 1994
)
0.29
" Drugs used to treat PD, such as levodopa, offer symptomatic relief but often have neuropsychiatric adverse effects, most prominently psychosis and delirium."( Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.
Camicioli, R; Ganzini, L; Young, BK, 1997
)
0.3
" It was established that catecholaminergic effects account for the mechanism of therapeutic action of bromantan, while cholinergic effects determine the drug action in toxic doses."( [An acute toxicity study of bromantane].
Bugaeva, LI; Iezhitsa, IN; Spasov, AA; Verovskiĭ, VE,
)
0.13
" While data suggest that rimantadine is better tolerated, there are no data examining the rate of adverse reactions in elderly patients who receive amantadine vs rimantadine."( Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients.
Bertino, JS; Karl, M; Keyser, LA; Nafziger, AN, 2000
)
0.75
" Patients were assessed for central nervous system adverse effects and therapy discontinuation occurring with each agent."( Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients.
Bertino, JS; Karl, M; Keyser, LA; Nafziger, AN, 2000
)
0.55
"6%) of the 156 patients experienced an adverse effect when receiving amantadine compared with 3 patients (1."( Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients.
Bertino, JS; Karl, M; Keyser, LA; Nafziger, AN, 2000
)
0.79
"Amantadine use was associated with a significantly higher incidence of central nervous system adverse events than rimantadine use in this elderly population receiving influenza prophylaxis."( Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients.
Bertino, JS; Karl, M; Keyser, LA; Nafziger, AN, 2000
)
2
"The experiments on rats showed for bemithyl LD50 = 581."( [Acute toxicity of bemithyl and bromithyl].
Bugaeva, LI; Iezhitsa, IN; Spasov, AA; Verovskiĭ, VE,
)
0.13
" We studied the severity of illness due to influenza among adults residing in a center for the developmentally disabled and assessed adverse reactions to amantadine and oseltamivir prophylaxis."( Adverse effects of amantadine and oseltamivir used during respiratory outbreaks in a center for developmentally disabled adults.
Benjamin, JH; Gardner, C; Green, K; Lee, W; Loeb, M; McArthur, M; McGeer, AJ; Simor, AE, 2004
)
0.85
" Potential adverse events were documented during amantadine and oseltamivir therapy, and during a baseline period with neither medication."( Adverse effects of amantadine and oseltamivir used during respiratory outbreaks in a center for developmentally disabled adults.
Benjamin, JH; Gardner, C; Green, K; Lee, W; Loeb, M; McArthur, M; McGeer, AJ; Simor, AE, 2004
)
0.91
" Twenty-eight (25%) of 112 residents had an adverse neurologic event while receiving amantadine prophylaxis, compared with 3 (2."( Adverse effects of amantadine and oseltamivir used during respiratory outbreaks in a center for developmentally disabled adults.
Benjamin, JH; Gardner, C; Green, K; Lee, W; Loeb, M; McArthur, M; McGeer, AJ; Simor, AE, 2004
)
0.88
" The rate of adverse neurologic events associated with amantadine was significantly higher than that associated with oseltamivir."( Adverse effects of amantadine and oseltamivir used during respiratory outbreaks in a center for developmentally disabled adults.
Benjamin, JH; Gardner, C; Green, K; Lee, W; Loeb, M; McArthur, M; McGeer, AJ; Simor, AE, 2004
)
0.9
" Twenty-four drug-related adverse events were recorded of which four were regarded as serious."( Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G, 2006
)
0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Limited efficacy in patients with hepatitis C virus (HCV) genotype 1 and the side effect profile will necessitate the development of new therapeutic approaches."( Treating viral hepatitis C: efficacy, side effects, and complications.
Cornberg, M; Manns, MP; Wedemeyer, H, 2006
)
0.33
" No adverse effects of amantadine or postoperative complications were recorded."( Safety of perioperative treatment with intravenous amantadine in patients with Parkinson disease.
Djaldetti, R; Lev, N; Orbach-Zinger, S; Raz, A,
)
0.69
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" The primary outcome measure was safety assessed through adverse events (AEs)."( ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.
Felt, L; Hauser, RA; Isaacson, SH; Johnson, R; Oertel, W; Pahwa, R; Stempien, MJ; Tanner, CM, 2017
)
0.86
" The most frequent adverse events (AEs) were dry mouth, constipation, and insomnia."( Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
Brown, TR; Chernoff, DN; Cohen, JA; Gudesblatt, M; Hunter, SF; Llorens, L; Patni, R; Ruby, AE; Souza-Prien, CJ; Thrower, BW, 2019
)
0.8
" For each subgroup, changes from baseline in PD diary measures ("off" time and "on" time with and without troublesome dyskinesia), Unified Parkinson Disease Rating Scale Parts II + III scores, and adverse events were analyzed, comparing ER CD-LD with the active comparator."( Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.
Gupta, S; Kell, S; Khanna, S; LeWitt, PA; Rubens, R; Verhagen Metman, L,
)
0.13
" The most common adverse reactions with amantadine are constipation, cardiovascular dysfunction including QT prolongation, orthostatic hypotension and edema, neuropsychiatric symptoms such as hallucinations, confusion and delirium, nausea and livedo reticularis."( Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.
Perez-Lloret, S; Rascol, O, 2018
)
1.06
" As compared with placebo (38 [31%] of 124 patients), higher proportions of participants reported adverse events while taking amantadine (49 [39%] of 127 patients), modafinil (50 [40%] of 125 patients), and methylphenidate (51 [40%] of 129 patients)."( Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021
)
1.14
"Amantadine, modafinil, and methylphenidate were not superior to placebo in improving multiple sclerosis fatigue and caused more frequent adverse events."( Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021
)
2.37
" Numeric dose response was seen for some secondary efficacy outcomes and adverse events."( A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
Cameron, MH; Cohen, JA; Elfont, R; Goldman, MD; Goodman, AD; Johnson, R; Llorens, L; Miller, AE; Patni, R; Rollins, A, 2022
)
0.95
" splendens showed that they are scarcely toxic even at the maximum dosage of 1000 ppm (34."( Larvicidal and repellent activity of N-methyl-1-adamantylamine and oleic acid a major derivative of bael tree ethanol leaf extracts against dengue mosquito vector and their biosafety on natural predator.
Al Farraj, DA; Ali, AM; Chellappandian, M; Elshikh, MS; Hunter, WB; Kalaivani, K; Karthi, S; Senthil-Nathan, S; Vasantha-Srinivasan, P; Veerabahu, C, 2022
)
0.72
" This case demonstrates the safe use of memantine as an adjunctive agent in an adolescent with catatonia."( Safe Use of Memantine in a Pediatric Patient With Catatonia.
Chaffkin, J; Josephs, IA; Katz, ER, 2022
)
0.72

Pharmacokinetics

Amantadine concentrations in human brain tissue were assessed in order to estimate population pharmacokinetic parameters using the computer program NONMEM. The average half-life of amantadne in eight patients studied while receiving maintenance hemodialysis was 24.

ExcerptReferenceRelevance
" The half-life of amantadine after 42 days ingestion was 15."( Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults.
Aoki, FY; Sitar, DS, 1992
)
0.95
"A pharmacokinetic profile of 14C-AdDP with uniformly labelled alanine was investigated."( Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide derivative in mice.
Buchar, E; Flegel, M; Janků, I; Machková, Z; Masek, K; Vrba, T; Walder, P, 1991
)
0.28
"22 micrograms/ml), plasma elimination half-life (36."( Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults.
Hayden, FG; Hoffman, HE; Minocha, A; Spyker, DA, 1985
)
0.53
" Plasma half-life averaged 68."( Amantadine hydrochloride pharmacokinetics in patients with impaired renal function.
Daugirdas, JT; Gandhi, VC; Hano, JE; Ing, TS; Soung, LS; Wu, MJ, 1982
)
1.71
" The half-life of elimination in subjects with normal renal function was 11."( Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function.
Brater, DC; Garriott, JC; Horadam, VW; McAnalley, BH; Prati, RC; Sharp, JG; Smilack, JD; Stephens, MK, 1981
)
0.59
" The average half-life of amantadine in eight patients studied while receiving maintenance hemodialysis was 24."( Amantadine hydrochloride pharmacokinetics in hemodialysis patients.
Daugirdas, JT; Gandhi, VC; Hano, JE; Ing, TS; Ivanovich, PT; Soung, LS; Viol, GW; Wu, MJ, 1980
)
2
" We investigated 1) the antiviral efficacy, 2) analytical detection, 3) bioavailability and disposition, 4) pharmacokinetic modelling and 5) adverse reactions of amantadine in the horse."( Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse.
Blouin, RA; Chambers, TM; Fenger, C; Harkins, JD; Holland, RE; Lu, M; Rees, WA; Tobin, T; Woods, WE, 1997
)
1.94
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" The pharmacokinetic interaction can be excluded, since AMA did not change significantly the antidepressant level in the rat plasma and brain, measured 1 h after exposure to the forced swimming test."( Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioral and pharmacokinetic studies.
Daniel, WA; Kot, M; Kuśmider, M; Rogóz, Z; Skuza, G; Wójcikowski, J,
)
0.4
" On the other hand, pharmacokinetic parameters of AMA did not significantly change."( Simultaneous determination of amantadine and rimantadine by HPLC in rat plasma with pre-column derivatization and fluorescence detection for pharmacokinetic studies.
Fujii, Y; Higashi, Y; Uemori, I, 2005
)
0.62
"Amantadine concentrations in human brain tissue were assessed in order to estimate population pharmacokinetic parameters using the computer program NONMEM."( Pharmacokinetic characterization of amantadine in human brain tissue.
Bleich, S; Kornhuber, J; Kraus, T; Meineke, I; Riederer, P; Wiltfang, J, 2006
)
2.05
" Although many more subjects would need to be studied to rule out a synergistic increase in adverse events, the combination in this small human drug-drug interaction trial appears safe and without pharmacokinetic consequences."( A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination.
Amer, A; Evans, TG; Howard, D; Morrison, D; Rayner, C; Roy, S; Smith, JR, 2007
)
0.58
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Plasma concentrations of amantadine were determined for pharmacokinetic parameter estimation and evaluation of the exposure-response relationship."( Pharmacokinetics of amantadine in children with impaired consciousness due to acquired brain injury: preliminary findings using a sparse-sampling technique.
Bean, J; McMahon, MA; Michaud, LJ; Vargus-Adams, JN; Vinks, AA, 2010
)
0.98
"17 L/h/kg with a half-life of 13."( Pharmacokinetics of amantadine in children with impaired consciousness due to acquired brain injury: preliminary findings using a sparse-sampling technique.
Bean, J; McMahon, MA; Michaud, LJ; Vargus-Adams, JN; Vinks, AA, 2010
)
0.68
" The pharmacokinetics of platinum was analyzed by population modelling and post hoc Bayesian estimation as well as using non-compartmental pharmacokinetic analysis of the mean concentration-time curves."( A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and s
Chládek, J; Chládková, J; Chlubnová, H; Hrusková, V; Kroutil, A; Mistr, A; Semerád, M; Sova, P, 2011
)
0.37
"In conclusion, this first comparative pharmacokinetic study with LA-12 and satraplatin shows that characteristics of platinum exposure evaluated in the plasma, plasma ultrafiltrate and kidney and liver tissues increase less than in proportion to dose following a single-dose administration of 37."( A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and s
Chládek, J; Chládková, J; Chlubnová, H; Hrusková, V; Kroutil, A; Mistr, A; Semerád, M; Sova, P, 2011
)
0.37
" Noncompartmental pharmacokinetic analyses were performed."( Pharmacokinetics of oral amantadine in greyhound dogs.
KuKanich, B; Norkus, C; Rankin, D; Warner, M, 2015
)
0.72
" pharmacokinetic profile of a drug is unchanged in the presence of CD."( The effect of intravenous sulfobutylether7 -β-cyclodextrin on the pharmacokinetics of a series of adamantane-containing compounds.
Leong, NJ; Mcintosh, MP; Prankerd, RJ; Shackleford, DM, 2015
)
0.42
" Pharmacokinetic parameter estimates were determined via noncompartmental analysis."( Pharmacokinetics of amantadine after oral administration of single and multiple doses to orange-winged Amazon parrots (
Berg, KJ; Drazenovich, TL; Knych, HK; Paul-Murphy, JR; Sanchez-Migallon Guzman, D, 2020
)
0.88

Compound-Compound Interactions

The further therapeutic benefit of piribedil when combined with amantadine or Levodopa was studied by a double-blind, cross-over trial in 15 patients with Parkinson's disease. The efficacy of induction doses of interferon-alpha-2a monotherapy or in combination with ribavirin and/or amanadine was evaluated in non-responders with chronic hepatitis C.

ExcerptReferenceRelevance
"The further therapeutic benefit of piribedil when combined with amantadine or Levodopa was studied by a double-blind, cross-over trial in 15 patients with Parkinson's disease."( Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa.
Callaghan, N; Fitzpatrick, E; O'Mahony, JB, 1975
)
0.72
" They must be administered with caution during pregnancy, because some are known teratogens (e."( Adverse effects and drug interactions of clinical importance with antiviral drugs.
Morris, DJ, 1994
)
0.29
" A variety of drugs have been investigated alone or in combination with alpha interferons."( The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C.
Perrillo, RP; Younossi, ZM, 1999
)
0.67
" Patients were randomized for either IFN/Riba and amantadine (Ama) including a 2-week initial high IFN induction course (18 MU IFN daily) (group A) or the same 2-week IFN induction course combined with Riba/Ama, followed by Riba/Ama without IFN (group B)."( Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study.
Beld, MG; Dijkgraaf, MG; Reesink, HW; Sentjens, RE; Weegink, CJ, 2003
)
0.77
"Two hundred twenty five consecutive non-responders to previous antiviral treatment(s) with IFN-alpha alone or in combination with ribavirin or amantadine were treated with IFN-alpha 2b 5 MU daily for 4 weeks, 5 MU tiw for 20 weeks, followed by 3 MU tiw for additional 24 weeks combined with ribavirin 1000-1200 mg/d."( Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C.
Arnold, R; Berg, T; Herrmann, E; Junge, U; Kullmann, F; Lafrenz, M; Musch, E; Pascu, M; Pausch, J; Ramadori, G; Teuber, G; Weidenbach, H; Wiedmann, KH; Zankel, M; Zeuzem, S, 2003
)
0.74
"To study antiviral activity of arbidol in relation to various antigenic subtypes of influenza virus isolated from humans; efficacy of arbidol action in combination with adamantanic antiviral drugs, ribavirin and ribamidil on reproduction of influenza virus A (IVA) in cell culture."( [Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A].
Fediakina, IT; Glushkov, RG; Gus'kova, TA; Leneva, IA, 2005
)
0.33
" The inhibiting activity of arbidolin on cell culture viral reproduction enhanced if arbidol was used in combination with amantadine, remantadin, ribavirin and ribamidil."( [Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A].
Fediakina, IT; Glushkov, RG; Gus'kova, TA; Leneva, IA, 2005
)
0.54
"Efficacy and safety of interferon induction therapy alone or in combination with ribavirin or ribavirin plus amantadine were evaluated in chronic hepatitis C patients who were nonresponders to primary antiviral treatment."( A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C.
Andreone, P; Attard, L; Bernardi, M; Biselli, M; Boccia, S; Bonvicini, F; Cursaro, C; Furlini, G; Galli, S; Giacomoni, PL; Gramenzi, A; Lorenzini, S; Verucchi, G, 2007
)
0.76
" The aim of this study was to compare virological response rates in patients with chronic hepatitis C virus (HCV)-1 infection treated with 400 mg amantadine or placebo in combination with peginterferon alfa-2a (40 kD) and ribavirin for 48 weeks."( Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.
Berg, T; Buggisch, P; Gerken, G; Goeser, T; Herrmann, E; Hinrichsen, H; Hofmann, WP; Manns, M; Spengler, U; Teuber, G; von Wagner, M; Weidenbach, H; Zeuzem, S, 2008
)
0.82
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009
)
0.35
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
" Its combination with pegylated interferon and ribavirin needs further evaluation."( Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non-responders and relapsers.
Abbas, Z; Hamid, S; Jafri, W; Raza, S, 2012
)
0.63

Bioavailability

Amantadine ER provides higher and more continuous amantadines plasma bioavailability than conventional immediate-release formulations, which require administration up to three times daily. We investigated the antiviral efficacy, analytical detection, bioavailability and disposition, 4) pharmacokinetic modelling and 5) adverse reactions of amantdine in the horse.

ExcerptReferenceRelevance
" A 1-compartment open model and complete bioavailability were assumed."( Amantadine kinetics in healthy young subjects after long-term dosing.
Aoki, FY; Ogilvie, RI; Sitar, DS, 1979
)
1.7
" The bioavailability after an oral dose of 40 mg/kg was 58."( Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs.
Blasecki, JW; Gaylord, JC; Hoffman, HE; Shalaby, LM; Whitney, CC, 1988
)
0.27
" It is available only in oral formulations from which it is well absorbed and widely distributed, little drug being present in the circulation."( Clinical pharmacokinetics of amantadine hydrochloride.
Aoki, FY; Sitar, DS, 1988
)
0.57
"0 hr after dosing, but the calculated AUC was proportional to dose, indicating that relative bioavailability was independent of dose."( Amantadine kinetics in healthy elderly men: implications for influenza prevention.
Aoki, FY; Sitar, DS, 1985
)
1.71
" Assuming complete bioavailability of the drug, less than 5% of the dose was removed by each 4-hour hemodialysis."( Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function.
Brater, DC; Garriott, JC; Horadam, VW; McAnalley, BH; Prati, RC; Sharp, JG; Smilack, JD; Stephens, MK, 1981
)
0.59
" While readily bioavailable by systemic routes, it was poorly bioavailable by the oral route."( Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase).
Dempsey, MH; Penn, CR; Ryan, DM; Ticehurst, J, 1994
)
0.29
" We investigated 1) the antiviral efficacy, 2) analytical detection, 3) bioavailability and disposition, 4) pharmacokinetic modelling and 5) adverse reactions of amantadine in the horse."( Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse.
Blouin, RA; Chambers, TM; Fenger, C; Harkins, JD; Holland, RE; Lu, M; Rees, WA; Tobin, T; Woods, WE, 1997
)
1.94
" It is obvious that most important problem in clinical use of anti-FluV drugs should be its side effects, bioavailability and stability in human bodies."( [Current status of research and development for anti-influenza virus drugs--chemotherapy for influenza].
Shigeta, S, 1997
)
0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" The aim of this study was to label and evaluate the bioavailability of the AMA labelled with 99mTc (99mTc-AMA) in Wistar female rats."( Study of the biodistribution of the amantadine labelled with technetium-99m in Wistar female rats.
Bernardo-Filho, M; Fonseca, AS; Oliveira, MB; Santos, R, 2002
)
0.59
" Bioavailability of AMA and RIM was 34."( Simultaneous determination of amantadine and rimantadine by HPLC in rat plasma with pre-column derivatization and fluorescence detection for pharmacokinetic studies.
Fujii, Y; Higashi, Y; Uemori, I, 2005
)
0.62
" Dopamine deficiency has been associated with several neurological disorders; it has been shown to have good systemic bioavailability and significant uptake into the CNS following intranasal administration."( Metabolism of dopamine by the nasal mucosa.
Chemuturi, NV; Donovan, MD, 2006
)
0.33
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" These findings together with the dose-related elevation in the pharmacokinetic characteristics V/F and CL/F of platinum and ultrafiltrate platinum as well as a drop in platinum urinary recovery are consistent with a dose-related decrease in the extent of oral bioavailability most likely due to saturable intestinal absorption."( A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and s
Chládek, J; Chládková, J; Chlubnová, H; Hrusková, V; Kroutil, A; Mistr, A; Semerád, M; Sova, P, 2011
)
0.37
" N-(1-adamantyl)-2-oxo-chromene-3-carboxamide (8), N-adamantan-1-yl-5-dimethyl-amino-1-naphthalenesulfonic acid (11) and N-(1-cyano-2H-isoindol-2-yl) adamantan-1-amine (12) were found to possess a high degree of multifunctionality with favourable physical-chemical properties for bioavailability and blood-brain barrier permeability."( Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
Green, IR; Joubert, J; Malan, SF; van Dyk, S, 2011
)
0.37
" Oral bioavailability was not affected (F = 64 ± 4 versus 59 ± 11; knockout versus wild type)."( Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
Bedwell, DW; Higgins, JW; Zamek-Gliszczynski, MJ, 2012
)
0.38
" This effort led to the discovery of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo[3,4-b]pyrazine (PF470, 14) as a highly potent, selective, and orally bioavailable mGluR5 NAM."( Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat
Balan, G; Barreiro, G; Boscoe, BP; Chen, L; Chenard, LK; Cianfrogna, J; Claffey, MM; Coffman, KJ; Drozda, SE; Dunetz, JR; Fonseca, KR; Galatsis, P; Grimwood, S; Lazzaro, JT; Mancuso, JY; Miller, EL; Reese, MR; Rogers, BN; Sakurada, I; Shaffer, CL; Skaddan, M; Smith, DL; Stepan, AF; Trapa, P; Tuttle, JB; Verhoest, PR; Walker, DP; Wright, AS; Zaleska, MM; Zasadny, K; Zhang, L, 2014
)
0.4
" As resistance to the only orally bioavailable drug, oseltamivir, has been continuously reported, there is a clear need to develop the next-generation of anti-influenza drugs."( Discovery of Potent Antivirals against Amantadine-Resistant Influenza A Viruses by Targeting the M2-S31N Proton Channel.
Hu, Y; Li, F; Ma, C; Wang, J; Wang, Y, 2016
)
0.7
" Amantadine ER provides higher and more continuous amantadine plasma bioavailability than conventional immediate-release formulations, which require administration up to three times daily."( Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia.
Möhr, JD; Müller, T, 2019
)
1.42
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The main objective was to modify therapy with adamantane derivatives: amantadine and rimantadine, to increase their bioavailability and evaluate the influence of such therapy on drug metabolism using Saccharomyces cerevisiae as the model organism."( Metabolic profiling to evaluate the impact of amantadine and rimantadine on the secondary metabolism of a model organism.
Barchanska, H; Kostina-Bednarz, M; Płonka, J, 2023
)
1.4

Dosage Studied

We investigated triple combination treatment with induction dosing of interferon-alpha plus ribavirin plus amantadine in these difficult-to-treat patients. When subchronically fed to rats at a daily dosage of approximately 180 mg/kg, amantAdine induced ultrastructural symptoms of generalized lipidosis. Gross and subtle side effects of amantADine observed in this study on currently recommended dosage are higher than previously reported.

ExcerptRelevanceReference
" In 14 patients who showed no response whatever, further treatment, with bromocriptine in doses raised gradually to a final daily dosage of 15 mg, was effective in four cases, though the improvement was generally only moderate."( Therapy of extrapyramidal side effects, with particular reference to persistent dyskinesia and lithium tremor.
Pöldinger, W, 1978
)
0.26
" Higher dosage of amantadine decreases cardiac contractility significantly."( [Effects of amantadine on heart and circulation].
Deuster, JE; Mast, GJ; Schmier, J; van Ackern, K, 1975
)
0.97
" In the antipsychotic classification, special attention is given to side effects (extrapyramidal motor signs, tardive dyskinesias, akathisis) and to dosage for the elderly."( Observations on the psychopharmacology of the aged.
Eisdorfer, C, 1975
)
0.25
" The dosage used was 200 mg daily."( Prevention of Russian influenza by amantadine.
Bandyk, MG; Gunn, RA; King, CL; Monto, AS, 1979
)
0.54
" Dose-response curves for dopamine and apomorphine inhibition were displaced to the right by administration of phenothiazines (chlorpromazine and perphenazine) and butyrophenones (haloperidol and spiroperidol)."( Effects of dopamine analogues and antagonists on carotid body chemosensors in situ.
Llados, F; Zapata, P, 1978
)
0.26
"Nineteen patients with senile brain disease (including 2 with parkinsonian symptoms) were treated with amantadine in an oral dosage of 200--300 mg daily."( Amantadine in senile dementia: electroencephalographic and clinical effects.
Boillat, J; Cole, M; Dastoor, DP; Klingner, A; Müller, HF, 1979
)
1.92
" Side effects (hallucinations, confusion, dyskinesias) were frequent, but were usually reversible by lowering the dosage of levodopa or the accompanying anticholinergic medication."( Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
Feigenson, JS; McDowell, FH; Sweet, RD, 1976
)
0.26
" The current level of dosage of vaccine for adults is 1200 chick cell agglutinating units, almost double what it was a dozen years ago."( Influenza.
Knight, V, 1976
)
0.26
" Although directly related to daily dosage of levodopa, the myoclonus was specifically blocked by the serotonin antagonist, methysergide."( Levodopa-induced myoclonus.
Bergen, D; Goetz, C; Klawans, HL, 1975
)
0.25
" Dextroamphetamine in lower dosage also reduced disability by some 17 percent."( Amphetamines in the treatment of Parkinson's disease.
Asselman, P; Bovill, KT; Marsden, CD; Parkes, JD; Phipps, JA; Rose, P; Tarsy, D, 1975
)
0.25
" Time- and dose-response data with all three drugs suggest a direct inhibitory action on the caudate nucleus consistent with their proposed mechanism for treatment of Parkinson symptomatology."( Head-turning induced by electrical stimulation of the caudate nucleus and its antagonism by anti-parkinson drugs.
Barnett, A; Goldstein, J, 1975
)
0.25
" Statistically significant relationships were found between CPSSt and dosage (in mg/kg/day) and serum creatinine."( Comparison of pharmacokinetic and safety profiles of amantadine 50- and 100-mg daily doses in elderly nursing home residents.
Cooper, SL; Degelau, J; Ehresman, D; Guay, DR; Somani, SK; Zaske, D, 1991
)
0.53
" BMA caused "flattening" of the dose-response curves for 86Rb efflux induced by L-PIA, adenosine and carbachol with a significant reduction in response at the highest concentrations of adenosine and carbachol."( 86Rubidium efflux and negative inotropy induced by P1- and muscarinic-receptor agonists in guinea-pig left atria. Effects of potassium channel blockers.
Broadley, KJ; Rothaul, AL; Urquhart, RA, 1991
)
0.28
" Mean plasma concentration of desipramine in a subsample of our subjects was less than that recommended for treatment of depression, thus the dosage of desipramine may have been subtherapeutic."( Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence.
Brown, BS; Haertzen, CA; Hess, JM; Jaffe, JH; Kolar, AF; Mahaffey, JR; Weddington, WW, 1991
)
0.64
"01-1 mg/kg) increased the number of penile erections with bell-shaped dose-response curves."( Septohippocampal cholinergic pathway and penile erections induced by dopaminergic and cholinergic stimulants.
Maeda, N; Matsuoka, N; Yamaguchi, I, 1990
)
0.28
" This allowed a total dosage not much less than might have been given by other routes, but with the advantage that it was evenly deposited over the surface of the infected respiratory tract beginning within seconds of the start of treatment and reached higher concentration in nasal secretions than in serum."( Chemotherapy of respiratory viruses.
Gilbert, BE; Knight, V, 1986
)
0.27
" Memory scores were correlated with age, sex, education, marital status, length of illness, age at onset of illness, dosage and time on medication, functional status, and the major symptoms of parkinsonism."( Correlates of memory in Parkinson's disease.
Reynolds, CM; Riklan, M; Stellar, S, 1989
)
0.28
" This finding prompted us to re-investigate the metabolism of amantadine under a therapeutic dosing regimen."( A revision of the metabolic disposition of amantadine.
Köppel, C; Tenczer, J, 1985
)
0.77
" These questions concern appropriate routes of administration for antiviral compounds, optimal dosage regimens, risks of long-term prophylaxis, and the emergence of resistant organisms."( Antiviral chemotherapy and chemoprophylaxis.
Dolin, R, 1985
)
0.27
" Changes include addition of statements about the route of vaccine administration; the use of amantadine in medical personnel during influenza A outbreaks; the need to prepare contingency plans to expedite use of amantadine in aborting influenza A outbreaks among residents of institutions; and reduction in the dosage of amantadine for older patients or persons with seizure disorders."( Prevention and control of influenza. Recommendation of the Immunization Practices Advisory Committee. Centers for Disease Control, Department of Health and Human Services.
, 1985
)
0.49
" When subchronically fed to rats at a daily dosage of approximately 180 mg/kg, amantadine induced ultrastructural symptoms of generalized lipidosis, the degree of which was, however, by far less marked than that previously reported for chlorphentermine."( Amantadine-induced lipidosis. A cytological and physicochemical study.
Burmester, J; Hanpft, R; Kröplin, K; Lüllmann-Rauch, R; Patten, M, 1987
)
1.94
" Changes include statements about 1) updating of the influenza strains in the trivalent vaccine for 1988-89, 2) increased emphasis on the need for vaccination of health-care workers, 3) prevention of influenza in persons with human immunodeficiency virus (HIV) infection, and 4) dosage considerations for amantadine."( Recommendations of the Immunization Practices Advisory Committee, Centers for Disease Control. Prevention and control of influenza.
, 1988
)
0.45
" These findings illustrate the benefits of influenza vaccination and support the use of amantadine hydrochloride at a dosage of 100 mg daily for outbreak control among elderly persons."( The roles of vaccination and amantadine prophylaxis in controlling an outbreak of influenza A (H3N2) in a nursing home.
Arden, NH; Fasano, MB; Harmon, MW; Kendal, AP; Lui, KJ; Patriarca, PA; Rimland, D, 1988
)
0.79
" The tolerance of the preparation was good in virtually all cases and a gradually increasing dosage is recommended."( Treatment of impaired cerebral function in psychogeriatric patients with memantine--results of a phase II double-blind study.
Ambrozi, L; Danielczyk, W, 1988
)
0.27
" A dosage of 200 mg of either drug for a 3-5-day period is effective but treatment has to commence on the first day of symptoms."( Current status of amantadine and rimantadine as anti-influenza-A agents: memorandum from a WHO meeting.
, 1985
)
0.6
" An increase in dosage also had only a transient effect."( Development of tolerance to the therapeutic effect of amantadine on akathisia.
Barreira, P; Lipinski, JF; Zubenko, GS, 1984
)
0.52
" Administration of 50 mg of the drug for 15-30 days was effective for prevention of influenza, and administration, early in the course of illness, of dosage of 150 mg per day for three to five days resulted in a favorable clinical response."( Study of rimantadine in the USSR: a review of the literature.
Kamforin, LE; Kovaleva, TP; Kubar, OI; Zlydnikov, DM,
)
0.13
" The amount by which dosage must be reduced can be estimated based on creatinine clearance."( Amantadine hydrochloride pharmacokinetics in patients with impaired renal function.
Daugirdas, JT; Gandhi, VC; Hano, JE; Ing, TS; Soung, LS; Wu, MJ, 1982
)
1.71
" Gross and subtle side effects of amantadine observed in this study on currently recommended dosage are higher than previously reported, which may be an important factor in consideration of mass prophylaxis."( A prospective double-blind study of side effects associated with the administration of amantadine for influenza A virus prophylaxis.
Bryson, YJ; Monahan, C; Pollack, M; Shields, WD, 1980
)
0.76
"To provide a review of rimantadine, including its antiviral activity, pharmacokinetics, efficacy, adverse effects, drug interactions, and dosage and administration."( Rimantadine: a clinical perspective.
Nahata, MC; Wintermeyer, SM, 1995
)
0.29
" Careful attention to published dosage adjustment guidelines for these compounds, avoidance of interacting drugs and avoiding these agents in patients with a history of seizures may be the best means to reduce the risk of toxicity in elderly patients."( Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective.
Guay, DR, 1994
)
1.73
" Adverse effects are more prominent in the elderly but can be minimized by dosage reductions."( Use of antivirals in influenza in the elderly: prophylaxis and therapy.
Nicholson, KG, 1996
)
0.29
" Only a regular daily dosing schedule of amantadine has been used for the treatment of sexual dysfunction so far."( Intermittent amantadine for fluoxetine-induced anorgasmia.
Balon, R, 1996
)
0.93
" Used as adjuvant treatment to levodopa, they help lowering the dosage of levodopa."( [Initial treatment of Parkinson's disease].
Kulisevsky, J; López-Villegas, D, 1997
)
0.3
" Acute dystonias consist of abnormal muscle spasms and postures and usually occur three to five days after antipsychotic therapy begins or the dosage is increased."( Management of acute extrapyramidal effects induced by antipsychotic drugs.
Holloman, LC; Marder, SR, 1997
)
0.3
" In the statistical investigation by the multivariate analysis (quantification method type II), the age of initial levodopa therapy, the duration from the onset to the initiation of levodopa therapy, and the duration of levodopa therapy were not closely related to the development of any adverse reaction, while Hoehn & Yahr's stage and the dosage of levodopa had the most significant influence on the development of adverse reactions."( [Multivariate analysis of the problems of long-term levodopa therapy in Parkinson's disease].
Endo, S; Hikiji, A; Nakamura, Y; Yoshinaga, J, 1997
)
0.3
" This long range study demonstrates, through multiple varied dosing schedules, a trade off between the benefits and side effects of dopaminergic therapy, with implications for a larger brain injury population."( Effects of dopaminergic combination therapy for frontal lobe dysfunction in traumatic brain injury rehabilitation.
Burke, DT; Calvanio, R; Fitzpatrick, M; Karli, DC; Kim, HJ; Lepak, P; Macneil, M; Pesez, K; Temple, D, 1999
)
0.3
" Coupled with our previous in vitro demonstration of bicarbonate-dependent organic cation transport, the present study suggests that bicarbonate inhibition of renal tubule organic cation secretion may explain the previous observation that bicarbonate dosing decreases amantadine excretion by the kidney."( In vivo analysis of amantadine renal clearance in the uninephrectomized rat: functional significance of in vitro bicarbonate-dependent amantadine renal tubule transport.
Goralski, KB; Sitar, DS; Smyth, DD, 1999
)
0.81
" Pharmacists confirmed a total of 22 adverse effects; generally the problem was solved by reducing the dosage rather than discontinuing the drug."( Influenza outbreak in a long-term-care facility: considerations for pharmacy.
Bowles, SK; Collins, V; Kennie, N; Louie, M; Ruston, L; Simor, A, 1999
)
0.3
"5 mg/kg per day) or placebo for the next week, and then bid dosing (5."( Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.
Cantwell, E; Cook, EH; Davanzo, PA; Dourish, CT; Dykens, EM; Handen, BL; Hooper, SR; Jaselskis, CA; King, BH; Leventhal, BL; Levitt, J; Lord, C; Lubetsky, MJ; McMahon, W; Myers, SM; Ozonoff, S; Shah, BG; Shernoff, EW; Sikich, L; Snape, M; Williamson, K; Wright, DM; Zimmerman, AW, 2001
)
0.57
"5 MU daily plus amantadine 200 mg/day for 4 weeks and then IFN 6 MU thrice weekly plus amantadine 200 mg/day for an additional 5 months (group A) or (ii) IFN alone at the same dosage and duration (group B)."( Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study.
Ascione, T; Budillon, G; Cimino, L; Gaeta, GB; Pasquazzi, C; Piccinino, F; Stanzione, M; Stornaiuolo, G; Taliani, G, 2001
)
0.97
" A clear adjuvant dose-response relationship was observed on the increment of Ova-specific serum antibody titers when AdDP was used as adjuvant, irrespectively of the administration route."( Adamantylamide dipeptide as effective immunoadjuvant in rabbits and mice.
Becker, PD; Corral, RS; Grinstein, S; Guzmán, CA, 2001
)
0.31
" We characterized the effects of amantadine and bromocriptine on PPI across species, assessing: (1) dose-response effects on PPI in rats over 10- to 120-ms prepulse intervals; (2) drug effects on PPI in humans, using this same range of prepulse intervals; and (3) drug effects on measures related to PPI, including PPI of perceived stimulus intensity (PPIPSI), and startle habituation."( Effects of amantadine and bromocriptine on startle and sensorimotor gating: parametric studies and cross-species comparisons.
Auerbach, PP; Ross, L; Shoemaker, JM; Stephany, N; Swerdlow, NR; Talledo, J; Wasserman, LC, 2002
)
0.99
" The dosage was increased to 300 mg on September 18 because there was no improvement and no side effects."( Amantadine-induced multiple spike waves on an electroencephalogram of a schizophrenic patient.
Kojima, T; Matsushima, E; Matsuura, M; Ohta, K; Toru, M, 2000
)
1.75
"We tested the hypothesis that individualized dosing of amantadine hydrochloride, based upon a patient's creatinine clearance, would maintain efficacy against influenza A infection while reducing adverse reactions to the drug."( An amantadine hydrochloride dosing program adjusted for renal function during an influenza outbreak in elderly institutionalized patients.
Campbell, G; Kolbe, F; Papaioannou, A; Sitar, DS, 2003
)
1.19
" We investigated triple combination treatment with induction dosing of interferon-alpha plus ribavirin plus amantadine in these difficult-to-treat patients."( Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine.
Datz, C; Hackl, F; Hegenbarth, K; Hofer, H; Jessner, W; Peter, F; Schütze, K; Stauber, RE; Steindl-Munda, P, 2004
)
0.74
" The side effects were reversed when the medication was stopped or the dosage decreased."( Amantadine in pediatric patients with traumatic brain injury: a retrospective, case-controlled study.
Green, LB; Hornyak, JE; Hurvitz, EA, 2004
)
1.77
" Although amantadine has a lower acquisition cost than oseltamivir, it is associated with more adverse events, lower efficacy, and individualized dosing requirements, leading to higher overall costs and more influenza-like illness cases than oseltamivir."( Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities.
Bowles, SK; McGeer, A; Oh, PI; Risebrough, NA; Simor, AE, 2005
)
0.73
" Wearing-off can be treated by dietary manipulation, shortening the dosing interval, substituting sustained-release levodopa, adding amantadine, or monoamine oxidase type B inhibitors, and other options, including catechol-O-methyltransferase inhibitors and the approved dopamine agonists addressed in another chapter."( Other pharmacological treatments for motor complications and dyskinesias.
Waters, C, 2005
)
0.53
" No interference could be observed from the excipients commonly present in dosage forms."( Simple fluorimetric method for determination of certain antiviral drugs via their oxidation with cerium (IV).
Askal, HF; Darwish, IA; Khedr, AS; Mahmoud, RM,
)
0.13
" Further investigations are needed to define optimal dosing and formulation of amantadine, and its appropriate role in management of CHC infection."( Amantadine in treatment of chronic hepatitis C virus infection?
Cheung, RC; Lim, JK; Siegel, R; Wooten, D, 2005
)
2
" Only amantadine preparations are available on our local market, and application of the method to the analysis of amantadine in formulation and in the urine of a dosed subject was demonstrated and proved feasible."( Fluorimetric liquid chromatographic analysis of amantadine in urine and pharmaceutical formulation.
Duh, TH; Kou, HS; Pan, CW; Wu, HL, 2005
)
1.06
" Medication dosage was increased over 4 weeks, weaned over 2 weeks, and then discontinued."( Dopamine agonist therapy in low-response children following traumatic brain injury.
Blackman, JA; Buck, ML; Conaway, MR; Gurka, MJ; Mabry, JL; Patrick, PD, 2006
)
0.33
" Because no prospective data exist on the efficacy of these agents in humans for H5N1 strains, the dosage and duration of therapy in adults and children may differ from those documented to be effective for epidemic influenza strains."( Antiviral therapy and prophylaxis for influenza in children.
, 2007
)
0.34
" Therefore, their interchangeable use cannot be advocated in the dosing of medications until further prospective validations are performed."( Use of GFR equations to adjust drug doses in an elderly multi-ethnic group--a cautionary tale.
Djurdjev, O; Gill, J; Levin, A; Malyuk, R, 2007
)
0.34
" Dosage use and side effect profiles were consistent with expected norms."( Amantadine treatment following traumatic brain injury in children.
Williams, SE, 2007
)
1.78
" Dose-response curves were generated for all drug combinations, and the degree of drug interaction was quantified using a model that calculates the synergy (or antagonism) between the drugs in double and triple combinations."( Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.
Driebe, EM; Engelthaler, DM; Hoopes, JD; Keim, PS; Le, MH; Nguyen, JT; Prichard, MN; Smee, DF; Spence, RP; Went, GT, 2009
)
0.63
" Notably, drug dosage and the measure chosen to assess outcome influenced the probability of finding a treatment benefit."( Impact of early pharmacological treatment on cognitive and behavioral outcome after traumatic brain injury in adults: a meta-analysis.
Mathias, JL; Vink, R; Wheaton, P, 2009
)
0.35
" Based on the preliminary data, higher dosing may be considered in the setting of brain injury."( Pharmacokinetics of amantadine in children with impaired consciousness due to acquired brain injury: preliminary findings using a sparse-sampling technique.
Bean, J; McMahon, MA; Michaud, LJ; Vargus-Adams, JN; Vinks, AA, 2010
)
0.68
" We present the results of our own study on the effect of amantadine sulfate, prescribed in the dosage of 300 mg during 6 months, on cognitive disorders in 25 PD patients."( [The effect of amantadine sulfate on cognitive disorders in patients with Parkinson's disease].
Bel'gusheva, ME; Fedorova, NV; Iablonskaia, AIu, 2010
)
0.96
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" This case report serves as a reminder of the importance that patients receive their anti-Parkinsonian medications perioperatively, and highlights the potential benefits of inserting a gastric tube to continue anti-Parkinson's medication dosing during prolonged surgery."( Nasogastric medication for perioperative Parkinson's rigidity during anaesthesia emergence.
Grice, T; Stagg, P, 2011
)
0.37
" Based on the significant quenching of the supramolecular complex fluorescence intensity, a fluorescent probe method of high sensitivity and selectivity was developed to determine AMA or RIM in their pharmaceutical dosage forms and in urine samples with good precision and accuracy."( Determination of amantadine and rimantadine using a sensitive fluorescent probe.
Chang, YX; Du, LM; Jing, X; Li, JF; Qin, YF; Wang, GQ; Wu, H, 2012
)
0.72
" Median amantadine dosage was 100 mg twice daily, and treatment duration was 20 months (range, 6-66 months)."( Amantadine for freezing of gait in patients with Parkinson disease.
Borushko, E; Malkani, R; Melen, O; Simuni, T; Videnovic, A; Zadikoff, C,
)
2.01
" Amantadine or saline control was administered intraperitoneally, starting at 1 h after TBI followed by dosing three times daily for 16 consecutive days at 15, 45, and 135 mg/kg/day."( Amantadine improves cognitive outcome and increases neuronal survival after fluid percussion traumatic brain injury in rats.
Huang, XJ; Lyeth, BG; Nguyen, JT; Van, KC; Wang, T; Went, GT, 2014
)
2.76
" Staff familiarity with Parkinson disease, and especially carbidopa-levodopa dosing and dynamics, may prevent such problems and streamline hospital and nursing home care."( Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.
Ahlskog, JE, 2014
)
0.4
" While fractionation of levodopa dosage is the most frequently utilized strategy, many patients require deep brain stimulation to control their troublesome motor fluctuations and LIDs."( Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.
Jankovic, J; Vijayakumar, D, 2016
)
0.43
" For reasons that are not entirely understood, abrupt changes in amantadine dosage can produce a severe withdrawal syndrome."( The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status.
Fox, J; Fryml, LD; Pelic, CG; Revuelta, GJ; Robert, S; Sahlem, G; Short, EB; Williams, KR, 2017
)
1.07
" The dose-response curves were constructed after intrathecally injecting the rats with five doses of 2-adamantanamine and a common local anesthetic mepivacaine."( 2-Adamantanamine produces prolonged spinal block in rats.
Chen, CM; Chen, YW; Hung, CH; Liu, KS; Wang, JJ, 2017
)
0.46
" Two groups received either 20 or 40 µl/kg body weight/day Zataria multiflora essential oils (ZM) seven days before the challenge while two other groups received the essential oil at the same dosage but after H9N2 challenge."( Zataria multiflora essential oil reduces replication rate of avian influenza virus (H9N2 subtype) in challenged broiler chicks.
Barin, A; Ghalyanchilangeroudi, A; Karimi, V; Shayeganmehr, A; Vasfi Marandi, M, 2018
)
0.48
" ADS-5102 is an extended release amantadine capsule formulation, designed for once-daily dosing at bedtime (qhs) to provide high concentrations upon waking and throughout the day, with lower concentrations in the evening."( Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia.
Hauser, RA; Johnson, R; McClure, N; Nguyen, JT; Pahwa, R; Patni, R; Souza-Prien, CJ; Wargin, WA; Went, GT, 2019
)
1.08
" These results indicate that dosing should be carefully considered when assessing the effects of pharmacotherapies after TBI so that potential benefits are not inadvertently missed."( Dose-dependent neurorestorative effects of amantadine after cortical impact injury.
Bao, GC; Bleimeister, IH; Bondi, CO; Cheng, JP; Helkowski, MS; Kline, AE; Lam, TR; Okigbo, AA; Royes, BJ, 2019
)
0.78
" Analysis of changes in the patients with PD based on the daily dosage of amantadine showed greater change in endothelial parameters in patients who were on 400 mg amantadine."( Corneal Evaluation in Patients With Parkinsonism on Long-Term Amantadine Therapy.
Daggumilli, S; Ganger, A; Goyal, V; Tandon, R; Vanathi, M, 2019
)
0.99
" Micro-sampling strategies, like dried plasma spot, would be particularly useful because ambulatory patients that do not attend a clinic can easily sample a few drops of blood by themselves at the required time of the dosing interval."( Amantadine hydrochloride monitoring by dried plasma spot technique: High-performance liquid chromatography-tandem mass spectrometry based clinical assay.
Huang, J; Jiang, Y; Li, Y; Li, Z; Lin, T; Wan, Q; Xu, G; Yang, X, 2020
)
2
"To describe dosing practices for amantadine hydrochloride and related adverse effects among children and young adults with traumatic brain injury (TBI) admitted to pediatric inpatient rehabilitation units."( Prescribing Patterns of Amantadine During Pediatric Inpatient Rehabilitation After Traumatic Brain Injury: A Multicentered Retrospective Review From the Pediatric Brain Injury Consortium.
Baum, KT; Blackwell, LS; Caliendo, E; Hoskinson, KR; Koterba, CH; Kurowski, B; Lowder, R; McLaughlin, MJ; Shah, SA; Suskauer, SJ; Tlustos, SJ; Watson, WD; Zimmerman, KO,
)
0.72
" Dosing varied widely, with weight-based dosing for younger/smaller children at both lower and higher doses than what had been previously reported."( Prescribing Patterns of Amantadine During Pediatric Inpatient Rehabilitation After Traumatic Brain Injury: A Multicentered Retrospective Review From the Pediatric Brain Injury Consortium.
Baum, KT; Blackwell, LS; Caliendo, E; Hoskinson, KR; Koterba, CH; Kurowski, B; Lowder, R; McLaughlin, MJ; Shah, SA; Suskauer, SJ; Tlustos, SJ; Watson, WD; Zimmerman, KO,
)
0.44
"60%) at the maximum dosage of 100 ppm."( Larvicidal and repellent activity of N-methyl-1-adamantylamine and oleic acid a major derivative of bael tree ethanol leaf extracts against dengue mosquito vector and their biosafety on natural predator.
Al Farraj, DA; Ali, AM; Chellappandian, M; Elshikh, MS; Hunter, WB; Kalaivani, K; Karthi, S; Senthil-Nathan, S; Vasantha-Srinivasan, P; Veerabahu, C, 2022
)
0.72
" However prolonged administration and high dosing leads to the emergence of motor complications, which are involuntary movements, so called dyskinesia, and ‘OFF’ episodes."( GOCOVRI
Müller, T, 2022
)
0.72
" A retrospective review of electronic medical records was conducted by researchers and data were collected on the following measures: ordered psycho-pharmacological agents, frequency, dosing and duration of orders, whether each administered psycho-pharmacological agent was started before or after psychiatric consultation, and psycho-pharmacological agents prescribed upon discharge."( A descriptive analysis of pharmacological management of aggression and/or agitation in patients with traumatic brain injury in a Southwest Virginia inpatient population.
Kablinger, A; Lemelle, T; Rahmani, E; Sharp, H; Smarbafzadeh, E, 2022
)
0.72
" Amantadine will be administered intravenously for five days at a dosage of 100 mg bid."( Amantadine for NeuroenhaNcement in acutE patients Study - a protocol for a prospective pilot proof of concept phase IIb study in intensive and intermediate care unit patients (ANNES).
Adeyemi, K; Blum, C; Bösel, R; Brendel, B; Feil, K; Häberle, HA; Haug, I; Hofmann, A; Martus, P; Mengel, A; Rattay, TW; Riessen, R; Schwarz, P; Single, C; Siokas, V; Zago, M; Ziemann, U, 2023
)
3.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
antiviral drugA substance used in the prophylaxis or therapy of virus diseases.
antiparkinson drugA drug used in the treatment of Parkinson's disease.
dopaminergic agentA drug used for its effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.
analgesicAn agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms.
NMDA receptor antagonistAny substance that inhibits the action of N-methyl-D-aspartate (NMDA) receptors. They tend to induce a state known as dissociative anesthesia, marked by catalepsy, amnesia, and analgesia, while side effects can include hallucinations, nightmares, and confusion. Due to their psychotomimetic effects, many NMDA receptor antagonists are used as recreational drugs.
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
primary aliphatic amine
adamantanesCompounds containing an adamantane skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (41)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency0.87090.002541.796015,848.9004AID1347398
thioredoxin reductaseRattus norvegicus (Norway rat)Potency6.29730.100020.879379.4328AID588453; AID588456
RAR-related orphan receptor gammaMus musculus (house mouse)Potency33.49150.006038.004119,952.5996AID1159521
NFKB1 protein, partialHomo sapiens (human)Potency2.81840.02827.055915.8489AID895; AID928
GLI family zinc finger 3Homo sapiens (human)Potency0.98850.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency27.35740.000221.22318,912.5098AID743035; AID743063
signal transducer and activator of transcription 6, interleukin-4 inducedHomo sapiens (human)Potency100.00002.51199.410115.8489AID934
thyroid stimulating hormone receptorHomo sapiens (human)Potency6.30960.001318.074339.8107AID926; AID938
regulator of G-protein signaling 4Homo sapiens (human)Potency0.84290.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency25.62520.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
estrogen nuclear receptor alphaHomo sapiens (human)Potency33.49150.000229.305416,493.5996AID743079
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.18890.035520.977089.1251AID504332
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency33.49150.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency13.33220.042027.378961.6448AID743210
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency16.13660.005612.367736.1254AID624032
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency15.84890.891312.067628.1838AID1487
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.63100.009610.525035.4813AID1479145
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency3.01310.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 2Homo sapiens (human)IC50 (µMol)23.00000.40003.10009.7000AID682000
Glutamate receptor ionotropic, NMDA 2DHomo sapiens (human)Ki10.50000.00120.70256.0000AID156805
Glutamate receptor ionotropic, NMDA 3BHomo sapiens (human)Ki10.50000.00120.70256.0000AID156805
Matrix protein 2Influenza A virus (A/udorn/1972(H3N2))IC50 (µMol)109.86004.70004.70004.7000AID1056009; AID1156033; AID1281069; AID1409732; AID1409733
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)160.57140.00071.600310.0000AID1181437; AID1909434; AID388526; AID388528; AID416368; AID456466; AID456467
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)160.57140.00071.630610.0000AID1181437; AID1909434; AID388526; AID388528; AID416368; AID456466; AID456467
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)180.66670.00061.525710.0000AID1181437; AID388526; AID388528; AID416368; AID456466; AID456467
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)180.66670.00071.747210.0000AID1181437; AID388526; AID388528; AID416368; AID456466; AID456467
Glutamate receptor ionotropic, NMDA 1Homo sapiens (human)Ki10.50000.00120.48246.0000AID156805
Glutamate receptor ionotropic, NMDA 2AHomo sapiens (human)Ki10.50000.00120.62056.0000AID156805
Glutamate receptor ionotropic, NMDA 2BHomo sapiens (human)Ki10.50000.00120.32686.0000AID156805
Glutamate receptor ionotropic, NMDA 2CHomo sapiens (human)Ki10.50000.00120.70256.0000AID156805
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)180.66670.00071.741110.0000AID1181437; AID388526; AID388528; AID416368; AID456466; AID456467
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)IC50 (µMol)285.43330.18003.68578.8000AID678995; AID678996; AID679317
Glutamate receptor ionotropic, NMDA 3AHomo sapiens (human)Ki10.50000.00120.70256.0000AID156805
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)180.66670.00071.741110.0000AID1181437; AID388526; AID388528; AID416368; AID456466; AID456467
Multidrug and toxin extrusion protein 1Homo sapiens (human)IC50 (µMol)37.80000.01002.765610.0000AID721754
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)IC50 (µMol)256.96671.00004.446710.0000AID678968; AID678969; AID679293
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)180.66670.00071.741110.0000AID1181437; AID388526; AID388528; AID416368; AID456466; AID456467
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Matrix protein 2Influenza A virus (A/Puerto Rico/8/1934(H1N1))Kd0.32000.01600.89872.3600AID489224
Matrix protein 2Influenza A virus (A/udorn/1972(H3N2))EC50 (µMol)0.66000.66000.66000.6600AID1418309; AID1637796
Matrix protein 2Influenza A virus (A/udorn/1972(H3N2))Kd58.29250.51004.67009.0000AID1409720; AID1409737; AID1409745; AID1438098
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 2Homo sapiens (human)Km27.00000.02891.04072.6000AID679500
Solute carrier family 22 member 1 Homo sapiens (human)Activity18.40000.71005.30179.7000AID681117
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (108)

Processvia Protein(s)Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic processSolute carrier family 22 member 2Homo sapiens (human)
positive regulation of gene expressionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
monoatomic cation transportSolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin transportSolute carrier family 22 member 2Homo sapiens (human)
body fluid secretionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 2Homo sapiens (human)
amine transportSolute carrier family 22 member 2Homo sapiens (human)
putrescine transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transportSolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 2Homo sapiens (human)
choline transportSolute carrier family 22 member 2Homo sapiens (human)
dopamine transportSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 2Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
histamine transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 2Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
amino acid import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
L-arginine import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
export across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
L-alpha-amino acid transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
startle responseGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
adult locomotory behaviorGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of sensory perception of painGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
cellular response to L-glutamateGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
protein insertion into membraneGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
regulation of calcium ion transportGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
calcium ion transmembrane transportGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
uncoating of virusMatrix protein 2Influenza A virus (A/Puerto Rico/8/1934(H1N1))
cellular response to amyloid-betaGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
monoatomic cation transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
visual learningGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of calcium ion transport into cytosolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
propylene metabolic processGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of membrane potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein heterotetramerizationGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion homeostasisGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of reactive oxygen species biosynthetic processGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
response to glycineGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
cellular response to amyloid-betaGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
startle responseGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to amphetamineGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
learning or memoryGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
memoryGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
visual learningGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to xenobiotic stimulusGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to woundingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
sensory perception of painGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
neurogenesisGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein catabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
sleepGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
directional locomotionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
negative regulation of protein catabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
dopamine metabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
serotonin metabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of apoptotic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
activation of cysteine-type endopeptidase activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein localization to postsynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
learning or memoryGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
protein heterotetramerizationGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
negative regulation of dendritic spine maintenanceGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
response to woundingGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
directional locomotionGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
negative regulation of protein catabolic processGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
neuromuscular process controlling balanceGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
protein localization to postsynaptic membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
calcium ion transportGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
dendrite developmentGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
rhythmic processGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
prepulse inhibitionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
negative regulation of dendritic spine developmentGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
calcium ion transmembrane transportGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
xenobiotic transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
amino acid import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-alpha-amino acid transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (48)

Processvia Protein(s)Taxonomy
amine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-amino acid transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
choline transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
efflux transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
voltage-gated monoatomic cation channel activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
calcium channel activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
monoatomic cation channel activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
neurotransmitter receptor activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
glutamate receptor activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
proton transmembrane transporter activityMatrix protein 2Influenza A virus (A/Puerto Rico/8/1934(H1N1))
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calmodulin bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein-containing complex bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
signaling receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
ligand-gated monoatomic ion channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
zinc ion bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
zinc ion bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
calcium channel activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
identical protein bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
protein phosphatase 2A bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
glutamate receptor activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
protein bindingMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-amino acid transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
membraneSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 2Homo sapiens (human)
presynapseSolute carrier family 22 member 2Homo sapiens (human)
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
presynaptic active zone membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
hippocampal mossy fiber to CA3 synapseGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
neuronal cell bodyGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
extracellular regionMatrix protein 2Influenza A virus (A/Puerto Rico/8/1934(H1N1))
plasma membraneMatrix protein 2Influenza A virus (A/Puerto Rico/8/1934(H1N1))
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
cytoplasmGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic vesicleGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
dendriteGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic cleftGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
terminal boutonGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
dendritic spineGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic vesicleGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cytoplasmic vesicle membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
presynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
dendritic spineGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cytoplasmGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
lysosomeGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
late endosomeGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
cytoskeletonGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
neuronal cell bodyGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
presynapseGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
basolateral plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (709)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1409736Inhibition of Influenza A virus A/Udorn/72 wild-type M2 proton channel expressed in Xenopus laevis oocytes assessed as dissociation constant at pH 5.5 by two-electrode voltage clamp assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1130404Antiviral activity against Influenza virus A2/Asian/J305 infected in mouse assessed as survival at 50 mg/kg, ip administered 3 doses on day of viral infection followed by 2 doses on next day and single dose per day for next 2 days relative to control1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Adamantylthiourea derivatives as antiviral agents.
AID105960Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in madin-Darby canine kidney cells (MDCK)2001Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16
Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus-identification of aminoadamantane derivatives bearing two pharmacophoric amine groups.
AID1360696Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as protection against virus-induced reduction in cell viability after 3 to 6 days by MTS assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
AID313148Reduction in post-surgical neuropathic pain intensity in cancer patient2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
N-methyl-D-aspartate antagonists and neuropathic pain: the search for relief.
AID768212Cytotoxicity against MDCK cells assessed as cell viability after 4 days by MTS assay2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID681999TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Amantadine: 100 uM) in OCT2A-expressing HEK293 cells2002Journal of the American Society of Nephrology : JASN, Jul, Volume: 13, Issue:7
cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
AID744866Cytotoxicity against MDCK cells by MTT assay2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1055987Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) harboring M2 channel S31N and V27T mutant infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by MTS assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1156046Cytotoxicity against MDCK cells assessed as alteration in cell morphology after 72 hrs2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID548442Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID1505281Antiviral activity against Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 48 hrs by microscopic analysis2018Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12
Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses.
AID105770Inhibitory concentration against influenza virus B in MDCK cells1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Synthesis and antiviral activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9-dideazapurine) derivatives.
AID1210304Induction of human PMAT activity expressed in Xenopus laevis oocytes assessed as induction of inward current at 2.5 mM in NaCl buffer at pH 7.5 by two-microelectrode voltage-clamp method2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.
AID105956Antiviral activity against influenza A virus (Taiwan) in Madin Darby canine kidney (MDCK) cell culture1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiviral activity of metabolites of rimantadine.
AID1637796Inhibition of wild type Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) M2 expressed in yeast cells after 46 to 48 hrs2019MedChemComm, Jan-01, Volume: 10, Issue:1
Design and synthesis of heteroaromatic-based benzenesulfonamide derivatives as potent inhibitors of H5N1 influenza A virus.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID733264Antiviral activity against Influenza B virus (B/Brisbane/60/2008) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis2013European journal of medicinal chemistry, Apr, Volume: 62Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.
AID1418304Cytotoxicity against MDCK cells assessed as reduction in cell viability after 24 hrs by MTT assay2018European journal of medicinal chemistry, Nov-05, Volume: 159Synthesis and structure-activity relationship study of arylsulfonamides as novel potent H5N1 inhibitors.
AID1438087Binding affinity to synthetic Influenza A virus (A/Udorn/307/72) M2 transmembrane domain S31N mutant (22 to 46 residues) in DMPC lipid bilayer assessed as shift in helical shift angle by OS ssNMR spectral analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1280345Cytotoxicity against MDCK cells after 40 hrs by Celltiter-Glo assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID387576Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTS assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure.
AID1152165Antiviral activity against Influenza A virus A2/Taiwan/1/64(H2N2) infected in MDCK cells expressing wild type M2 after overnight incubation by fluorescence-based miniplaque assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID18737Selectivity of guest-induced changes in membrane potential at pH 5.0 for PVC matrix liquid membranes incorporated with o-Tolyloxy-acetic acid decyl ester polymer1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Dopamine-selective response in membrane potential by homooxacalix[3]arene triether host incorporated in PVC liquid membrane.
AID1202562Octanol-water partition coefficient, log P of the compound2015European journal of medicinal chemistry, , Volume: 96New polycyclic dual inhibitors of the wild type and the V27A mutant M2 channel of the influenza A virus with unexpected binding mode.
AID416785Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1485245Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1210303Induction of human PMAT activity expressed in Xenopus laevis oocytes assessed as induction of inward current at 2.5 mM in NaCl buffer at pH 6 by two-microelectrode voltage-clamp method2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.
AID1055983Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by MTS assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID395327Dissociation constant, pKa by capillary electrophoresis2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1181483Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID1637793Selectivity index, ratio of CC50 for MDCK cells to EC50 for amantadine-sensitive Influenza A virus (A/chicken/Hubei/327/2004(H5N1))2019MedChemComm, Jan-01, Volume: 10, Issue:1
Design and synthesis of heteroaromatic-based benzenesulfonamide derivatives as potent inhibitors of H5N1 influenza A virus.
AID548444Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID658750Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID712816Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID1409739Irreversible inhibition of Influenza A virus A/Udorn/72 M2 proton channel V28I mutant expressed in Xenopus laevis oocytes at pH 5.5 by two-electrode voltage clamp assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1113454Antiviral activity against Unidentified Influenza A virus (H1N1) infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4
Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID1650129Antiviral activity against IInfluenza A virus H3N2 A/HK/7/87 infected in MDCK cells after 4 days by MTS assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones.
AID105799Tested for minimum inhibitory concentration required to cause a microscopically detectable alteration of normal cell morphology by 50% on MDCK cell line1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID395324Lipophilicity, log D at pH 7.4 by liquid chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID26110pKa value of compound was calculated by the method of clarke1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1150286Acute toxicity in po dosed albino CFW mouse assessed as mortality measured over 48 hrs1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Adamantane and protoadamantanealkanamines as potential anti-Parkinson agents.
AID1056003Inhibition of Influenza A virus Udorn/72 M2 ion channel V27A mutant expressed in Xenopus oocyte plasma membranes at 100 uM after 2 mins by two-electrode voltage clamp assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID478320Antiviral activity against influenza A virus H1N1 assessed as inhibition of viral induced cytopathic effect2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
AID1485246Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1113453Antiviral activity against Influenza A virus H3N2 infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4
Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID1408329Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells after 3 days by MTS assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1418309Inhibition of wild type Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) M2 channel expressed in yeast after 46 to 48 hrs by yeast growth restoration assay2018European journal of medicinal chemistry, Nov-05, Volume: 159Synthesis and structure-activity relationship study of arylsulfonamides as novel potent H5N1 inhibitors.
AID1456573Cytotoxicity against MDCK cells assessed as cell death by MTT assay2017Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10
Synthesis of camphecene derivatives using click chemistry methodology and study of their antiviral activity.
AID105957Antiviral activity against influenza B virus (Ann Arbor) in Madin Darby canine kidney (MDCK) cell culture1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiviral activity of metabolites of rimantadine.
AID1505280Antiviral activity against Influenza A virus (A/WSN/33 (H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 48 hrs by microscopic analysis2018Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12
Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses.
AID456466Antagonist activity at NMDA receptor in rat cerebellar granule neurons assessed as inhibition of glutamate-induced increase in intracellular calcium level by fluorometric assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities.
AID1055984Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by microsocopic analysis2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1056004Inhibition of Influenza A virus Udorn/72 M2 ion channel S31N mutant expressed in Xenopus oocyte plasma membranes after 2 mins by two-electrode voltage clamp assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1130413Antiviral activity against Semliki forest virus infected in ip dosed mouse assessed as protection against viral infection1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Adamantylthiourea derivatives as antiviral agents.
AID111366Stimulation of spontaneous locomotor activity of compound was measured in mice at a dose of 0.4 mmol/kg)1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID1156032Inhibition of wild type Influenza A virus (A/udorn/72(H3N2)) M2 channel expressed in Xenopus oocyte plasma membrane at 100 uM incubated for 2 mins measured over 48 to 72 hrs by two-electrode voltage clamp method relative to control2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID1637792Cytotoxicity against MDCK cells assessed as reduction in cell viability after 24 hrs by MTT assay2019MedChemComm, Jan-01, Volume: 10, Issue:1
Design and synthesis of heteroaromatic-based benzenesulfonamide derivatives as potent inhibitors of H5N1 influenza A virus.
AID1485250Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1) infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1438099Binding affinity to Influenza virus A (A/Udorn/72 (H3N2)) M2 protein at pH 7.5 in presence of KCl by electrophysiology method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID105953Antiviral activity against influenza A virus (Mississippi) in Madin Darby canine kidney (MDCK) cell culture1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiviral activity of metabolites of rimantadine.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1150287Acute toxicity in ip dosed albino CFW mouse assessed as mortality measured over 48 hrs1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Adamantane and protoadamantanealkanamines as potential anti-Parkinson agents.
AID1237860Displacement of [3H]-(+)-MK-801 from phencyclidine binding site of NMDA receptor in human frontal cortex after 22 hrs by scintillation counting analysis2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Stereoselective synthesis and pharmacological evaluation of [4.3.3]propellan-8-amines as analogs of adamantanamines.
AID1438104Binding affinity to synthetic Influenza A virus (A/Udorn/307/72) M2 transmembrane domain S31N mutant (22 to 46 residues) in DPC micelles assessed as deltaH values measured at pH 8 by ITC method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1636440Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID604213Antioxidant activity assessed as inhibition of ABTS free radicals at 0.01 mM after 30 mins by UV-visible spectrophotometer analysis relative to control2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
AID1156050Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID1183506Antiviral activity against Influenza A virus A/Texas/48/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.
AID620265Antagonist activity at voltage gated calcium channel in Sprague-Dawley rat striatal synaptoneurosomes assessed as inhibition of KCl-induced calcium flux at 100 uM by spectrofluorimetric analysis relative to control2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis, evaluation and application of polycyclic fluorescent analogues as N-methyl-D-aspartate receptor and voltage gated calcium channel ligands.
AID156805The compound was tested for its ability to block PCP N-methyl-D-aspartate glutamate receptor at the PCP (phencyclidine) binding site in postmortem human frontal cortex.1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site.
AID1438098Binding affinity to Influenza A virus M2 transmembrane domain by analytical ultracentrifugation method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1438096Cytotoxicity against MDCK cells measured after 72 hrs et staining-based microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1485249Antiviral activity against Influenza A virus A/Ned/378/05(H1N1) infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1418303Antiviral activity against Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) infected in MDCK cells after 40 mins by crystal violet staining-based plaque reduction assay2018European journal of medicinal chemistry, Nov-05, Volume: 159Synthesis and structure-activity relationship study of arylsulfonamides as novel potent H5N1 inhibitors.
AID1360699Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 3 to 6 days by MTS assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID416778Cytotoxicity against MDCK cells assessed as drug level causing microscopically detectable alteration of normal cell morphology2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1202563Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis2015European journal of medicinal chemistry, , Volume: 96New polycyclic dual inhibitors of the wild type and the V27A mutant M2 channel of the influenza A virus with unexpected binding mode.
AID1610161Cytotoxicity against dog MDCK cells assessed as minimum cytotoxic concentration by observing alteration in cell morphology incubated for 3 days by microscopic analysis2019European journal of medicinal chemistry, Dec-15, Volume: 184Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID1317463Antiviral activity against Influenza A virus A/Puerto Rico/8/34 expressing wild type M2 proton channel infected in MDCK cells assessed as inhibition of viral replication at >= 0.8 uM measured after 10 hrs by miniplaque assay2016European journal of medicinal chemistry, Sep-14, Volume: 120Novel spirothiazamenthane inhibitors of the influenza A M2 proton channel.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1409744Inhibition of Influenza A virus A/Udorn/72 M2 proton channel S31N mutant expressed in Xenopus laevis oocytes assessed as dissociation constant at pH 5.5 by two-electrode voltage clamp assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1438092Inhibition of Influenza A virus (A/California/07/2009(H1N1)) M2 proton channel S31N mutant expressed in HEK cells assessed as inhibition of low-pH-dependent inward proton currents at 10 uM and pH 5.5 measured after 3 mins in presence of CaCl2 by electroph2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1571468Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay2018MedChemComm, Dec-01, Volume: 9, Issue:12
Synthesis of d-(+)-camphor-based
AID416383Antitrypanosomal activity against Trypanosoma brucei 427 assessed as parasite growth inhibition after 48 hrs2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Synthesis and pharmacological evaluation of (2-oxaadamant-1-yl)amines.
AID536243Selectivity index, ratio of MCC for MDCK cells to EC50 for Influenza A virus (A/Hong Kong/7/1987(H3N2))2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Design and synthesis of bioactive adamantanaminoalcohols and adamantanamines.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1438085Binding affinity to synthetic wild-type Influenza A virus (A/Udorn/307/72) M2 transmembrane domain (22 to 46 residues) in DMPC lipid bilayer assessed as helical tilt angle for N-terminus by OS ssNMR spectral analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1236290Cytoprotective activity against MPP+-induced cell death in human SH-SY5Y cells assessed as increase in cell viability at 20 uM after 24 hrs by crystal violet assay2014MedChemComm, Oct-01, Volume: 5, Issue:10
Cytoprotective effects of hydrogen sulfide-releasing
AID1181481Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID1415635Cytotoxicity against MDCK cells after 48 hrs by MTT assay2017MedChemComm, May-01, Volume: 8, Issue:5
Synthesis and
AID1113452Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4
Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID679500TP_TRANSPORTER: uptake (electrogenesis) in Xenopus laevis oocytes1998Molecular pharmacology, Aug, Volume: 54, Issue:2
Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine.
AID1150316Antiparkinsonian activity in CFW mouse assessed as reversal of reserpine-induced catalepsy at 0.21 mmol/kg, sc measured every 30 mins up to 1.5 hrs1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Adamantane and protoadamantanealkanamines as potential anti-Parkinson agents.
AID766706Cytotoxicity against MDCK cells assessed as morphological changes2013European journal of medicinal chemistry, Sep, Volume: 67Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID86511Tested for minimum inhibitory concentration required to cause a microscopically detectable alteration of normal cell morphology by 50% on HeLa cell line1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID733269Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis2013European journal of medicinal chemistry, Apr, Volume: 62Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.
AID1545454Antiviral activity against Hepatitis A virus infected in HepG2 cells assessed as virus inhibition at 40 ug/L incubated overnight with virus followed by inoculation and measured after 1 hr by crystal violet staining based plaque reduction assay2019Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7
Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID658751Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID393165Selectivity index, ratio of MCC for MDCK cells to EC50 for influenza A virus H3N22009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1220557Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1505282Antiviral activity against Influenza A virus (A/PR/8/34 (H1N1)(NA-H274Y)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 48 hrs by microscopic analysis2018Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12
Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses.
AID388523Trypanocidal activity against Trypanosoma brucei 427 blood stream after 48 hrs by hemocytometer2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs.
AID1409724Antiviral activity against Influenza A virus A/WSN/33 H1N1 harboring N31S mutant infected in MDCK cells assessed as reduction in virus-induced cytopathic effect by crystal violet staining based light-microscopic analysis2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID679777TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: ? uM, Amantadine: 100 uM) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID1152158Blockade of Influenza A virus (A/England/195/2009(H1N1)) full length M2 proton channel expressed in HEK cells after 3 mins by voltage clamp technique2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID122562Modification of circling behavior in mice with unilateral striatal lesions produced by 6-hydroxydopamine injection was measured at a dose of 0.2 mmol/kg1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID1150302Antidepressant activity in CFW mouse assessed as reversal of reserpine-induced hypothermia by measuring temperature index at 0.21 mmol/kg, sc measured every 30 mins up to 1.5 hrs1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Adamantane and protoadamantanealkanamines as potential anti-Parkinson agents.
AID733265Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis2013European journal of medicinal chemistry, Apr, Volume: 62Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.
AID1150324Antiparkinsonian activity in Wistar rat assessed as reversal of reserpine-induced catalepsy at 0.21 mmol/kg, po measured every 30 mins up to 1.5 hrs1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Adamantane and protoadamantanealkanamines as potential anti-Parkinson agents.
AID582757Antiviral activity against Influenza A virus/NWS/1933(H1N1) infected in BALB/c mouse assessed as reduction in mortality rate at 2 mg, ip administered once daily for 10 days and dosed 30 mins post infection relative to untreated control2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID596929Inhibition of Influenza A virus (A/Udorn/72) matrix protein 2 V27A mutant expressed in xenopus oocytes after 2 mins by two-electrode voltage clamp assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.
AID744868Antiviral activity against H5N1 subtype infected in MDCK cells2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism.
AID1317462Antiviral activity against Influenza A virus A/Puerto Rico/8/34 expressing wild type M2 proton channel infected in MDCK cells assessed as inhibition of viral replication measured after 10 hrs by miniplaque assay2016European journal of medicinal chemistry, Sep-14, Volume: 120Novel spirothiazamenthane inhibitors of the influenza A M2 proton channel.
AID1156036Inhibition of amantadine-resistant Influenza A virus (A/udorn/72(H3N2)) M2 V27A mutant channel expressed in Xenopus oocyte plasma membrane at 100 uM incubated for 2 mins measured over 48 to 72 hrs by two-electrode voltage clamp method relative to control2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1156042Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID1505279Cytotoxicity against MDCK cells assessed as change in cell morphology after 48 hrs by microscopic analysis2018Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12
Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID1409738Irreversible inhibition of Influenza A virus A/Udorn/72 wild-type M2 proton channel expressed in Xenopus laevis oocytes at pH 5.5 by two-electrode voltage clamp assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1472387Antiviral activity against Influenza A virus (A/Virginia/ATCC3/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 72 hrs by microscopic method2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.
AID1130418Acute toxicity in ip dosed mouse measured for 24 hrs1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Adamantylthiourea derivatives as antiviral agents.
AID1610158Antiviral activity against Influenza A virus (A/Ned/378/05(H1N1)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by MTS assay2019European journal of medicinal chemistry, Dec-15, Volume: 184Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID1482891Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus.
AID604209Inhibition of nNOS in Sprague-Dawley rat brain homogenates assessed as conversion of oxyhemoglobin to methemoglobin measured for 10 mins by UV-visible spectrophotometer analysis2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
AID1220555Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1498142Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced visual cytopathicity2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID1611059Cytotoxicity against dog MDCK cells assessed as cell death incubated for 48 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Synthesis and structure-activity relationships of novel camphecene analogues as anti-influenza agents.
AID536238Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity by MTS assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Design and synthesis of bioactive adamantanaminoalcohols and adamantanamines.
AID1276986Antiviral activity against amantadine-resistant Influenza A virus A/WSN/33(H1N1) expressing M2 S31N mutant ion channel infected in MDCK cells assessed as protection against virus induced cytopathic effect after 48 hrs by microscopic analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Imidazole-based pinanamine derivatives: Discovery of dual inhibitors of the wild-type and drug-resistant mutant of the influenza A virus.
AID681946TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Amantadine: 100 uM) in OCT1-expressing HeLa cells1998The Journal of pharmacology and experimental therapeutics, Jul, Volume: 286, Issue:1
Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa).
AID1438103Binding affinity to synthetic Influenza A virus (A/Udorn/307/72) M2 transmembrane domain S31N mutant (22 to 46 residues) in DPC micelles assessed as deltaG values measured at pH 8 by ITC method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID717280Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1498139Cytotoxicity against MDCK cells assessed as alteration of cell morphology by microscopic analysis2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID443829Antiviral activity against Influenza A virus (A/Hong Kong/7/87(H3N2)) assessed as inhibition of virus-induced cytopathic effect by cell-based assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID18739Selectivity of guest-induced changes in membrane potential at pH 5.0 for PVC matrix liquid membranes incorporated with (2-Butoxy-5-tert-butyl-3-methyl-phenyl)-methanol polymer1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Dopamine-selective response in membrane potential by homooxacalix[3]arene triether host incorporated in PVC liquid membrane.
AID604212Antioxidant activity assessed as inhibition of DPPH free radicals at 1 mM after 30 mins by UV-visible spectrophotometer analysis relative to control2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
AID292396Antiviral activity against Influenza A virus (A/WSN/33/London (H1N1)) in MDCK cells after 72 hrs by neutral red dye uptake assy2007Journal of natural products, Jul, Volume: 70, Issue:7
Cyclic depsipeptides, ichthyopeptins A and B, from Microcystis ichthyoblabe.
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID105954Antiviral activity against influenza A virus (NY/83/5) in Madin Darby canine kidney (MDCK) cell culture1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiviral activity of metabolites of rimantadine.
AID393162Antiviral activity against influenza A virus H3N2 assessed as inhibition of virus-induced cytopathic effect after 72 hrs by MTS assay2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity.
AID604216Antioxidant activity assessed as inhibition of DPPH free radicals after 30 mins by UV-visible spectrophotometer analysis relative to control2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
AID1130407Antiviral activity against Influenza virus A2/Asian/J305 infected in mouse assessed as survival at 100 mg/kg, ip administered two doses at 48 hrs post viral infection followed by single dose for subsequent days relative to control1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Adamantylthiourea derivatives as antiviral agents.
AID1438100Binding affinity to synthetic wild-type C-terminally amidated Influenza A virus (A/Udorn/307/72) M2 transmembrane domain (22 to 46 residues) in DPC micelles assessed as deltaG values at pH 8 by ITC method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID658606Cytotoxicity against MDCK cells assessed as cell viability by colorimetric formazan-based MTS assay2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID729292Antiviral activity against influenza A virus A/WSN/33-S31N infected in dog MDCK cells after 2 days by naphthalene black dye staining based plaque reduction assay2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus.
AID105801Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on MDCK cell line infected with influenza B virus1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID548443Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID105955Antiviral activity against influenza A virus (NY/83/R6) in Madin Darby canine kidney (MDCK) cell culture1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiviral activity of metabolites of rimantadine.
AID1055980Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as concentration required to 2 log10 reduction of virus yield after 24 hrs by RT-PCR analysis2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1426030Antiviral activity against Influenza A virus (A/California/07/09(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 48 hrs by hemagglutination test2017European journal of medicinal chemistry, Feb-15, Volume: 127Aliphatic and alicyclic camphor imines as effective inhibitors of influenza virus H1N1.
AID1472390Cytotoxicity against MDCK cells assessed as effect on cell morphology after 72 hrs by microscopic method2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.
AID596932Cytotoxicity against MDCK cells after 72 hrs by MTS assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.
AID478323Antiviral activity against Influenza A virus H3N2 assessed as cell viability by cell based MTS assay2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
AID1418310Inhibition of wild type Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) M2 proton channel V27A/S31N mutant expressed in yeast after 46 to 48 hrs by yeast growth restoration assay2018European journal of medicinal chemistry, Nov-05, Volume: 159Synthesis and structure-activity relationship study of arylsulfonamides as novel potent H5N1 inhibitors.
AID658746Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID393164Cytotoxicity against MDCK cells assessed as changes in cell morphology after 72 hrs by MTS assay2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1409722Antiviral activity against Influenza A virus (A/Hong Kong/68(H3N2)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect by crystal violet staining based light-microscopic analysis2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID681623TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
The cation transporters rOCT1 and rOCT2 interact with bicarbonate but play only a minor role for amantadine uptake into rat renal proximal tubules.
AID388541Inhibition of [3H]dopamine uptake in Wistar rat striatum synaptosomes at 100 uM by scintillation spectrometry2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs.
AID1280362Antiviral activity against amantadine-resistant influenza A virus JX/312 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID1298254Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus-induced cytopathic effect measured after 4 days by formazan-based MTS assay2016Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11
1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID1571470Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells2018MedChemComm, Dec-01, Volume: 9, Issue:12
Synthesis of d-(+)-camphor-based
AID693525Antiviral activity against Influenza A/HK/7/87 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay2012European journal of medicinal chemistry, Dec, Volume: 58Synthesis of fluorescent ristocetin aglycon derivatives with remarkable antibacterial and antiviral activities.
AID1276984Antiviral activity against amantadine-sensitive Influenza A virus A/HK/68 (H3N2) expressing wild type M2 ion channel infected in MDCK cells assessed as protection against virus induced cytopathic effect after 48 hrs by microscopic analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Imidazole-based pinanamine derivatives: Discovery of dual inhibitors of the wild-type and drug-resistant mutant of the influenza A virus.
AID128983Anticataleptic activity for reversing the reserpine-induced catalepsy in mice.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and biological activity of D3-trishomocubyl-4-amines.
AID712796Cytotoxicity against dog MDCK cells assessed as cell morphology alterations2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID1280365Antiviral activity against Influenza A virus A/WSN/33 (H1N1) infected in dog MDCK cells assessed as plaque formation at 50 uM measured at sixth passage of multi passaging test by microscopic analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID388526Antagonist activity at NMDA receptor in cerebellar granule neurons assessed as inhibition of glutamate-induced increase in intracellular calcium concentration by fluorometric assay2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs.
AID87191Concentration that protects by 50% the cytopathic effect induced by herpes simplex virus - 1.1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Uridine 5'-diphosphate glucose analogues. Inhibitors of protein glycosylation that show antiviral activity.
AID718742Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID766686Antiviral activity against Influenza A virus H3N3 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity2013European journal of medicinal chemistry, Sep, Volume: 67Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID718740Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1130417Antiviral activity against Rhinovirus 42 infected in human WI38 cells assessed as growth inhibition after 7 days by tube dilution method1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Adamantylthiourea derivatives as antiviral agents.
AID693524Antiviral activity against Influenza A/PR/8/34 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay2012European journal of medicinal chemistry, Dec, Volume: 58Synthesis of fluorescent ristocetin aglycon derivatives with remarkable antibacterial and antiviral activities.
AID1055981Cytotoxicity against MDCK cells assessed as minimum cytotoxic concentration after 72 hrs by MTS assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1594041Inhibition of HAV protease 3C expressed in Escherichia coli BL21(DE3) pLysS using Dabcyl-GLRTQSND (edans) G as substrate preincubated for 3 mins before enzyme addition by fluorescence method2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
Anti-HAV evaluation and molecular docking of newly synthesized 3-benzyl(phenethyl)benzo[g]quinazolines.
AID1055982Cytotoxicity against MDCK cells after 72 hrs by MTS assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1113455Cytotoxicity against MDCK cells assessed as change in cellular morphology2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4
Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID402534Cytotoxicity against MDCK cells by neutral red assay1997Journal of natural products, Jun, Volume: 60, Issue:6
Two new lignans with activity against influenza virus from the medicinal plant Rhinacanthus nasutus.
AID1201116Cytotoxicity against MDCK cells after 72 hrs by MTS assay2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID1637794Antiviral activity against amantadine-resistant Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) infected in MDCK cells after 40 mins by crystal violet staining-based plaque reduction assay2019MedChemComm, Jan-01, Volume: 10, Issue:1
Design and synthesis of heteroaromatic-based benzenesulfonamide derivatives as potent inhibitors of H5N1 influenza A virus.
AID471279Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days by XTT assay2009Journal of natural products, Sep, Volume: 72, Issue:9
Influenza A (H(1)N(1)) Antiviral and Cytotoxic Agents from Ferula assa-foetida.
AID1610155Antiviral activity against Influenza A virus (A/Ned/378/05(H1N1)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis2019European journal of medicinal chemistry, Dec-15, Volume: 184Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID1276988Inhibition of Influenza A virus wild type M2 ion channel expressed in Xenopus oocytes at 100 uM after 2 mins by two-electrode voltage clamp assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Imidazole-based pinanamine derivatives: Discovery of dual inhibitors of the wild-type and drug-resistant mutant of the influenza A virus.
AID1456574Antiviral activity against rimantadine-resistant Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells2017Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10
Synthesis of camphecene derivatives using click chemistry methodology and study of their antiviral activity.
AID1220559Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID105963Anti-influenza virus activity was evaluated in Madin-Darby canine kidney (MDCK) cells against influenza A H2N2 strain (A2 Japan/305/57)1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Synthesis of 2-(2-adamantyl)piperidines and structure anti-influenza virus A activity relationship study using a combination of NMR spectroscopy and molecular modeling.
AID744865Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus (A/Vietnam/1194/2004(H5N1))2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism.
AID1237863Antiviral activity against Influenza virus A/FPV/Bratislava/79(H7N7) infected in human A549 cells assessed as viral replication at 5 uM after 24 hrs by plaque assay relative to control2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Stereoselective synthesis and pharmacological evaluation of [4.3.3]propellan-8-amines as analogs of adamantanamines.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1202566Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay2015European journal of medicinal chemistry, , Volume: 96New polycyclic dual inhibitors of the wild type and the V27A mutant M2 channel of the influenza A virus with unexpected binding mode.
AID311933Inhibition of ASM in rat PC12 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1298255Cytotoxicity against MDCK cells assessed as cell viability measured after 4 days by formazan-based MTS assay2016Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11
1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID539958Antiviral activity against influenza B virus infected in MDCK cells assessed as cell viability after 2 days by MTS assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1408333Cytotoxicity against MDCK cells assessed as alteration in cell morphology after 3 days by microscopic method2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1201121Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID721753Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1637801Antiviral activity against amantadine-sensitive Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) infected in MDCK cells assessed as reduction in early stage viral replication by measuring viral titer at 1.7 uM measured after 12 hrs by crystal violet sta2019MedChemComm, Jan-01, Volume: 10, Issue:1
Design and synthesis of heteroaromatic-based benzenesulfonamide derivatives as potent inhibitors of H5N1 influenza A virus.
AID1181437Antagonist activity at NMDA receptor in Wistar rat cerebellar granule neurons assessed as inhibition of NMDA-induced intracellular calcium by Fura-2 fluorescence assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Tryptophanol-derived oxazolopiperidone lactams: identification of a hit compound as NMDA receptor antagonist.
AID480112Inhibition of avian influenza virus H5N1 matrix 2 protein expressed in HEK293 cells assessed as cell viability after 24 hrs2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library.
AID596931Binding affinity to Influenza A virus (A/Udorn/72) transmembrane domain of matrix protein 2 (22 to 46) at pH 7.4 by circular dichroism analysis2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.
AID105800Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on MDCK cell line infected with influenza A virus1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID1505276Antiviral activity against Influenza A virus (A/Guangzhou/GIRD/07/2009 (H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 48 hrs by microscopic analysis2018Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12
Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses.
AID308659Selectivity index, ratio of EC50 for influenza A/Hong Kong/7/87 (H3N2) to MCC for MDCK cells2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Design and synthesis of bioactive adamantane spiro heterocycles.
AID1209593Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1650130Cytotoxicity against MDCK cells assessed as minimum cytotoxic concentration after 4 days by MTS assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones.
AID1183507Antiviral activity against Influenza A virus A/Puerto Rico/8/34 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.
AID1409742Inhibition of Influenza A virus A/Udorn/72 M2 proton channel S31N mutant expressed in Xenopus laevis oocytes assessed as blockade of inward currents at 100 uM at pH 5.5 after 10 mins by two-electrode voltage clamp assay relative to control2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1438105Binding affinity to synthetic Influenza A virus (A/Udorn/307/72) M2 transmembrane domain S31N mutant (22 to 46 residues) in DPC micelles assessed as TdeltaS values measured at pH 8 by ITC method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID388539Antiviral activity against influenza virus B/Hong Kong/5/72 in MDCK cells assessed as effect on virus-induced cytopathogenicity by MTS assay2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs.
AID1201117Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID1611058Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) pdm09 infected in MDCK cells assessed as inhibition of virus replication compound incubated with uninfected host cell for 1 hr followed by viral infection for 24 hrs measured after vi2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Synthesis and structure-activity relationships of novel camphecene analogues as anti-influenza agents.
AID548439Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID1408323Antiviral activity against Influenza A virus A/PR/8/34(H1N1) infected in MDCK cells after 3 days by MTS assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID443838Antiviral activity against Influenza B virus (B/Hong Kong/5/72) assessed as cell viability at subtoxic concentration by cell-based MTS assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID658748Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID1201122Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID1130412Antiviral activity against Herpes simplex virus infected in ip dosed mouse assessed as protection against viral infection1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Adamantylthiourea derivatives as antiviral agents.
AID1409731Inhibition of Influenza A virus A/Udorn/72 wild-type M2 proton channel expressed in Xenopus laevis oocytes assessed as blockade of inward currents at 100 uM at pH 5.5 after 10 mins by two-electrode voltage clamp assay relative to control2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID548437Cytotoxicity against MDCK cells assessed as cell viability by MTS assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID1181493Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID604211Antioxidant activity assessed as inhibition of DPPH free radicals at 0.1 mM after 30 mins by UV-visible spectrophotometer analysis relative to control2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1317460Antiviral activity against amantadine-sensitive Influenza A virus A/Hong Kong/1/68(H3N2) infected in MDCK cells assessed as protection from virus-induced cell death at 1 uM measured after 72 hrs by MTT assay2016European journal of medicinal chemistry, Sep-14, Volume: 120Novel spirothiazamenthane inhibitors of the influenza A M2 proton channel.
AID1220554Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID416783Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1201120Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID1152159Blockade of Influenza A virus (A/England/195/2009(H1N1)) full length M2 S31N mutant expressed in HEK cells at 100 uM after 3 mins by voltage clamp technique2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID1280364Antiviral activity against influenza B virus B/SZ/155 infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID134262Anti-oxotremorine activity (anticholinergic property) and reduction of tremor in mice at a dose of 100 mg/kg.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and biological activity of D3-trishomocubyl-4-amines.
AID1408325Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1pdm) infected in MDCK cells after 3 days by MTS assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1360698Cytotoxicity against MDCK cells assessed as alterations in normal cell morphology measured after 3 to 6 days by microscopic analysis2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
AID1152622Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 2 to 3 days by crystal violet staining-based plaque reduction assay2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Design, synthesis and biological evaluation of small molecular polyphenols as entry inhibitors against H(5)N(1).
AID1616107Inhibition of F1F0-ATP synthase in Escherichia coli after 60 mins2019European journal of medicinal chemistry, Nov-15, Volume: 182Recent advancements in mechanistic studies and structure activity relationship of F
AID717281Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID539957Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as cell viability after 2 days by MTS assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1152163Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells expressing M2 V27T/S31N mutant after overnight incubation by fluorescence-based miniplaque assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID712810Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID87444Concentration that induces 50% cell toxicity was determined using monolayers of uninfected HeLa cells1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Uridine 5'-diphosphate glucose analogues. Inhibitors of protein glycosylation that show antiviral activity.
AID1237859Displacement of [3H]-(+)-MK-801 from phencyclidine binding site of NMDA receptor in pig membranes after 150 mins by scintillation counting analysis2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Stereoselective synthesis and pharmacological evaluation of [4.3.3]propellan-8-amines as analogs of adamantanamines.
AID712807Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID416781Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID712812Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID1637795Antiviral activity against amantadine-sensitive Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) infected in MDCK cells after 40 mins by crystal violet staining-based plaque reduction assay2019MedChemComm, Jan-01, Volume: 10, Issue:1
Design and synthesis of heteroaromatic-based benzenesulfonamide derivatives as potent inhibitors of H5N1 influenza A virus.
AID478322Antiviral activity against Influenza A virus H3N2 assessed as inhibition of viral induced cytopathic effect2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
AID1426032Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 48 hrs by hemagglutination test2017European journal of medicinal chemistry, Feb-15, Volume: 127Aliphatic and alicyclic camphor imines as effective inhibitors of influenza virus H1N1.
AID539955Antiviral activity against influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID392525Antiviral activity against influenza B virus2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID1276985Antiviral activity against amantadine-sensitive Influenza A virus A/HK/68 (H3N2) expressing wild type M2 ion channel infected in MDCK cells assessed as cell viability after 48 hrs by MTT assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Imidazole-based pinanamine derivatives: Discovery of dual inhibitors of the wild-type and drug-resistant mutant of the influenza A virus.
AID1611060Selectivity index, ratio of CTD50 for dog MDCK cells to IC50 for Influenza A virus (A/Puerto Rico/8/34 (H1N1)) pdm09 infected in MDCK cells2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Synthesis and structure-activity relationships of novel camphecene analogues as anti-influenza agents.
AID1616108Inhibition of F1F0-ATP synthase in Escherichia coli after 60 mins relative to control2019European journal of medicinal chemistry, Nov-15, Volume: 182Recent advancements in mechanistic studies and structure activity relationship of F
AID1438093Inhibition of Influenza A virus (A/California/07/2009(H1N1)) M2 proton channel S31N mutant expressed in HEK cells assessed as inhibition of low-pH-dependent inward proton currents at pH 5.5 in presence of CaCl2 by electrophysiology method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID712808Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID1298244Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus induced cytopathic effect measured by visual scoring of cytopathic effect2016Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11
1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID548440Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID1426033Selectivity index, ratio of CTD50 for MDCK cells to ED50 for Influenza A virus (A/Puerto Rico/8/34(H1N1))2017European journal of medicinal chemistry, Feb-15, Volume: 127Aliphatic and alicyclic camphor imines as effective inhibitors of influenza virus H1N1.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID717171Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID1485251Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1) infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1201119Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID678968TP_TRANSPORTER: inhibition of TEA uptake (in the presence of bicarbonate) (TEA: 20 uM) in OCT2-expressing HEK293 cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
The cation transporters rOCT1 and rOCT2 interact with bicarbonate but play only a minor role for amantadine uptake into rat renal proximal tubules.
AID1505283Antiviral activity against Influenza A virus (A/HK/68(H3N2)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 48 hrs by microscopic analysis2018Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12
Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses.
AID18738Selectivity of guest-induced changes in membrane potential at pH 5.0 for PVC matrix liquid membranes incorporated with o-Tolyloxy-acetic acid ethyl ester polymer1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Dopamine-selective response in membrane potential by homooxacalix[3]arene triether host incorporated in PVC liquid membrane.
AID678996TP_TRANSPORTER: inhibition of TEA uptake (in the absence of bicarbonate) (TEA: 20 uM) in OCT1-expressing HEK293 cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
The cation transporters rOCT1 and rOCT2 interact with bicarbonate but play only a minor role for amantadine uptake into rat renal proximal tubules.
AID604214Antioxidant activity assessed as inhibition of ABTS free radicals at 0.1 mM after 30 mins by UV-visible spectrophotometer analysis relative to control2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
AID1408327Antiviral activity against Influenza A virus A/HK/7/87(H3N2) infected in MDCK cells after 3 days by MTS assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1472386Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 72 hrs by MTS assay2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.
AID1181485Cytotoxicity against MDCK cells assessed as change in cell morphology after 72 hrs by microscopy2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID1472385Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 72 hrs by microscopic method2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.
AID18740Selectivity of guest-induced changes in membrane potential at pH 5.0 for PVC matrix liquid membranes incorporated with 6,7,9,10,17,18,20,21-Octahydro-5,8,11,16,19,22-hexaoxa-dibenzo[a,j]cyclooctadecene1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Dopamine-selective response in membrane potential by homooxacalix[3]arene triether host incorporated in PVC liquid membrane.
AID1280344Antiviral activity against Influenza A virus A/WSN/1933 (H1N1) infected in MDCK cells assessed as protection against virus induced cytopathic effect after 40 hrs by Celltiter-Glo assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID1409737Binding affinity to Influenza A virus A/Udorn/72 wild-type M2 proton channel expressed in Xenopus laevis oocytes at pH 5.5 by two-electrode voltage clamp assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID416780Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1472388Antiviral activity against Influenza A virus (A/Virginia/ATCC3/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 72 hrs by MTS assay2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.
AID443830Antiviral activity against Influenza A virus (A/Hong Kong/7/87(H3N2)) assessed as cell viability by cell-based MTS assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID1610160Antiviral activity against Influenza B virus (B/Ned/537/05) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by MTS assay2019European journal of medicinal chemistry, Dec-15, Volume: 184Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID134370Acute toxicity in mice (24 hours).1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and biological activity of D3-trishomocubyl-4-amines.
AID1181484Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID1511218Inhibition of diphtheria induced toxicity in human A549 cells assessed as protection fold at 30 uM incubated for 20 hrs followed by replacement of [14c]-Leucine containing medium and measured after 4 hrs by liquid scintillation analysis relative to ABMA2019ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8
DABMA: A Derivative of ABMA with Improved Broad-Spectrum Inhibitory Activity of Toxins and Viruses.
AID416367Antagonist activity against glutamate receptor in rat cerebellar granule neurons assessed as inhibition of glutamate-induced increase in intracellular calcium level by Fura-2 AM dye based fluorimetry2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Synthesis and pharmacological evaluation of (2-oxaadamant-1-yl)amines.
AID1183510Antiviral activity against Influenza A virus A/New York/18/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.
AID1408332Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by MTS assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID662369Cytotoxicity against MDCK cells after 3 days by CCK-8 assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Design, synthesis, and in vitro biological evaluation of 1H-1,2,3-triazole-4-carboxamide derivatives as new anti-influenza A agents targeting virus nucleoprotein.
AID1409745Binding affinity to Influenza A virus A/Udorn/72 M2 proton channel S31N mutant expressed in Xenopus laevis oocytes at pH 5.5 by two-electrode voltage clamp assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1741564Antagonist activity at NMDA receptor (unknown origin)2020European journal of medicinal chemistry, Oct-15, Volume: 204Open and rearranged norbornane derived polycyclic cage molecules as potential neuroprotective agents through attenuation of MPP
AID1409733Inhibition of Influenza A virus A/Udorn/72 wild-type M2 proton channel expressed in Xenopus laevis oocytes assessed as blockade of inward currents at pH 5.5 after 5 mins by two-electrode voltage clamp assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID354677Antiviral activity against influenza A virus by hemadsorption inhibition assay1996Journal of natural products, Aug, Volume: 59, Issue:8
Two new naphthoquinones with antiviral activity from Rhinacanthus nasutus.
AID105959Minimum cytotoxic concentration required to cause a microscopically detectable alteration of MDCK, Madin-Darby canine kidney cell morphology.2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Spiro[pyrrolidine-2,2'-adamantanes]: synthesis, anti-influenza virus activity and conformational properties.
AID1181478Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID387575Cytotoxicity against MDCK cells assessed as alteration in cell morphology by MTS assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure.
AID539949Cytotoxicity against MDCK cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1124987Antiviral activity against rimantidine, amantadine-resistant Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in MDCK cells assessed as inhibition of viral replication by hemagglutinin titer assay2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Camphor-based symmetric diimines as inhibitors of influenza virus reproduction.
AID1418305Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/chicken/Hubei/327/2004(H5N1))2018European journal of medicinal chemistry, Nov-05, Volume: 159Synthesis and structure-activity relationship study of arylsulfonamides as novel potent H5N1 inhibitors.
AID1130406Antiviral activity against Influenza virus A2/Asian/J305 infected in mouse assessed as survival at 100 mg/kg, ip administered two doses at 24 hrs post viral infection followed by single dose for subsequent days relative to control1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Adamantylthiourea derivatives as antiviral agents.
AID1360697Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as protection against virus-induced reduction in cell viability after 3 to 6 days by MTS assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
AID624628Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID682000TP_TRANSPORTER: inhibition of Dopamine uptake (Dopamine: 200 uM) in Xenopus laevis oocytes1998Molecular pharmacology, Aug, Volume: 54, Issue:2
Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID637740Antagonist activity at NMDAR in rat cerebellar granule neurons assessed as inhibition of NMDA-induced calcium flux after 5 mins using FURA-2AM in presence of glycine2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Synthesis of benzopolycyclic cage amines: NMDA receptor antagonist, trypanocidal and antiviral activities.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1409726Cytotoxicity against MDCK cells after 72 hrs by crystal violet staining based spectrophotometric method2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID580443Antiviral activity against Influenza A virus/NWS/1933(H1N1) infected in BALB/c mouse assessed as survival rate at 2 mg, ip administered once daily for 10 days and dosed 30 mins post infection2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection.
AID1571469Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction in virus titer pretreated with cells for 1 hr followed by viral infection for 1 hr and subsequent unbound virion washout measured after 242018MedChemComm, Dec-01, Volume: 9, Issue:12
Synthesis of d-(+)-camphor-based
AID1482898Inhibition of Influenza A virus A/Udorn307/72 H3N2 amantadine-resistant M2 proton channel V27A mutant expressed in Xenopus laevis oocytes assessed as dissociation rate constant at pH 5.5 incubated for 2 mins followed by compound washout at -20 mV holding 2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus.
AID596927Inhibition of Influenza A virus (A/Udorn/72) matrix protein 2 S31N mutant expressed in xenopus oocytes after 2 mins by two-electrode voltage clamp assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.
AID392527Antiviral activity against influenza H1N1 virus2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID1160745Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay2014ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8
Identification and synthesis of quinolizidines with anti-influenza a virus activity.
AID596930Antiviral activity against Influenza A virus (A/Udorn/72) expressing wild-type matrix protein 2 infected in MDCK cells assessed as inhibition of plaque formation at 5 uM measured after 2 days2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.
AID768188Antiviral activity against influenza A virus H3N3 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID1731309Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 48 hrs by crystal violet staining based assay2021European journal of medicinal chemistry, Mar-05, Volume: 213Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors.
AID1130403Antiviral activity against Influenza virus A2/Asian/J305 infected in po dosed mouse assessed as concentration required to cause survival at 21 days1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Adamantylthiourea derivatives as antiviral agents.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1130402Antiviral activity against Influenza virus A2/Asian/J305 infected in ip dosed mouse assessed as concentration required to cause survival at 21 days1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Adamantylthiourea derivatives as antiviral agents.
AID1130405Antiviral activity against Influenza virus A2/Asian/J305 infected in mouse assessed as survival at 100 mg/kg, ip administered single dose at 5 mins post viral infection followed by 2 doses per day for next 3 days relative to control1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Adamantylthiourea derivatives as antiviral agents.
AID1438102Binding affinity to synthetic wild-type C-terminally amidated Influenza A virus (A/Udorn/307/72) M2 transmembrane domain (22 to 46 residues) in DPC micelles assessed as TdeltaS values at pH 8 by ITC method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1409735Inhibition of Influenza A virus A/Udorn/72 wild-type M2 proton channel expressed in Xenopus laevis oocytes assessed as association constant at pH 5.5 by two-electrode voltage clamp assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1226071Antiviral activity against oseltamivir/amantadine-resistant Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytocidal effect after 48 hrs by CellTiter-Glo assay2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Phenolic diterpenoid derivatives as anti-influenza a virus agents.
AID718739Toxicity in MDCK cells assessed as induction of cell morphology changes2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID1637797Inhibition of Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) M2 V27A/S31N double mutant expressed in yeast cells after 46 to 48 hrs2019MedChemComm, Jan-01, Volume: 10, Issue:1
Design and synthesis of heteroaromatic-based benzenesulfonamide derivatives as potent inhibitors of H5N1 influenza A virus.
AID1152167Cytotoxicity against MDCK cells at 50 uM after 18 hrs2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID1409729Inhibition of Influenza A virus A/Udorn/72 wild-type M2 proton channel expressed in Xenopus laevis oocytes assessed as blockade of inward currents at 100 uM at pH 5.5 after 2 mins by two-electrode voltage clamp assay relative to control2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1594039Selectivity index, ratio of CC50 for African green monkey Vero cells to EC50 for HAV HM175 infected in African green monkey Vero cells2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
Anti-HAV evaluation and molecular docking of newly synthesized 3-benzyl(phenethyl)benzo[g]quinazolines.
AID1181494Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID432198Antiviral activity against HAV MBB in human HepG2 cells assessed as reduction in viral titer at 20 ug/ml by plaque reduction assay2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Synthesis of new acridines and hydrazones derived from cyclic beta-diketone for cytotoxic and antiviral evaluation.
AID679317TP_TRANSPORTER: inhibition pramipexole uptake in rOCT1-injected oocytes2005Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 33, Issue:4
Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney.
AID1202567Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as virus plaque reduction preincubated for 1 hr followed by compound wash out and incubated for 72 hrs by crystal violet staining2015European journal of medicinal chemistry, , Volume: 96New polycyclic dual inhibitors of the wild type and the V27A mutant M2 channel of the influenza A virus with unexpected binding mode.
AID1317465Antiviral activity against amantadine-resistant Influenza A virus A/Puerto Rico/8/34 expressing M2 proton channel V27A mutant infected in MDCK cells assessed as inhibition of viral replication at 0.001 to 100 uM measured after 10 hrs by miniplaque assay2016European journal of medicinal chemistry, Sep-14, Volume: 120Novel spirothiazamenthane inhibitors of the influenza A M2 proton channel.
AID1731311Selectivity index, ratio of TC50 for MDCK cells to EC50 for antiviral activity against Influenza A virus A/Hebei Xinhua/SWL1106/2017 (H1N1) pdm09 infected in MDCK cells2021European journal of medicinal chemistry, Mar-05, Volume: 213Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors.
AID1280361Antiviral activity against oseltamivir-resistant influenza A virus LN/1109 (H1N1) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID1438101Binding affinity to synthetic wild-type C-terminally amidated Influenza A virus (A/Udorn/307/72) M2 transmembrane domain (22 to 46 residues) in DPC micelles assessed as deltaH values at pH 8 by ITC method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1281064Antiviral activity against Influenza A virus A/udorn/72(H3N2) expressing wild type M2 proton channel infected in MDCK cells assessed as reduction in plaque formation preincubated for 30 mins followed by infection measured on day 2 post infection by naphth2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Discovery of Highly Potent Inhibitors Targeting the Predominant Drug-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel.
AID681116TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID1152170Antiviral activity against Influenza A virus A/Victoria/3/75(H3N2) infected in MDCK cells at 50 uM after 1 passage by fluorescence-based miniplaque assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID105788Antiviral activity against influenza A,H2N2 virus infected MDCK cell lines.1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID1498123Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity by MTS assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID778917Antiviral activity against Influenza virus A/California/07/09 (H1N1)pdm09 infected in MDCK cells assessed as inhibition of viral replication incubated for 1 hr prior to viral infection measured after 48 hrs by hemagglutination reaction2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New quaternary ammonium camphor derivatives and their antiviral activity, genotoxic effects and cytotoxicity.
AID105946Antiviral activity against influenza A H2N2(A2 japan/305/57) in MDCK cells2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Spiro[pyrrolidine-2,2'-adamantanes]: synthesis, anti-influenza virus activity and conformational properties.
AID624626Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1130415Antiviral activity against Influenza virus A2/Asian/J305 infected in rhesus monkey kidney cells assessed as concentration required to reduce viral titer by >= 2 logarithms after 4 days by tube dilution method1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Adamantylthiourea derivatives as antiviral agents.
AID700833Drug excretion in human urine assessed as unchanged compound level2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
The many faces of the adamantyl group in drug design.
AID1156044Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as 2 log10 reduction in virus yield after 24 hrs by qRT-PCR analysis2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID1220560Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1209582Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID624629Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID768189Antiviral activity against influenza A virus H1N1 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID1183505Antiviral activity against Influenza A virus A/Georgia/20/2006 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.
AID478325Antiviral activity against influenza B virus assessed as cell viability by cell based MTS assay2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
AID733266Antiviral activity against Influenza B virus (B/Taiwan/2/62) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis2013European journal of medicinal chemistry, Apr, Volume: 62Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.
AID1183509Antiviral activity against Influenza A virus A/Mexico/4108/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.
AID678969TP_TRANSPORTER: inhibition of TEA uptake (in the absence of bicarbonate) (TEA: 20 uM) in OCT2-expressing HEK293 cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
The cation transporters rOCT1 and rOCT2 interact with bicarbonate but play only a minor role for amantadine uptake into rat renal proximal tubules.
AID478324Antiviral activity against influenza B virus assessed as inhibition of viral induced cytopathic effect2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
AID480118Inhibition of avian influenza virus (H5N1) matrix 2 protein S31N/L26I double mutant expressed in HEK293 cells at 50 uM by path clamp electrophysiology method2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library.
AID1610157Antiviral activity against Influenza B virus (B/Ned/537/05) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis2019European journal of medicinal chemistry, Dec-15, Volume: 184Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID1438097Binding affinity to Influenza A virus (A/Udorn/307/72) M2 transmembrane domain by ITC method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1408326Antiviral activity against Influenza A virus A/HK/7/87(H3N2) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID604215Antioxidant activity assessed as inhibition of ABTS free radicals at 1 mM after 30 mins by UV-visible spectrophotometer analysis relative to control2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
AID1056005Inhibition of Influenza A virus Udorn/72 M2 ion channel S31N mutant expressed in Xenopus oocyte plasma membranes at 100 uM after 2 mins by two-electrode voltage clamp assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1317464Antiviral activity against amantadine-resistant Influenza A virus A/Puerto Rico/8/34 expressing M2 proton channel S31N mutant infected in MDCK cells assessed as inhibition of viral replication at 0.001 to 100 uM measured after 10 hrs by miniplaque assay2016European journal of medicinal chemistry, Sep-14, Volume: 120Novel spirothiazamenthane inhibitors of the influenza A M2 proton channel.
AID105458Evaluated for cytotoxic activity in MDBK cells2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Anti-influenza virus activities of 2-alkoxyimino-n-(2-isoxazolin-3-ylmethyl)acetamides.
AID1456575Selectivity index, ratio of CTD50 for MDCK cells to ED50 for Influenza A virus (A/Puerto Rico/8/34(H1N1))2017Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10
Synthesis of camphecene derivatives using click chemistry methodology and study of their antiviral activity.
AID681117TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells2003Molecular pharmacology, Mar, Volume: 63, Issue:3
Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1.
AID480266Inhibition of avian influenza virus (H5N1) matrix 2 protein S31N mutant expressed in HEK293 cells at 50 uM by path clamp electrophysiology method2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library.
AID604210Antioxidant activity assessed as inhibition of DPPH free radicals at 0.01 mM after 30 mins by UV-visible spectrophotometer analysis relative to control2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
AID86523Minimum toxic concentration required to cause a microscopically detectable alteration of normal HeLa cell morphology1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Synthesis and antiviral activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9-dideazapurine) derivatives.
AID1409721Binding affinity to Influenza A virus A/Udorn/72 M2 proton channel S31N mutant by isothermal calorimetric titration2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1438083Binding affinity to synthetic wild-type C-terminally amidated Influenza A virus (A/Udorn/307/72) M2 transmembrane domain (22 to 46 residues) in DPC micelles at pH 8 by ITC method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1055988Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) harboring M2 channel S31N and V27T mutant infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by microsocopic analysis2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1650128Antiviral activity against Influenza A virus H3N2 A/HK/7/87 infected in MDCK cells assessed as reduction in virus induced cytopathic effect after 4 days by microscopy based method2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones.
AID1181482Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID658749Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1482890Antiviral activity against Influenza A virus A//HK/7/87 (H3N2) expressing wild-type M2 proton channel infected in MDCK cells assessed as reduction in viral yield after 24 hrs by RT-qPCR method2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus.
AID620266Antagonist activity at voltage gated calcium channel in Sprague-Dawley rat striatal synaptoneurosomes assessed as inhibition of NMDA/glycine-induced calcium flux at 100 uM by spectrofluorimetric analysis relative to control2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis, evaluation and application of polycyclic fluorescent analogues as N-methyl-D-aspartate receptor and voltage gated calcium channel ligands.
AID693527Cytotoxicity against MDCK cells assessed as minimum concentration required to cause microscopically detectable alteration measured on day 3 post infection by MTS assay2012European journal of medicinal chemistry, Dec, Volume: 58Synthesis of fluorescent ristocetin aglycon derivatives with remarkable antibacterial and antiviral activities.
AID456467Antagonist activity at NMDA receptor in rat cerebellar granule neurons assessed as inhibition of NMDA-induced increase in intracellular calcium level by fluorometric assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities.
AID768187Antiviral activity against influenza B virus infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1130420Toxicity in mouse assessed as CNS related side effects at 100 mg/kg, ip and 300 mg/kg, po measured for 24 hrs1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Adamantylthiourea derivatives as antiviral agents.
AID18736Selectivity of guest-induced changes in membrane potential at pH 5.0 for PVC matrix liquid membrane without any host1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Dopamine-selective response in membrane potential by homooxacalix[3]arene triether host incorporated in PVC liquid membrane.
AID86512Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HeLa cell line infected with RSV virus1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID539954Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID733270Cytotoxicity against MDCK cells after 3 days by fluorescein diacetate-based fluorimetric analysis2013European journal of medicinal chemistry, Apr, Volume: 62Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID392529Antiviral activity against influenza H3N2 virus2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID588966Substrates of transporters of clinical importance in the absorption and disposition of drugs, OCT22010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID1181480Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID721754Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1415634Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction in viral titer preincubated with cells for 1 hr followed by viral inoculation and measured after 48 hrs by hemagglutination test2017MedChemComm, May-01, Volume: 8, Issue:5
Synthesis and
AID1498125Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity by MTS assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID443837Antiviral activity against Influenza B virus (B/Hong Kong/5/72) assessed as inhibition of virus-induced cytopathic effect at highest concentration by cell-based assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID1156037Inhibition of amantadine-resistant Influenza A virus (A/udorn/72(H3N2)) M2 V27A mutant channel expressed in Xenopus oocyte plasma membrane incubated for 2 mins measured over 48 to 72 hrs by two-electrode voltage clamp method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID1201118Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID105787Antiviral activity tested against influenza A,H1N1 virus infected MDCK cell lines.1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID1152623Cytotoxicity against MDCK cells after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Design, synthesis and biological evaluation of small molecular polyphenols as entry inhibitors against H(5)N(1).
AID1156035Inhibition of amantadine-resistant Influenza A virus (A/udorn/72(H3N2)) M2 S31N mutant channel expressed in Xenopus oocyte plasma membrane incubated for 2 mins measured over 48 to 72 hrs by two-electrode voltage clamp method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID388528Antagonist activity at NMDA receptor in cerebellar granule neurons assessed as inhibition of NMDA-induced increase in intracellular calcium concentration by fluorometric assay2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs.
AID1409740Inhibition of Influenza A virus A/Udorn/72 M2 proton channel S31N mutant expressed in Xenopus laevis oocytes assessed as blockade of inward currents at 100 uM at pH 5.5 after 2 mins by two-electrode voltage clamp assay relative to control2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1156043Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID1409741Inhibition of Influenza A virus A/Udorn/72 M2 proton channel S31N mutant expressed in Xenopus laevis oocytes assessed as blockade of inward currents at 100 uM at pH 5.5 after 5 mins by two-electrode voltage clamp assay relative to control2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID308660Antiparasitic activity against Trypanosoma brucei 221 blood stream form at pH 7.42007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Design and synthesis of bioactive adamantane spiro heterocycles.
AID1071390Antiparkinsonian effect in cynomolgus monkey MPTP-rendered Parkinsonian L-DOPA-induced dyskinesia model assessed as reduction in dyskinesia at 20 mg/kg, po after 6 hrs2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat
AID1156045Cytotoxicity against MDCK cells assessed as cell viability after 72 hrs by MTS assay2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID1056007Inhibition of Influenza A virus Udorn/72 wild type M2 ion channel expressed in Xenopus oocyte plasma membranes at 100 uM after 2 mins by two-electrode voltage clamp assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1485248Antiviral activity against Influenza A virus A/Ned/378/05(H1N1) infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1281065Antiviral activity against Influenza A virus A/WSN/33(H1N1) expressing M2 proton channel S31N mutant infected in MDCK cells assessed as reduction in plaque formation preincubated for 30 mins followed by infection measured on day 2 post infection by naphth2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Discovery of Highly Potent Inhibitors Targeting the Predominant Drug-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel.
AID1202565Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis2015European journal of medicinal chemistry, , Volume: 96New polycyclic dual inhibitors of the wild type and the V27A mutant M2 channel of the influenza A virus with unexpected binding mode.
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1209583Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1152161Blockade of Influenza A virus (A/England/195/2009(H1N1)) full length M2 proton channel expressed in HEK cells at 10 uM after 3 mins by voltage clamp technique2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID548438Cytotoxicity against MDCK cells assessed as altered cell morphology2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID1408324Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1pdm) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID717170Cytotoxicity against dog MDCK cells assessed as cell morphology alterations by microscopic analysis2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID1124988Selectivity index, ratio of CTD50 for MDCK cells to ED50 for Influenza A virus (A/California/07/09(H1N1)) pdm092014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Camphor-based symmetric diimines as inhibitors of influenza virus reproduction.
AID1236289Cytoprotective activity against MPP+-induced cell death in human SH-SY5Y cells assessed as increase in cell viability at 20 uM after 24 hrs by MTT assay2014MedChemComm, Oct-01, Volume: 5, Issue:10
Cytoprotective effects of hydrogen sulfide-releasing
AID766685Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity2013European journal of medicinal chemistry, Sep, Volume: 67Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID480115Inhibition of avian influenza virus (H5N1) matrix 2 protein S31N mutant expressed in HEK293 cells by path clamp electrophysiology method2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library.
AID105769Inhibitory concentration against influenza virus A in MDCK cells1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Synthesis and antiviral activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9-dideazapurine) derivatives.
AID647176Cytotoxicity against MDCK cells by MTT assay2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Synthesis and antiviral activities of novel gossypol derivatives.
AID1415636Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/Puerto Rico/8/34(H1N1))2017MedChemComm, May-01, Volume: 8, Issue:5
Synthesis and
AID1660669Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect at 25 ug/ml measured after 4 passages by crystal violet staining based assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Chemoreactive-Inspired Discovery of Influenza A Virus Dual Inhibitor to Block Hemagglutinin-Mediated Adsorption and Membrane Fusion.
AID1498140Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced visual cytopathicity2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID778918Cytotoxicity against MDCK cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New quaternary ammonium camphor derivatives and their antiviral activity, genotoxic effects and cytotoxicity.
AID1210823Selectivity for OCT2 (unknown origin) over OCT1 (unknown origin)2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID744869Selectivity index, ratio of cytotoxicity against MDCK cells to antiviral activity against H5N1 subtype2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism.
AID111362Stimulation of spontaneous locomotor activity of compound was measured in mice at a dose of 0.1 mmol/kg)1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID402531Antiviral activity against influenza A virus NJH1N1 in MDCK cells by hemadsorption-inhibition assay1997Journal of natural products, Jun, Volume: 60, Issue:6
Two new lignans with activity against influenza virus from the medicinal plant Rhinacanthus nasutus.
AID1909434Inhibition of eGFP-tagged rat GluN1-1a/GluN2A transfected in human tsA201 cells assessed as inhibition glutamate-induced current measured at -65 mV holding potential applied for 10 secs by whole-cell patch-clamp method2022European journal of medicinal chemistry, Jun-05, Volume: 236Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID443827Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) assessed as inhibition of virus-induced cytopathic effect by cell-based assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1183508Antiviral activity against Influenza A virus A/California/07/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.
AID235813Selectivity ratio of MCC50 to that of EC50 of influenza A H2N2(A2 japan/305/57)2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Spiro[pyrrolidine-2,2'-adamantanes]: synthesis, anti-influenza virus activity and conformational properties.
AID105806Minimum toxic concentration required to cause a microscopically detectable alteration of normal MDCK cell morphology1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Synthesis and antiviral activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9-dideazapurine) derivatives.
AID416784Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1130419Acute toxicity in po dosed mouse measured for 24 hrs1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Adamantylthiourea derivatives as antiviral agents.
AID1156040Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) harboring M2 S31N/V27T double mutant channel infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID596928Inhibition of Influenza A virus (A/Udorn/72) matrix protein 2 V27A mutant expressed in xenopus oocytes at 100 uM after 2 mins by two-electrode voltage clamp assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.
AID105967Minimum inhibitory concentration required to reduce influenza A H2N2 virus induced cytopathogenicity by 50% in madin-Darby canine kidney cells (MDCK)2001Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16
Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus-identification of aminoadamantane derivatives bearing two pharmacophoric amine groups.
AID1202564Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay2015European journal of medicinal chemistry, , Volume: 96New polycyclic dual inhibitors of the wild type and the V27A mutant M2 channel of the influenza A virus with unexpected binding mode.
AID395326Fraction unbound in rat brain2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID480113Antiviral activity against Influenza A virus (A/Hong Kong/8/1968(H2N2)) infected in MDCK cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library.
AID717173Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID1594038Cytotoxicity against African green monkey Vero cells measured after 48 hrs by crystal violet staining based colorimetric method2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
Anti-HAV evaluation and molecular docking of newly synthesized 3-benzyl(phenethyl)benzo[g]quinazolines.
AID1156034Inhibition of amantadine-resistant Influenza A virus (A/udorn/72(H3N2)) M2 S31N mutant channel expressed in Xenopus oocyte plasma membrane at 100 uM incubated for 2 mins measured over 48 to 72 hrs by two-electrode voltage clamp method relative to control2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID111364Stimulation of spontaneous locomotor activity of compound was measured in mice at a dose of 0.2 mmol/kg)1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID1055986Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as concentration required to 1 log10 reduction of virus yield after 24 hrs by RT-PCR analysis2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID717172Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID733268Antiviral activity against Influenza A virus (A/Hong kong/8/1968(H2N3)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis2013European journal of medicinal chemistry, Apr, Volume: 62Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.
AID766694Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity2013European journal of medicinal chemistry, Sep, Volume: 67Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID432197Antiviral activity against HAV MBB in human HepG2 cells assessed as reduction in viral titer at 10 ug/ml by plaque reduction assay2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Synthesis of new acridines and hydrazones derived from cyclic beta-diketone for cytotoxic and antiviral evaluation.
AID388527Antiviral activity against influenza virus A/Puerto Rico/8/34 H1N1 in MDCK cells assessed as effect on virus-induced cytopathogenicity by MTS assay2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1650127Cytotoxicity against MDCK cells assessed as reduction in cell viability after 4 days by MTS assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones.
AID1636357Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1438084Binding affinity to synthetic Influenza A virus (A/Udorn/307/72) M2 transmembrane domain S31N mutant (22 to 46 residues) in DPC micelles measured at pH 8 by ITC method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1485247Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID717169Cytotoxicity against dog MDCK cells assessed as cell viability by MTS assay2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID1152624Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus (A/Vietnam/1194/2004(H5N1))2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Design, synthesis and biological evaluation of small molecular polyphenols as entry inhibitors against H(5)N(1).
AID604217Antioxidant activity assessed as inhibition of ABTS free radicals after 30 mins by UV-visible spectrophotometer analysis relative to control2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
AID480114Inhibition of avian influenza virus (H5N1) matrix 2 protein expressed in HEK293 cells by path clamp electrophysiology method2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library.
AID1409743Inhibition of Influenza A virus A/Udorn/72 M2 proton channel S31N mutant expressed in Xenopus laevis oocytes assessed as association constant at pH 5.5 by two-electrode voltage clamp assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1482897Inhibition of Influenza A virus A/Udorn/307/72 H3N2 amantadine-resistant M2 proton channel V27A mutant expressed in Xenopus laevis oocytes assessed as association rate constant at pH 5.5 after 2 mins at -20 mV holding potential by two-electrode voltage cl2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus.
AID1438094Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) expressing M2 proton channel S31N mutant infected in MDCK cells assessed as reduction in cytopathic effect after 48 hrs by crystal violet staining-based microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID105968Minimum inhibitory concentration required to reduce influenza A H3N2 (X31) virus induced cytopathogenicity by 50% in madin-Darby canine kidney cells (MDCK)2001Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16
Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus-identification of aminoadamantane derivatives bearing two pharmacophoric amine groups.
AID1409732Inhibition of Influenza A virus A/Udorn/72 wild-type M2 proton channel expressed in Xenopus laevis oocytes assessed as blockade of inward currents at pH 5.5 after 2 mins by two-electrode voltage clamp assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1610156Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis2019European journal of medicinal chemistry, Dec-15, Volume: 184Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID712811Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID1220556Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID679293TP_TRANSPORTER: inhibition pramipexole uptake in rOCT2-injected oocytes2005Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 33, Issue:4
Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney.
AID478321Antiviral activity against influenza A virus H1N1 assessed as cell viability by cell based MTS assay2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
AID1152162Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cells expressing M2 S31N mutant after overnight incubation by fluorescence-based miniplaque assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID1209581Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1409723Antiviral activity against Influenza A virus A/Udorn/72 H3N2 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect by crystal violet staining based light-microscopic analysis2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1418311Cytotoxicity in yeast assessed as reduction in cell proliferation2018European journal of medicinal chemistry, Nov-05, Volume: 159Synthesis and structure-activity relationship study of arylsulfonamides as novel potent H5N1 inhibitors.
AID1156033Inhibition of wild type Influenza A virus (A/udorn/72(H3N2)) M2 channel expressed in Xenopus oocyte plasma membrane incubated for 2 mins measured over 48 to 72 hrs by two-electrode voltage clamp method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID1610162Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 3 days by coulter counter method2019European journal of medicinal chemistry, Dec-15, Volume: 184Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID308657Antiviral activity against influenza A/Hong Kong/7/87 (H3N2) in MDCK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Design and synthesis of bioactive adamantane spiro heterocycles.
AID1418308Antiviral activity against Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) infected in MDCK cells assessed as inhibition of early stages of viral replication at 2.8 uM up to 8 hrs by crystal violet staining based plaque reduction assay dependent time-o2018European journal of medicinal chemistry, Nov-05, Volume: 159Synthesis and structure-activity relationship study of arylsulfonamides as novel potent H5N1 inhibitors.
AID678995TP_TRANSPORTER: inhibition of TEA uptake (in the presence of bicarbonate) (TEA: 20 uM) in OCT1-expressing HEK293 cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
The cation transporters rOCT1 and rOCT2 interact with bicarbonate but play only a minor role for amantadine uptake into rat renal proximal tubules.
AID778916Selectivity index, ratio of CTD50 for MDCK cells to EC50 for Influenza A virus California/07/09(H1N1) pdm09 infected in MDCK cells2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New quaternary ammonium camphor derivatives and their antiviral activity, genotoxic effects and cytotoxicity.
AID23236Partition coefficient (logP)1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Dopamine-selective response in membrane potential by homooxacalix[3]arene triether host incorporated in PVC liquid membrane.
AID311935Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID712809Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID1202568Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as 2-log10 reduction in virus yield after 24 hrs by RT-qPCR analysis2015European journal of medicinal chemistry, , Volume: 96New polycyclic dual inhibitors of the wild type and the V27A mutant M2 channel of the influenza A virus with unexpected binding mode.
AID1409720Binding affinity to Influenza A virus A/Udorn/72 wild-type M2 proton channel by isothermal calorimetric titration2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID604207Antagonist activity at VGCC in Sprague-Dawley rat brain synaptoneurosomes assessed as inhibition of Kcl-induced calcium flux at 100 uM after 5 mins using FURA-2AM by fluorescent spectrometer analysis relative to control2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
AID647175Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral replication by plaque reduction assay2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Synthesis and antiviral activities of novel gossypol derivatives.
AID1409730Inhibition of Influenza A virus A/Udorn/72 wild-type M2 proton channel expressed in Xenopus laevis oocytes assessed as blockade of inward currents at 100 uM at pH 5.5 after 5 mins by two-electrode voltage clamp assay relative to control2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID489224Binding affinity to Influenza A Weybridge(H7N7) virus Matrix protein 2 by spectrophotometry2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Interaction of aminoadamantane derivatives with the influenza A virus M2 channel-docking using a pore blocking model.
AID1408322Antiviral activity against Influenza A virus A/PR/8/34(H1N1) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID604208Antagonist activity at NMDAR in Sprague-Dawley rat brain synaptoneurosomes assessed as inhibition of NMDA/glycine-induced calcium flux at 100 uM after 5 mins using FURA-2AM by fluorescent spectrometer analysis relative to control2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
AID658747Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID388540Cytotoxicity against MDCK cells by MTS assay2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs.
AID596933Inhibition of Influenza A virus matrix protein 22011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.
AID393166Antiviral activity against influenza B virus2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity.
AID105603Antiviral activity against A/WSN/33 strain of influenza virus (H1N1 subtype) in MDBK cells using cell protection assay; expressed as 10-100 ppm2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Anti-influenza virus activities of 2-alkoxyimino-n-(2-isoxazolin-3-ylmethyl)acetamides.
AID70209Antiviral activity against influenza B (Hong kong/5/72) in human epithelial cells2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Spiro[pyrrolidine-2,2'-adamantanes]: synthesis, anti-influenza virus activity and conformational properties.
AID1409725Antiviral activity against Influenza A virus A/WSN/33 H1N1 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect by crystal violet staining based light-microscopic analysis2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID744867Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells by plaque reduction assay2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID388538Antiviral activity against influenza virus A/Hong Kong/7/87 H3N2 in MDCK cells assessed as effect on virus-induced cytopathogenicity by MTS assay2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs.
AID539953Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1731310Antiviral activity against Influenza A virus A/Hebei Xinhua/SWL1106/2017 (H1N1) pdm09 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect preincubated for 1 hr followed by viral infection and measured after 48 hrs by crystal vi2021European journal of medicinal chemistry, Mar-05, Volume: 213Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors.
AID1220558Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID88523Inhibitory concentration against respiratory syncytial virus in HeLa cells1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Synthesis and antiviral activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9-dideazapurine) derivatives.
AID1130416Antiviral activity against Influenza B virus (B/Lee/40) infected in rhesus monkey kidney cells assessed as growth inhibition after 4 days by tube dilution method1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Adamantylthiourea derivatives as antiviral agents.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1472389Cytotoxicity against MDCK cells assessed as decrease in cell viability after 72 hrs by MTS assay2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.
AID1482895Inhibition of Influenza A virus A/Udorn/307/72 H3N2 wild-type M2 proton channel expressed in Xenopus laevis oocytes assessed as association rate constant at pH 5.5 after 2 mins at -20 mV holding potential by two-electrode voltage clamp assay2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1280363Antiviral activity against amantadine-resistant influenza A virus HN/1222 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1498141Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced visual cytopathicity2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID1201115Cytotoxicity against MDCK cells after 72 hrs by microscopic analysis2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID647177Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus (A/Vietnam/1194/2004(H5N1))2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Synthesis and antiviral activities of novel gossypol derivatives.
AID1200484Cytotoxicity against MDCK cells assessed as cell growth after 40 hrs by CellTiter-Glo assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin.
AID402536Selectivity index, ratio of IC50 for MDCK cells to EC50 for influenza A virus NJH1N11997Journal of natural products, Jun, Volume: 60, Issue:6
Two new lignans with activity against influenza virus from the medicinal plant Rhinacanthus nasutus.
AID718741Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1610159Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by MTS assay2019European journal of medicinal chemistry, Dec-15, Volume: 184Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID548441Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID1055979Cytotoxicity against MDCK cells assessed as minimum cytotoxic concentration after 24 hrs by MTS assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1055999Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by microsocopic analysis2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1409727Antiviral activity against Influenza A virus A/Udorn/72 H3N2 infected in MDCK cells assessed as reduction in plaque formation by crystal violet staining based assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1426029Cytotoxicity against MDCK cells after 48 hrs by MTT assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Aliphatic and alicyclic camphor imines as effective inhibitors of influenza virus H1N1.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID662367Antiviral activity against Influenza A virus A/HK/8/68(H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Design, synthesis, and in vitro biological evaluation of 1H-1,2,3-triazole-4-carboxamide derivatives as new anti-influenza A agents targeting virus nucleoprotein.
AID1482889Antiviral activity against Influenza A virus A//HK/7/87 (H3N2) expressing wild-type M2 proton channel infected in MDCK cells assessed as reduction in plaque formation preincubated with virus for 1 hr followed by addition to cells measured after 72 hrs by 2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus.
AID1594037Antiviral activity against HAV HM175 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect measured after 48 hrs by crystal violet staining based assay2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
Anti-HAV evaluation and molecular docking of newly synthesized 3-benzyl(phenethyl)benzo[g]quinazolines.
AID596924Inhibition of Influenza A virus (A/Udorn/72) wild type matrix protein 2 expressed in xenopus oocytes at 100 uM after 2 mins by two-electrode voltage clamp assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.
AID624622Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID416368Antagonist activity against NMDA receptor in rat cerebellar granule neurons assessed as inhibition of NMDA -induced increase in intracellular calcium level by Fura-2 AM dye based fluorimetry2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Synthesis and pharmacological evaluation of (2-oxaadamant-1-yl)amines.
AID443828Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) assessed as cell viability by cell-based MTS assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID1317461Cytotoxicity against MDCK cells at 3 uM measured after 72 hrs by MTT assay2016European journal of medicinal chemistry, Sep-14, Volume: 120Novel spirothiazamenthane inhibitors of the influenza A M2 proton channel.
AID712814Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID1071389Antiparkinsonian effect in cynomolgus monkey MPTP-rendered Parkinsonian L-DOPA-induced dyskinesia model assessed as reduction in total disability at 20 mg/kg, po after 6 hrs2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat
AID733267Antiviral activity against Influenza B virus (B/Panama/45/1990) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis2013European journal of medicinal chemistry, Apr, Volume: 62Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.
AID624623Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1156041Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) harboring M2 S31N/V27T double mutant channel infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID1160744Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay2014ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8
Identification and synthesis of quinolizidines with anti-influenza a virus activity.
AID596926Inhibition of Influenza A virus (A/Udorn/72) matrix protein 2 S31N mutant expressed in xenopus oocytes at 100 uM after 2 mins by two-electrode voltage clamp assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.
AID596925Inhibition of Influenza A virus (A/Udorn/72) wild type matrix protein 2 expressed in xenopus oocytes after 2 mins by two-electrode voltage clamp assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.
AID1438086Binding affinity to synthetic wild-type Influenza A virus (A/Udorn/307/72) M2 transmembrane domain (22 to 46 residues) in DMPC lipid bilayer assessed as helical tilt angle for C-terminus by OS ssNMR spectral analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1281069Inhibition of Influenza A virus wild type M2 proton channel infected in Xenopus laevis oocytes after 2 mins by TEVC assay2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Discovery of Highly Potent Inhibitors Targeting the Predominant Drug-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel.
AID1152164Antiviral activity against Influenza A virus A/WS/33(H1N1) infected in MDCK cells expressing M2 S31N mutant after overnight incubation by fluorescence-based miniplaque assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID416779Cytotoxicity against MDCK cells by MTS assay2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID700832Drug excretion in human urine assessed as N-acetylamantadine level2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
The many faces of the adamantyl group in drug design.
AID416782Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID536241Cytotoxicity against MDCK cells by MTS assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Design and synthesis of bioactive adamantanaminoalcohols and adamantanamines.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID480117Inhibition of avian influenza virus (H5N1) matrix 2 protein expressed in HEK293 cells at 50 uM by path clamp electrophysiology method2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library.
AID395325Lipophilicity, log P by microemulsion electrokinetic chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1200496Antiviral activity against amantadine and ribavirin-resistant influenza A virus A/HuNan-huHui/1222/2010 (H3N2) strain2015European journal of medicinal chemistry, Mar-26, Volume: 93Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin.
AID1426031Selectivity index, ratio of CTD50 for MDCK cells to ED50 for Influenza A virus (A/California/07/09(H1N1))2017European journal of medicinal chemistry, Feb-15, Volume: 127Aliphatic and alicyclic camphor imines as effective inhibitors of influenza virus H1N1.
AID1281070Inhibition of Influenza A virus M2 proton channel S31N mutant infected in Xenopus laevis oocytes after 2 mins by TEVC assay2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Discovery of Highly Potent Inhibitors Targeting the Predominant Drug-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel.
AID1181479Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID1200495Antiviral activity against OSV-resistant influenza A virus A/LiaoNing-ZhenXing/1109/2010 (H1N1) strain2015European journal of medicinal chemistry, Mar-26, Volume: 93Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin.
AID566968Antiviral activity against amantadine-sensitive Influenza A virus A/Hong Kong/8/68 (H3N2) infected in MDCK cells assessed as host cell survival after 72 hrs by CCK8 method2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Discovery of highly potent agents against influenza A virus.
AID24229Partition coefficient (logP)1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID105973Concentration required to reduce the viability of MDCK cells1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Synthesis of 2-(2-adamantyl)piperidines and structure anti-influenza virus A activity relationship study using a combination of NMR spectroscopy and molecular modeling.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1152171Antiviral activity against Influenza A virus A/Victoria/3/75(H3N2) infected in MDCK cells at 50 uM after 2 passages by fluorescence-based miniplaque assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID539956Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as cell viability after 2 days by MTS assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID539948Cytotoxicity against MDCK cells by MTS assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID637739Antagonist activity at NMDAR in rat cerebellar granule neurons assessed as inhibition of glutamate-induced calcium flux after 5 mins using FURA-2AM in presence of glycine2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Synthesis of benzopolycyclic cage amines: NMDA receptor antagonist, trypanocidal and antiviral activities.
AID1637798Toxicity against yeast assessed as reduction in cell viability2019MedChemComm, Jan-01, Volume: 10, Issue:1
Design and synthesis of heteroaromatic-based benzenesulfonamide derivatives as potent inhibitors of H5N1 influenza A virus.
AID111359Stimulation of spontaneous locomotor activity of compound was measured in mice at a dose of 0.05 mmol/kg)1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID105793Antiviral activity of compound was tested against morphology virus infec+ted MDCK cell lines.1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID1055985Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by MTS assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1152166Antiviral activity against Influenza A virus A/Victoria/3/75(H3N2) infected in MDCK cells expressing wild type M2 after overnight incubation by fluorescence-based miniplaque assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID717174Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID781328pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 20052014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1438095Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) expressing wild-type M2 proton channel infected in MDCK cells assessed as reduction in cytopathic effect after 48 hrs by crystal violet staining-based microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID134257Anti-oxotremorine activity (anticholinergic property) and reduction of salivation in mice at a dose of 100 mg/kg.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and biological activity of D3-trishomocubyl-4-amines.
AID1124986Cytotoxicity against MDCK cells assessed as cell viability after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Camphor-based symmetric diimines as inhibitors of influenza virus reproduction.
AID1276990Inhibition of Influenza A virus M2 S31N mutant ion channel expressed in Xenopus oocytes at 100 uM after 2 mins by two-electrode voltage clamp assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Imidazole-based pinanamine derivatives: Discovery of dual inhibitors of the wild-type and drug-resistant mutant of the influenza A virus.
AID1408328Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID480116Inhibition of avian influenza virus (H5N1) matrix 2 protein S31N/L26I double mutant expressed in HEK293 cells by path clamp electrophysiology method2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library.
AID712795Cytotoxicity against dog MDCK cells assessed as cell viability after 72 hrs by MTS assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID1056002Inhibition of Influenza A virus Udorn/72 M2 ion channel V27A mutant expressed in Xenopus oocyte plasma membranes after 2 mins by two-electrode voltage clamp assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID693526Antiviral activity against Influenza B/HK/5/72 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay2012European journal of medicinal chemistry, Dec, Volume: 58Synthesis of fluorescent ristocetin aglycon derivatives with remarkable antibacterial and antiviral activities.
AID308658Cytotoxicity against MDCK cells assessed as changes in cell morphology2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Design and synthesis of bioactive adamantane spiro heterocycles.
AID679187TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
The cation transporters rOCT1 and rOCT2 interact with bicarbonate but play only a minor role for amantadine uptake into rat renal proximal tubules.
AID1056009Inhibition of Influenza A virus M2 ion channel V27A mutant by two-electrode voltage clamp assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1056006Inhibition of Influenza A virus Udorn/72 wild type M2 ion channel expressed in Xenopus oocyte plasma membranes after 2 mins by two-electrode voltage clamp assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1183511Antiviral activity against Influenza A virus A/Viet Nam/1203/2004(H5N1) infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.
AID41077Tested for the ability to stimulate TNF-alpha production in B78-H1 murine melanoma cells transduced with gene for human TNF-alpha, clone-9 at 10 uM concentration; In active2001Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
Adamantylaminopyrimidines and -pyridines are potent inducers of tumor necrosis factor-alpha.
AID1317453Inhibition of Influenza A virus A/udorn/72(H3N2) wild type M2 proton channel expressed in yeast assessed as growth restoration measured after 44 hrs by turbidometric assay2016European journal of medicinal chemistry, Sep-14, Volume: 120Novel spirothiazamenthane inhibitors of the influenza A M2 proton channel.
AID1130414Antiviral activity against Sendai virus infected in ip dosed mouse assessed as protection against viral infection1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Adamantylthiourea derivatives as antiviral agents.
AID1498124Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity by MTS assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID1485244Cytotoxicity against dog MDCK cells assessed as alterations in normal cell morphology measured after 5 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID658607Cytotoxicity against MDCK cells assessed as minimum compound concentration required to causes microscopically detectable alteration of normal cell morphology2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID662368Antiviral activity against amantidine-resistant Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Design, synthesis, and in vitro biological evaluation of 1H-1,2,3-triazole-4-carboxamide derivatives as new anti-influenza A agents targeting virus nucleoprotein.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1346601Human GluN2C (Ionotropic glutamate receptors)2007The Journal of physiology, May-15, Volume: 581, Issue:Pt 1
Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159585Biochemical screen of P. falciparum CDPK12016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159589Biochemical screen of P. falciparum MAPK22016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159586Biochemical screen of P. falciparum PK62016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159587Biochemical screen of P. falciparum PK72016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159588Biochemical screen of P. falciparum CDPK42016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,799)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901568 (41.27)18.7374
1990's542 (14.27)18.2507
2000's844 (22.22)29.6817
2010's635 (16.71)24.3611
2020's210 (5.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 92.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index92.80 (24.57)
Research Supply Index8.44 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index174.26 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (92.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials515 (12.53%)5.53%
Reviews569 (13.84%)6.00%
Case Studies378 (9.20%)4.05%
Observational9 (0.22%)0.25%
Other2,639 (64.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (86)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized Double-blind Placebo-controlled Trial of Intravenous Amantadine on Gait Freezing in Patients With Parkinson's Disease [NCT01313845]Phase 446 participants (Actual)Interventional2011-02-28Completed
[NCT03443037]56 participants (Anticipated)Observational2016-03-01Recruiting
Amantadine VS Ritalin in the Treatment of ADHD: a Double Blind Randomized Trial [NCT01099059]Phase 240 participants (Anticipated)Interventional2010-04-30Recruiting
Maintenance Therapy of Intravenous Amantadine in Patients With Idiopathic Parkinson Disease Who Are Not Optimally Treated With Anti Parkinson Medications [NCT01190553]20 participants (Anticipated)Interventional2010-11-30Not yet recruiting
The Implications of Amantadine Sulphate Usage in Spine Deformities Corrective Surgeries Patients as Regard Its Effect on the Duration of Wake up Test and Postoperative Opioid Consumption [NCT03178708]Phase 2/Phase 360 participants (Actual)Interventional2017-08-01Completed
Oral Amantadine Versus Gabapentin to Attenuate the Hemodynamic Response to Laryngoscopy and Tracheal Intubation and Their Effect on β-endorphin [NCT03172234]Phase 2/Phase 390 participants (Actual)Interventional2017-06-15Completed
A Multicenter, Open-Label Safety and Efficacy Study of ADS-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment [NCT03567057]Phase 3424 participants (Actual)Interventional2018-07-18Completed
Validation of Dyskinesia Rating Scales [NCT01071395]Phase 468 participants (Actual)Interventional2010-01-31Completed
Comparative Efficacy of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment-resistant Unipolar Depression: A Randomized Controlled Trial. [NCT04936126]Phase 4150 participants (Anticipated)Interventional2021-08-07Recruiting
A Multi-Center, Parallel-Group, Randomized, Double-Blind, Placebo-Controlled Trial of Amantadine Hydrochloride in the Treatment of Chronic Traumatic Brain Injury Irritability and Aggression: A Replication Study [NCT00779324]168 participants (Actual)Interventional2009-08-31Completed
A Randomized Open Label Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Amantadine and Ribavirin With Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immunocompromised Subjects [NCT00979251]Phase 22 participants (Actual)Interventional2009-09-30Completed
Gait Pattern Analysis in Neurological Disease [NCT02994719]120 participants (Anticipated)Observational2016-03-01Active, not recruiting
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment [NCT02471222]Phase 260 participants (Actual)Interventional2015-05-31Completed
Urinary Excretion of Acetylamantadine by Cancer Patients [NCT02277938]120 participants (Anticipated)Observational2013-08-31Recruiting
Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial [NCT04302870]Phase 2/Phase 3800 participants (Anticipated)Interventional2020-02-27Recruiting
Amantadine Addition to Paliperidone ER or Risperidone Consta Therapy for Prolactin Elevation [NCT00975611]Phase 46 participants (Actual)Interventional2009-10-31Terminated(stopped due to The sponsor withdrew support due to slow accrual of eligible subjects.)
Effects of Amantadine on Postoperative Cognitive Dysfunction in Elderly Patients With Elective Abdominal Surgery [NCT03527134]390 participants (Anticipated)Interventional2019-04-30Not yet recruiting
The Effect of Amantadine on Post-COVD-19 Fatigue: a Clinical Trial [NCT05667077]Phase 283 participants (Anticipated)Interventional2022-12-26Not yet recruiting
A Double Blind, Placebo-controlled Study for the Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy [NCT01313819]Phase 420 participants (Anticipated)Interventional2011-04-30Recruiting
Amantadine Therapy for Cognitive Impairment Related to Post-COVID Condition [NCT06055244]Phase 160 participants (Anticipated)Interventional2023-10-15Not yet recruiting
Evaluation of the Long-term Effects of Amantadine in Parkinsonian's Suffering From Dyskinesia Induced by Levodopa: Study Randomised Double-blind, Placebo - Cessation of a Chronic Prescription. STUDY AMANDYSK. [NCT00632762]Phase 480 participants (Anticipated)Interventional2007-11-30Completed
Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection [NCT00830323]Phase 260 participants (Anticipated)Interventional2009-01-31Terminated
The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia [NCT00950196]Phase 430 participants (Anticipated)Interventional2008-11-30Completed
Is Long-term Use of Amantadine Effective in Parkinson Disease? [NCT04260581]32 participants (Anticipated)Interventional2020-03-01Not yet recruiting
A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias [NCT02153645]Phase 387 participants (Actual)Interventional2014-08-18Terminated
Urinary Excretion of Acetylamantadine by Normal Healthy Volunteers [NCT01467258]20 participants (Actual)Interventional2011-11-30Completed
Promoting Recovery After STroke With Amantadine [NCT05140148]Phase 260 participants (Anticipated)Interventional2022-02-01Recruiting
The Assessment of the Safety, Efficacy, and Practicality of an Algorithm Including Amantadine, Metformin and Zonisamide for the Prevention of Olanzapine-Associated Weight Gain in Outpatients With Schizophrenia [NCT00401973]Phase 3199 participants (Actual)Interventional2006-11-30Completed
Mechanism of Amantadine and Functional Improvement Following Acquired Brain Injury as Measured by MRI Tractography; A Pilot Study [NCT02566720]10 participants (Anticipated)Interventional2016-01-31Not yet recruiting
A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias [NCT02153632]Phase 3135 participants (Actual)Interventional2014-07-30Terminated
Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability: A Randomized, Double-Blind, Placebo-Controlled Trial [NCT00627250]76 participants (Actual)Interventional2003-03-31Completed
A Multicenter Prospective Randomized Controlled Trial of the Effectiveness of Amantadine Hydrochloride in Promoting Recovery of Function Following Severe Traumatic Brain Injury [NCT00970944]Phase 2/Phase 3184 participants (Actual)Interventional2003-02-28Completed
Potential Impact of Amantadine on Traumatic Brain Injury Outcomes [NCT04527289]Phase 450 participants (Actual)Interventional2020-09-30Completed
Evaluation of the Effect of Preoperative Intravenous Amantadine Sulfate on the Postoperative Early Cognitive Functions in a Elderly Patient With Laparoscopic Radical Prostatectomy [NCT03988010]Phase 454 participants (Anticipated)Interventional2019-05-01Active, not recruiting
Efficacy of Amantadine Treatment in COVID-19 Patients [NCT04952519]Phase 3193 participants (Actual)Interventional2021-03-30Terminated(stopped due to The annual analysis did not show the efficacy of the investigational medicinal product in this application, therefore the study was not continued.)
Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine [NCT00600093]Phase 220 participants (Anticipated)Interventional2008-01-31Terminated(stopped due to PI leaving the institute for a fellowship.)
A Double-blind, Randomized, Placebo-controlled Trial With Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia [NCT00999505]Phase 340 participants (Anticipated)Interventional2010-05-31Recruiting
Amantadine Hydrochloride for Treatment of Symptoms of the Post-traumatic Confusional State Among Neurorehabilitation Admissions With TBI: A Randomized, Double-Blind, Placebo-Controlled Trial [NCT00693121]Phase 479 participants (Actual)Interventional2003-04-30Completed
A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Study of Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine [NCT04173832]100 participants (Anticipated)Interventional2020-01-01Recruiting
Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Patients Who Are Non-responders to Interferon Alpha Plus Ribavirin [NCT00538811]Phase 2/Phase 340 participants (Anticipated)InterventionalCompleted
Amantadine and Temporal Discrimination in Patients With Traumatic Brain Injury [NCT00800514]0 participants (Actual)Interventional2009-01-31Withdrawn(stopped due to Principal investigator took a position at another institution. No subjects enrolled.)
A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications [NCT01227967]Phase 2881 participants (Actual)Interventional2010-09-30Completed
Use of Amantadine in Treating Cognitive and Motor Impairments in Adolescents and Adults With Cerebral Palsy [NCT04273737]Phase 411 participants (Actual)Interventional2020-02-28Terminated(stopped due to PI left institution.)
Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease [NCT00794313]3 participants (Actual)Interventional2009-09-30Terminated(stopped due to Funding Ended)
An Open-Label, Multiple Dose, Randomized, Three-Period Crossover Study in Healthy Volunteers to Evaluate the Effect of co-Administration of Amantadine 100 mg BID and Oseltamivir 75 mg BID on the Pharmacokinetic Properties of Amantadine and Oseltamivir. [NCT00416962]Phase 118 participants Interventional2006-08-31Completed
Randomized, Open-Label, Multicenter Study Examining the Effects of Duration of Treatment of PEGASYS® in Combination With Daily COPEGUS® + Amantadine in Patients With Chronic HCV After Relapse to Previous (Peg)IFN + Ribavirin Therapy. [NCT00299923]Phase 3300 participants Interventional2005-11-30Active, not recruiting
Evaluation of Pharmacologically-induced Changes in Excitatory Glutamatergic Neurotransmission of Severe TBI Patients [NCT04244058]Early Phase 130 participants (Anticipated)Interventional2020-09-23Suspended(stopped due to Given CoVid-19 pandemic we could not recruit subjects/patients for the 1st year. Currently waiting for new sponsor to fulfill the aims.)
Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients [NCT00146016]Phase 3390 participants Interventional2000-02-29Completed
A Double-Blind, Placebo Controlled Trial of Propranolol and Amantadine for the Treatment of Cocaine Dependent Subjects With Severe Cocaine Withdrawal Symptoms [NCT00158132]Phase 2199 participants (Actual)Interventional1999-09-30Completed
Randomized Placebo-Controlled Trial of a Triple Therapy Combining Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine Versus Peginterferon Alfa-2a Plus Ribavirin Plus Placebo in Hepatitis C-Infected Patients Non Responders to a First-Line Therapy of Inte [NCT00221624]Phase 3131 participants (Actual)Interventional2001-11-30Completed
Impact of Amantadine on L-DOPA-induced Dyskinesia in Early Parkinson's Disease: a Placebo-controlled Randomized Study (the PREMANDYSK Study) [NCT01538329]Phase 2210 participants (Actual)Interventional2012-03-04Completed
Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous HCV Non Responders ANRSHC03 BITRI [NCT00122629]Phase 3405 participants Interventional2000-10-31Terminated
Prepulse Inhibition of Startle in Cocaine Dependence (Human) [NCT00015249]Phase 10 participants Interventional1997-02-28Completed
Modeling Impaired Judgement in Cocaine Abusers [NCT00015236]Phase 40 participants Interventional1997-03-31Completed
Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) [NCT00127114]Phase 40 participants (Actual)Interventional2005-09-30Withdrawn(stopped due to No funding and exclusion criteria were to stringent.)
Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatiti [NCT00127777]Phase 4700 participants Interventional2002-07-31Active, not recruiting
Effects of NMDA-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy in Young and Elderly Patients [NCT00188383]Phase 1/Phase 2132 participants Interventional2004-01-31Recruiting
Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-CoV2 Infection [NCT04367883]3,000 participants (Anticipated)Observational2020-03-01Recruiting
A Pilot, Randomized Study Comparing the Safety, Tolerability and Pharmacokinetics of Combination Therapy (Amantadine, Ribavirin, Oseltamivir) Versus Neuraminidase Inhibitor Monotherapy to Influenza Virus Infected Immunocompromised Patients [NCT00867139]Phase 1/Phase 27 participants (Actual)Interventional2009-03-31Completed
Comparison of the Efficacy and Safety of Immediate (b.i.d) and Modified (q.d.) Release Cefpodoxime Formulations in the Treatment of Acute Sinusitis: a Double-blind, Randomized, Phase III, Non-inferiority Study. [NCT03729258]Phase 3100 participants (Anticipated)Interventional2019-05-15Recruiting
Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma [NCT04530006]20 participants (Anticipated)Interventional2020-12-02Recruiting
Double Blind Placebo Controlled Investigation of Amantadine for Retarding Weight Gain in First Episode Adlt Psychotic Subjects Beginning Therapy With Olanzapine. [NCT00287352]Phase 140 participants (Actual)Interventional2005-05-31Completed
Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis: Phase III Study, Controlled, Randomized, Crossed Over and Double Blind. [NCT05809414]Phase 3144 participants (Anticipated)Interventional2022-11-28Recruiting
Efficacy of Amantadine for Gait Dysfunction and Gait Freezing in Patients With Parkinson's Disease [NCT01652534]Phase 33 participants (Actual)Interventional2011-06-30Terminated(stopped due to Due to lack of recruitment)
Amantadine to Speed Awakening After Cardiac Arrest [NCT02486211]Phase 214 participants (Actual)Interventional2015-09-30Completed
A Phase IIa, Double-blind, Placebo-controlled, Randomised, Fourfold Crossover Study to Investigate the Glucose Lowering Effects of Dextromethorphan and Amantadine in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test [NCT01441986]Phase 220 participants (Actual)Interventional2011-09-30Completed
Amantadine for Neuroenhancement in Acute Patients Study - A Prospective Pilot Proof of Concept Phase IIb Study in Intensive and Intermediate Care Unit Patients [NCT05479032]Phase 250 participants (Anticipated)Interventional2022-09-30Not yet recruiting
NMDA-Receptor Blockade in Huntington's Chorea [NCT00001930]Phase 225 participants Interventional1999-04-30Completed
Rapid Evaluation of Cocaine Pharmacotherapies (Amantadine) [NCT00000301]Phase 20 participants Interventional1996-03-31Completed
Pharmacotherapy for Schizophrenic Drug Users [NCT00000281]Phase 20 participants Interventional1994-09-30Completed
Amantadine + rTMS as a Neurotherapeutic for Disordered Consciousness [NCT02025439]4 participants (Actual)Interventional2014-02-28Completed
Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis [NCT03185065]Phase 3141 participants (Actual)Interventional2017-10-04Completed
Amantadine for COVID-19: A Randomized, Placebo Controlled, Double-blinded, Clinical Trial [NCT04894617]Phase 3226 participants (Anticipated)Interventional2021-06-01Recruiting
The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms in Patients Infected With the SARS-CoV-2 Virus [NCT04854759]Phase 3200 participants (Anticipated)Interventional2021-03-15Recruiting
Citicholine-Amantadine Trial in Traumatic Brain Injury [NCT03430817]Phase 445 participants (Actual)Interventional2017-12-07Active, not recruiting
The Impact and Outcomes of Combined Cerebrolysin and Amantadine Sulfate Administration on Management of Patients With Traumatic Brain Injury in the ICU [NCT06052787]Phase 3150 participants (Anticipated)Interventional2023-09-01Recruiting
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease [NCT01789047]Phase 242 participants (Actual)Interventional2013-03-31Terminated(stopped due to Sponsor withdrew support)
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) [NCT01397422]Phase 2/Phase 383 participants (Actual)Interventional2011-07-31Completed
Effect of Amantadine Administration on Spatial Functioning Following Traumatic Brain Injury [NCT02321761]Phase 410 participants (Anticipated)Interventional2014-06-30Recruiting
ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study) [NCT02274766]Phase 377 participants (Actual)Interventional2014-10-31Completed
A 3-arm, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment [NCT03436199]Phase 3558 participants (Actual)Interventional2018-03-29Completed
Oral Amantadine Versus IV Amantadine to Attenuate the Hemodynamic Response to Laryngoscopy, Tracheal Intubation and Surgical Incision and Their Effect on β-endorphin: A Randomized Clinical Trial [NCT03612921]Phase 260 participants (Anticipated)Interventional2018-08-15Recruiting
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID) [NCT02202551]Phase 3223 participants (Actual)Interventional2014-07-31Completed
Urinary Excretion of Acetylamantadine by Cancer Patients [NCT00755898]Phase 2150 participants (Actual)Interventional2003-12-31Completed
Evaluation of Treatments With Antihistamines and Amantadine in the Evolution of the SARS-CoV-2 Infection [NCT05504057]170,000 participants (Anticipated)Observational2020-03-01Recruiting
Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study) [NCT02136914]Phase 3126 participants (Actual)Interventional2014-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00401973 (11) [back to overview]Mean Change From Baseline to Endpoint in Fasting Glucose
NCT00401973 (11) [back to overview]Mean Change From Baseline to Endpoint in Hemoglobin A1c
NCT00401973 (11) [back to overview]Mean Change From Baseline to Endpoint in Fasting Triglycerides
NCT00401973 (11) [back to overview]Mean Change From Baseline to Endpoint in Fasting Total Cholesterol
NCT00401973 (11) [back to overview]Mean Change From Baseline to Endpoint in Fasting Low Density Lipoprotein (LDL) Cholesterol
NCT00401973 (11) [back to overview]Mean Change From Baseline to Endpoint in Fasting High Density Lipoprotein (HDL) Cholesterol
NCT00401973 (11) [back to overview]Correlations Between Weight Changes and Changes in Eating Inventory (EI) and Food Craving Inventory (FCI) at 2 Weeks and 22 Weeks
NCT00401973 (11) [back to overview]Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
NCT00401973 (11) [back to overview]Change From Baseline to Endpoint in Clinical Global Impression - Severity Scale (CGI-S)
NCT00401973 (11) [back to overview]Change From Baseline to Endpoint in Brief Psychiatric Rating Scale (BPRS) Total Score
NCT00401973 (11) [back to overview]Change From Baseline to Endpoint in Weight
NCT00779324 (10) [back to overview]Change in Neuropsychiatric Inventory - Irritability Domain Assessed by Observer Day 28
NCT00779324 (10) [back to overview]Change in Neuropsychiatric Inventory - Irritability Domain Assessed by Observers Day 60
NCT00779324 (10) [back to overview]Change in Neuropsychiatric Inventory - Irritability Domain Assessed by Participants Day 28
NCT00779324 (10) [back to overview]Change in Neuropsychiatric Inventory - Irritability Domain Assessed by Participants Day 60
NCT00779324 (10) [back to overview]Clinical Global Impressions Day 28
NCT00779324 (10) [back to overview]Clinical Global Impressions Day 60
NCT00779324 (10) [back to overview]Proportion of Participants With >2-point Increase on Neuropsychiatric Inventory - Irritability Domain Rated by Observer Day 28
NCT00779324 (10) [back to overview]Proportion of Participants With >2-point Increase on Neuropsychiatric Inventory - Irritability Domain Rated by Participant Day 28
NCT00779324 (10) [back to overview]Proportion of Participants With >2-point Increase on Neuropsychiatric Inventory - Irritability Domain Rated by Participant Day 60
NCT00779324 (10) [back to overview]Proportion of Participants With >2-point Increase on Neuropsychiatric Inventory Irritability Domain Rated by Observers Day 60
NCT00794313 (2) [back to overview]Forceplate AUC
NCT00794313 (2) [back to overview]Modified Abnormal Involuntary Movement Scale Area Under the Curve
NCT00867139 (12) [back to overview]Number of Participants With Intubations
NCT00867139 (12) [back to overview]Number of Participants With ICU Admissions
NCT00867139 (12) [back to overview]Number of Participants With Viral Load Decrease as a Function of Time
NCT00867139 (12) [back to overview]Number of Participants With Viral Resistance as a Function of Drug Exposure
NCT00867139 (12) [back to overview]Pharmacokinetics (AUC0-last) of TCAD
NCT00867139 (12) [back to overview]Number of Patients Not Shedding Virus at Day 5 +/-1 and Day 10 +/- 1
NCT00867139 (12) [back to overview]Number of Participants With Adverse Events (AEs), Drug Specific AEs or AEs Resulting in Treatment Interruption
NCT00867139 (12) [back to overview]Duration of Hospitalization
NCT00867139 (12) [back to overview]Duration of Symptoms
NCT00867139 (12) [back to overview]Days on Supplemental Oxygen
NCT00867139 (12) [back to overview]Number of Deaths
NCT00867139 (12) [back to overview]Frequency of Confirmed Pneumonia
NCT00970944 (2) [back to overview]Disability Rating Scale: Functional Status
NCT00970944 (2) [back to overview]JFK Coma Recovery Scale-Revised: Neurobehavioral Status
NCT01071395 (1) [back to overview]The Investigators Will Assess Effect Size With Each Scale for Detecting Change From Baseline and Change Between Amantadine and Placebo; Allowing Assessment of Sensitivity and Specificity for Each Scale Based on Receiver Operator Characteristics (ROC).
NCT01227967 (14) [back to overview]Time to Return of Physical Function to Pre-illness Leve
NCT01227967 (14) [back to overview]Time to Return to Pre-influenza Function
NCT01227967 (14) [back to overview]Percentage of Participants Who Develop Bronchitis, Pneumonia, or Other Complications of Influenza After Day 0.
NCT01227967 (14) [back to overview]qPCR Viral Shedding
NCT01227967 (14) [back to overview]Number of Participants by Virus Detection Status
NCT01227967 (14) [back to overview]Time to Absence of Fever
NCT01227967 (14) [back to overview]28-day Mortality
NCT01227967 (14) [back to overview]Percentage of Participants Who Required Hospitalization.
NCT01227967 (14) [back to overview]Percentage of Participants Who Required New or Increased Use of Supplemental Oxygen
NCT01227967 (14) [back to overview]Percentage of Participants With Clinical Failure at Day 5
NCT01227967 (14) [back to overview]Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs
NCT01227967 (14) [back to overview]Time to Alleviation of Influenza Clinical Symptoms.
NCT01227967 (14) [back to overview]Time to Feeling as Good as Before the Onset of the Influenza Illness
NCT01227967 (14) [back to overview]Time to Resolution of All Symptoms AND Fever
NCT01397422 (5) [back to overview]Change in Total Objective Score (III, IV) of the UDysRS From Baseline to Week 8
NCT01397422 (5) [back to overview]Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score From Baseline to Week 8
NCT01397422 (5) [back to overview]Change in the Fatigue Severity Score (FSS) From Baseline to Week 8
NCT01397422 (5) [back to overview]Change in ON Time Without Troublesome Dyskinesia (ON Without Dyskinesia Plus ON With Non-troublesome Dyskinesia) From Baseline to Week 8; Based on a Standardized PD Home Diary
NCT01397422 (5) [back to overview]Change in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Combined Scores (Parts I, II, III) From Baseline to Week 8
NCT01652534 (12) [back to overview]Parkinson's Disease Questionnaire-39 (PDQ-39)
NCT01652534 (12) [back to overview]Timed Up and Go (TUG) - OFF Usual Medication
NCT01652534 (12) [back to overview]Timed Up and Go (TUG) - ON Usual Medication
NCT01652534 (12) [back to overview]Timed Up and Go (TUG) - ON Usual Medication
NCT01652534 (12) [back to overview]Clinical Global Impression (CGI)
NCT01652534 (12) [back to overview]Number of Participants With Drug Safety Reports
NCT01652534 (12) [back to overview]Number Who Completed Medication as Randomized
NCT01652534 (12) [back to overview]Analysis of Motor Functioning Using the Parkinson's Home Diaries
NCT01652534 (12) [back to overview]Analysis of Motor Functioning Using the Parkinson's Home Diaries
NCT01652534 (12) [back to overview]Fatigue Severity Scale (FSS)
NCT01652534 (12) [back to overview]Freezing of Gait Questionnaire
NCT01652534 (12) [back to overview]Modified Timed Up and Go (mTUG)
NCT01789047 (1) [back to overview]The Unified Dyskinesia Rating Scale (UDysRS)
NCT02025439 (1) [back to overview]Intensity of Adverse Event
NCT02136914 (5) [back to overview]Change in the Standardized PD Home Diary (ON Time Without Troublesome Dyskinesia, ON Time With Troublesome Dyskinesia, OFF Time)
NCT02136914 (5) [back to overview]Change in the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Combined Score (Parts I, II, and III)
NCT02136914 (5) [back to overview]Change From Baseline in the Unified Dyskinesia Rating Scale (UDysRS) Score at Week 24
NCT02136914 (5) [back to overview]Change From Baseline in the Unified Dyskinesia Rating Scale (UDysRS) Score at Week 12
NCT02136914 (5) [back to overview]Clinician's Global Impression of Change (CGI-C) in Overall PD Symptoms
NCT02153632 (2) [back to overview]Unified Dyskinesia Rating Scale
NCT02153632 (2) [back to overview]Mobility State Self-Assessment - Subject Diary Cards
NCT02153645 (2) [back to overview]Unified Dyskinesia Rating Scale
NCT02153645 (2) [back to overview]Mobility State Self-Assessment - Subject Diary Cards
NCT02202551 (3) [back to overview]Change From Baseline in Movement Disorder's Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) (Parts I-III Combined Scores)
NCT02202551 (3) [back to overview]Change From Baseline in Movement Disorder's Society - Unified Parkinson's Disease Rating Scale MDS-UPDRS (Part IV - Motor Complications)
NCT02202551 (3) [back to overview]Number of Participants With Reported AEs and Safety-Related Study Drug Discontinuations
NCT02274766 (2) [back to overview]Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score
NCT02274766 (2) [back to overview]Change in the Standardized PD Home Diary (ON Time Without Dyskinesia, ON Time With Troublesome Dyskinesia, OFF Time)
NCT02486211 (5) [back to overview]Rate of Awakening (Number of Patients Who Are Able to Follow Commands)
NCT02486211 (5) [back to overview]Seizures (Number of Patients Who Experience Seizures as Detected by EEG Monitoring With or Without Clinical Correlate)
NCT02486211 (5) [back to overview]Time to Awakening
NCT02486211 (5) [back to overview]Nausea or Vomiting
NCT02486211 (5) [back to overview]Number of Participants With Severe or Intracranial Bleeding
NCT03185065 (4) [back to overview]Acceptability of Treatment as Assessed by a Single Question Questionnaire
NCT03185065 (4) [back to overview]Epworth Sleepiness Scale (ESS) Score
NCT03185065 (4) [back to overview]Modified Fatigue Impact Scale (MFIS) Score
NCT03185065 (4) [back to overview]Quality of Life in Neurological Disorders (Neuro-QoL) Item Bank - Fatigue Score
NCT03436199 (4) [back to overview]2-Minute Walk Test (2MWT): Change From Baseline at Week 16
NCT03436199 (4) [back to overview]Timed 25 Foot Walk (T25FW, Feet/Second): the Proportion of Subjects With a ≥ 20% Increase in Walking Speed (Measured by T25FW) From Baseline at Week 16 (Responder Analysis)
NCT03436199 (4) [back to overview]Timed 25 Foot Walk: Change From Baseline at Week 16
NCT03436199 (4) [back to overview]Timed Up and Go (TUG): Change From Baseline at Week 16
NCT03567057 (10) [back to overview]2-Minute Walk Test (Week 52 Value)
NCT03567057 (10) [back to overview]Number of Patients With Adverse Events
NCT03567057 (10) [back to overview]Timed 25-Foot Walk (Feet/Second) (Baseline Value)
NCT03567057 (10) [back to overview]Timed up and go (Baseline Value)
NCT03567057 (10) [back to overview]Timed up and go (Week 24 Value)
NCT03567057 (10) [back to overview]Timed up and go (Week 52 Value)
NCT03567057 (10) [back to overview]2-Minute Walk Test (Baseline Value)
NCT03567057 (10) [back to overview]2-Minute Walk Test (Week 24 Value)
NCT03567057 (10) [back to overview]Timed 25-Foot Walk (Feet/Second) (Week 52 Value)
NCT03567057 (10) [back to overview]Timed 25-Foot Walk (Feet/Second) (Week 24 Value)
NCT04273737 (6) [back to overview]Mean PHQ-9 Score
NCT04273737 (6) [back to overview]Mean Brief-A Score
NCT04273737 (6) [back to overview]Mean Brief-A Score
NCT04273737 (6) [back to overview]Mean PHQ-9 Score
NCT04273737 (6) [back to overview]Mean Brief-A Score
NCT04273737 (6) [back to overview]Mean PHQ-9 Score

Mean Change From Baseline to Endpoint in Fasting Glucose

(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,,
Interventionmillimole per Liter (mmol/L) (Mean)
BaselineChange from Baseline
Olanzapine5.320.26
Olanzapine + Amantadine5.250.10
Olanzapine + Metformin5.280.01

[back to top]

Mean Change From Baseline to Endpoint in Hemoglobin A1c

(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,,
Interventionpercent hemoglobin A1c (Mean)
BaselineChange from Baseline
Olanzapine5.510.09
Olanzapine + Amantadine5.480.10
Olanzapine + Metformin5.53-0.03

[back to top]

Mean Change From Baseline to Endpoint in Fasting Triglycerides

(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,,
Interventionmillimoles per Liter (mmol/L) (Mean)
BaselineChange from Baseline
Olanzapine1.580.33
Olanzapine + Amantadine1.610.35
Olanzapine + Metformin1.680.06

[back to top]

Mean Change From Baseline to Endpoint in Fasting Total Cholesterol

(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,,
Interventionmillimole per Liter (mmol/L) (Mean)
BaselineChange from Baseline
Olanzapine5.010.36
Olanzapine + Amantadine5.030.01
Olanzapine + Metformin4.91-0.08

[back to top]

Mean Change From Baseline to Endpoint in Fasting Low Density Lipoprotein (LDL) Cholesterol

(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,,
Interventionmillimole per Liter (mmol/L) (Mean)
BaselineChange from Baseline
Olanzapine3.020.16
Olanzapine + Amantadine3.06-0.04
Olanzapine + Metformin2.91-0.02

[back to top]

Mean Change From Baseline to Endpoint in Fasting High Density Lipoprotein (HDL) Cholesterol

(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,,
Interventionmillimole per liter (mmol/L) (Mean)
BaselineChange from Baseline
Olanzapine1.25-0.00
Olanzapine + Amantadine1.26-0.11
Olanzapine + Metformin1.22-0.08

[back to top]

Correlations Between Weight Changes and Changes in Eating Inventory (EI) and Food Craving Inventory (FCI) at 2 Weeks and 22 Weeks

To understand the drivers of weight gain as indicated by the correlation between weight changes and changes in the Eating Inventory (EI) and Food Craving Inventory (FCI). The EI is a 51-item inventory that measures dietary restraint, disinhibition, and perceived hunger. The FCI is a 28-item instrument measuring the frequency over the past month of general cravings and cravings for specific types of foods, namely: high fats, sweets, carbohydrates/starches, and fast-food fats. Correlations were computed on the combined treatment groups. (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,
Interventioncorrelation (Number)
EI: DisinhibitionEI: Cognitive RestraintEI: HungerFCI: Carbohydrates/Starches (N=186, N=141)FCI: Fast Food Fats (N=188, N=140)FCI: High Fats (N=186, N=138)FCI: Sweets (N=187, N=140)FCI: Total Score (N=184, N=137)
2 Weeks-0.034-0.273-0.1500.013-0.0190.0510.0220.039
22 Weeks0.285-0.0380.148-0.0640.0470.043-0.008-0.000

[back to top]

Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,,
Interventionunits on a scale (Mean)
BaselineChange from Baseline
Olanzapine12.76-6.39
Olanzapine + Amantadine14.22-4.12
Olanzapine + Metformin15.40-4.36

[back to top]

Change From Baseline to Endpoint in Clinical Global Impression - Severity Scale (CGI-S)

Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,,
Interventionunits on a scale (Mean)
BaselineChange from Baseline
Olanzapine4.06-0.98
Olanzapine + Amantadine4.03-0.72
Olanzapine + Metformin4.00-0.79

[back to top]

Change From Baseline to Endpoint in Brief Psychiatric Rating Scale (BPRS) Total Score

The BPRS is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Each item is rated on a scale from 1 (symptom not present) to 7 (symptom extremely severe). The BPRS total score ranges from 18 to 126. (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,,
Interventionunits on a scale (Mean)
BaselineChange from Baseline
Olanzapine48.24-13.89
Olanzapine + Amantadine45.90-9.90
Olanzapine + Metformin47.00-9.72

[back to top]

Change From Baseline to Endpoint in Weight

(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

Interventionkilograms (Least Squares Mean)
Olanzapine2.76
Olanzapine + Amantadine2.40
Olanzapine + Metformin0.65

[back to top]

Change in Neuropsychiatric Inventory - Irritability Domain Assessed by Observer Day 28

The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 28

Interventionscore on a scale (Median)
Amantadine-4
Placebo-4

[back to top]

Change in Neuropsychiatric Inventory - Irritability Domain Assessed by Observers Day 60

The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 60

Interventionscore on a scale (Median)
Amantadine-5
Placebo-4

[back to top]

Change in Neuropsychiatric Inventory - Irritability Domain Assessed by Participants Day 28

The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 28

Interventionscore on a scale (Median)
Amantadine-3
Placebo-2

[back to top]

Change in Neuropsychiatric Inventory - Irritability Domain Assessed by Participants Day 60

The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 60

Interventionscore on a scale (Median)
Amantadine-3
Placebo-2

[back to top]

Clinical Global Impressions Day 28

Study physician's impression of change since study onset. Clinicians Global Impressions of Change (CGI) is a sensitive, standardized tool to assess psychopharmacologic treatment response completed by the study physician. The Global Improvement (GI) CGI subscale documented the clinician's impression of change. The GI uses a 7-point scale to assess beneficial and negative effects. Low GI values (1 -3) indicate improvement; higher values (4-7) represent worsening. (NCT00779324)
Timeframe: 28 Days

Interventionscore on a scale (Median)
Amantadine3.00
Placebo3.00

[back to top]

Clinical Global Impressions Day 60

Study physician's impression of change since study onset. Clinicians Global Impressions of Change (CGI) is a sensitive, standardized tool to assess psychopharmacologic treatment response completed by the study physician. The Global Improvement (GI) CGI subscale documented the clinician's impression of change. The GI uses a 7-point scale to assess beneficial and negative effects. Low GI values (1 -3) indicate improvement; higher values (4-7) represent worsening. (NCT00779324)
Timeframe: 60 days

Interventionscore on a scale (Median)
Amantadine3.00
Placebo3.00

[back to top]

Proportion of Participants With >2-point Increase on Neuropsychiatric Inventory - Irritability Domain Rated by Observer Day 28

The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 28

Interventionpercentage of participants NPI improve>2 (Number)
Amantadine66.3
Placebo66.7

[back to top]

Proportion of Participants With >2-point Increase on Neuropsychiatric Inventory - Irritability Domain Rated by Participant Day 28

The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 28

Interventionpercentage of participants NPI improve>2 (Number)
Amantadine51.3
Placebo40.5

[back to top]

Proportion of Participants With >2-point Increase on Neuropsychiatric Inventory - Irritability Domain Rated by Participant Day 60

The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 60

Interventionpercentage of participants NPI improve>2 (Number)
Amantadine60.5
Placebo48.8

[back to top]

Proportion of Participants With >2-point Increase on Neuropsychiatric Inventory Irritability Domain Rated by Observers Day 60

As described above for the primary measure, assessed as a secondary measure at Day 60. The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: 60 days

Interventionpercentage of participants NPI improve>2 (Number)
Amantadine74.7
Placebo68.3

[back to top]

Forceplate AUC

Area under the curve for the root mean squared velocity in the anterior-posterior direction as measured by a forceplate. (NCT00794313)
Timeframe: Every 1/2 hour for 8 hour levodopa cycle

Intervention(meters/second)*hours (Mean)
Amantadine10.4
Amantadine Plus Topiramate9.4
Sugar Pill19.1

[back to top]

Modified Abnormal Involuntary Movement Scale Area Under the Curve

Area under the curve computed for whole body (total) mAIMS (Modified Abnormal Involuntary Movement Scale) scores at each time measurement. This is a commonly utilized scale that is completed by an observer who judges the severity of levodopa induced dyskinesia (LID) in 7 body parts (face, neck, trunk, both legs, and both arms). All body parts are rated separately on this 0 (none) to 4 (severe - markedly impairs activities) scale. Thus, the total score can range from 0 - 28 with 28 indicating the most severe LID. mAIMS ratings occur as the subject performs the cognitive task while standing on the force plate. mAIMS ratings are made every half hour during the levodopa (LD) dose cycle. (NCT00794313)
Timeframe: Measured every 1/2 hour for a levodopa dose cycle (starting 1 hour prior to infusion and ending 4 hours post 2-hour infusion)

InterventionUnits on a Scale * Hours (Mean)
Amantadine4.0
Amantadine Plus Topiramate5.3
Sugar Pill8.5

[back to top]

Number of Participants With Intubations

(NCT00867139)
Timeframe: 58 days

Interventionparticipants (Number)
TCAD0
Neuraminidase Inihibitor Monotherapy0
Open-labeled TCAD1

[back to top]

Number of Participants With ICU Admissions

The number of participants with ICU admissions was evaluated. (NCT00867139)
Timeframe: baseline and up to 58 days

Interventionparticipants (Number)
TCAD0
Neuraminidase Inihibitor Monotherapy0
Open-labeled TCAD1

[back to top]

Number of Participants With Viral Load Decrease as a Function of Time

Viral loads were measured by quantitative Polymerase Chain Reaction (PCR) on day 1, 3, 5, 7, 9, 15, 20 and 28, if applicable. (NCT00867139)
Timeframe: baseline and 28 days

Interventionnumber of participants (Number)
Neuraminidase Inhibitor Monotherapy0
Open-label TCAD2

[back to top]

Number of Participants With Viral Resistance as a Function of Drug Exposure

Viral resistance was assessed within 28 days after drug administration by detecting resistance-conferring mutation genes and compared to the value at baseline. (NCT00867139)
Timeframe: 28 days

InterventionNumber of participants (Number)
TCAD0
Neuraminidase Inihibitor Monotherapy1
Open-labeled TCAD0

[back to top]

Pharmacokinetics (AUC0-last) of TCAD

Only 5 patients had partial pharmacokinetic (PK) data available. Plasma concentration of oseltamivir was measured at several time points in one patient receiving neuraminidase inhibitor monotherapy. Plasma concentration of oseltamivir, amantadine, and ribavirin were measured at several time points in four patients receiving TCAD therapy. Area under the time-concentration curve up to the last measured time point (AUC0-last) was calculated from the plasma concentration-time profiles by non-compartmental analysis. (NCT00867139)
Timeframe: 5 days

Interventionng*hr/mL (Mean)
TCAD304
Neuraminidase Inhibitor Monotherapy1497
Open-lable TCAD2487

[back to top]

Number of Patients Not Shedding Virus at Day 5 +/-1 and Day 10 +/- 1

(NCT00867139)
Timeframe: 10 days

,
Interventionparticipants (Number)
Day 5 +/-1Day 10 +/- 1
Neuraminidase Inihibitor Monotherapy00
Open-labeled TCAD01

[back to top]

Number of Participants With Adverse Events (AEs), Drug Specific AEs or AEs Resulting in Treatment Interruption

"Abnormal lab data or newly appeared symptoms & signs were considered as AEs.~Examined lab data:~Blood cell count (WBC, differential count, Red Blood Cell (RBC), Hemoglobin, Hematocrit, Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin Concentration (MCHC), platelets), Chemistry (Cl, bicarbonate (HCO3), K, Na), Renal function test (BUN, Creatinine, Creatinine clearance), Liver function test (AST, Alanine aminotransferase(ALT), T.Bil, gamma-glutamyltransferase)" (NCT00867139)
Timeframe: 30 days after the final dose of study drug

Interventionnumber of participants with AEs (Number)
TCAD1
Neuraminidase Inihibitor Monotherapy1
Open-labeled TCAD1

[back to top]

Duration of Hospitalization

(NCT00867139)
Timeframe: from baseline up to 58 days

Interventiondays (Mean)
TCAD6
Neuraminidase Inihibitor Monotherapy6
Open-labeled TCAD1

[back to top]

Duration of Symptoms

"Calculated as the number of days (mean) any persistent symptom lasted per patient as listed below.~overall health, short of breath, chills, cough, diarrhea, ear pain, fatigue, fever, headache, hoarseness, muscle ache, phlegm, runny nose, sinus congestion, sneezing, sore throat, watery eyes, wheezing" (NCT00867139)
Timeframe: from baseline up to 28 days

Interventiondays (Mean)
TCAD4.5
Neuraminidase Inhibitor Monotherapy1
Open-label TCAD4.7

[back to top]

Days on Supplemental Oxygen

(NCT00867139)
Timeframe: 58 days

Interventiondays (Mean)
TCAD2
Neuraminidase Inihibitor Monotherapy0
Open-labeled TCAD0

[back to top]

Number of Deaths

(NCT00867139)
Timeframe: 58 days

Interventionparticipants (Number)
TCAD0
Neuraminidase Inihibitor Monotherapy0
Open-labeled TCAD0

[back to top]

Frequency of Confirmed Pneumonia

(NCT00867139)
Timeframe: 58 days

Interventionparticipants (Number)
TCAD0
Neuraminidase Inihibitor Monotherapy0
Open-labeled TCAD1

[back to top]

Disability Rating Scale: Functional Status

"Measure of function after traumatic brain injury (TBI) intended to measure function from coma to community. Minimum score= 0; Maximum score= 29 (High scores are indicative of greater degree of disability)." (NCT00970944)
Timeframe: Randomization and weekly for 6 weeks. The primary study endpoint was week 4 and drug washout was week 6.

,
Interventionunits on a scale (Mean)
Week 4 (Primary endpoint)Week 6 (Drug washout)
Amantadine17.317.1
Placebo18.717.8

[back to top]

JFK Coma Recovery Scale-Revised: Neurobehavioral Status

"Measure of neurobehavioral function and clinical change for individuals with severe alterations of consciousness.~Minimum score= 0; Maximum score= 23 (Higher scores are indicative of a higher-level of neurobehavioral function)." (NCT00970944)
Timeframe: Week 4 (primary endpoint); Week 6 (post-washout)

,
Interventionunits on a scale (Mean)
Week 4 (Primary endpoint)Week 6 (Post-washout)
Amantadine15.815.7
Placebo14.215.1

[back to top]

The Investigators Will Assess Effect Size With Each Scale for Detecting Change From Baseline and Change Between Amantadine and Placebo; Allowing Assessment of Sensitivity and Specificity for Each Scale Based on Receiver Operator Characteristics (ROC).

Analyses of primary outcome measures tested sensitivity to change in dyskinesia (time effect) as well as sensitivity to differences in treatment effect (time-by-treatment interaction). These analyses were conducted using repeated-measures ANOVA (RM-ANOVA) or nonparametric analyses (Friedman's ANOVA with follow-up Wilcoxon tests). The RM-ANOVAs tested for changes in scale scores over baseline, week 4, and week 8 visits across the entire sample (time effect), as well as differences in these changes over time between treatment groups (time-by-treatment interaction). Effect size of time to change was compared using a partial eta-square estimate of effect size. An eta-squared less than or equal to 0.01 is considered small; 0.06 is considered medium; and, 0.14 is considered large. (NCT01071395)
Timeframe: 18 months

Interventionunitless (Number)
Amantadine0.061
Placebo0.061

[back to top]

Time to Return of Physical Function to Pre-illness Leve

Time to return of physical function to pre-illness level was defined as the time from Day 0 to the first of two successive measurements at which the physical function score equals or is better than the pre-illness score (obtained by recall at enrollment).For subjects who did not have two successive records meeting this criterion, follow-up was censored for analysis purposes at the time of the last but one diary card record with physical function evaluated. (NCT01227967)
Timeframe: From treatment initiation to Day 28

InterventionDays (Median)
Combination Therapy7.0
Oseltamivir Monotherapy6.0

[back to top]

Time to Return to Pre-influenza Function

Time to return to pre-influenza function is defined as the time from Day 0 to the first of two successive 'Yes' answers to the global assessment question 'Are you functioning as well as you were before you had the flu'.For participants who did not have two successive records meeting this criterion, follow-up was censored for analysis purposes at the time of the last but one diary card record with question answered. (NCT01227967)
Timeframe: From treatment initiation to Day 28

InterventionDays (Median)
Combination Therapy7.0
Oseltamivir Monotherapy6.0

[back to top]

Percentage of Participants Who Develop Bronchitis, Pneumonia, or Other Complications of Influenza After Day 0.

Participants were assessed for the signs/symptoms suggestive of one of the following complications: Sinusitis, Otitis Media ,Bronchitis / Bronchiolitis, Pneumonia and antibiotic use for reason other than above. (NCT01227967)
Timeframe: From treatment initiation to Day 28

,
Interventionpercentage of participants analyzed (Number)
SinustisOtitis MediaBronchitis BronchiolitisPneumoniaAntibiotic use for other reasonsAt least one complication and/or use of antibiotic
Combination Therapy4.50.35.72.28.616.6
Oseltamivir Monotherapy4.51.03.51.99.315.4

[back to top]

qPCR Viral Shedding

Median, 25% and 75% percentile of the value of viral shedding (Results = LOD, NCT01227967)
Timeframe: At Day 0, 3 and 7

,
InterventionLog10 copies/mL (Median)
Day 0Day 3Day 7
Combination Therapy6.43.43.2
Oseltamivir Monotherapy6.73.93.2

[back to top]

Number of Participants by Virus Detection Status

Number of participants who had undetectable values (less than the limit of detection [LOD]), who had values between the LOD and the lower limit of quantification (LLOQ), and who had values ≥LLOQ (NCT01227967)
Timeframe: At Day 0, 3 and 7.

InterventionParticipants (Count of Participants)
Day 072298058Day 072298059Day 372298059Day 372298058Day 772298058Day 772298059
>=LOD, Missing>=LLOQ
Combination Therapy221
Oseltamivir Monotherapy200
Oseltamivir Monotherapy9
Combination Therapy5
Oseltamivir Monotherapy15
Combination Therapy0
Oseltamivir Monotherapy0
Combination Therapy65
Oseltamivir Monotherapy87
Combination Therapy22
Oseltamivir Monotherapy25
Combination Therapy134
Oseltamivir Monotherapy104
Combination Therapy9
Oseltamivir Monotherapy8
Combination Therapy19
Oseltamivir Monotherapy24
Combination Therapy4
Oseltamivir Monotherapy7
Combination Therapy193
Oseltamivir Monotherapy184
Combination Therapy14

[back to top]

Time to Absence of Fever

Fever was considered present based on the diary cards if a subject reported a maximal temperature ≥38.0°C (for the period since the diary card was previously completed) or reported having taken an antipyretic drug (also for the period since the diary card was previously completed). Otherwise, fever was considered not present during the period since the diary card was previously completed, except that the evaluation was considered missing if either the temperature or the antipyretic drug use entry was not completed on the diary card. The duration of fever was defined as the time from Day 0 to the first of two successive assessments (through to Day 7) or to the first assessment (Day 8 onwards) at which no fever was present according to this definition.For participants who did not have two successive records meeting this criterion, follow-up was censored for analysis purposes at the time of the last but one diary card record with fever evaluated. (NCT01227967)
Timeframe: From treatment initiation to Day 28

InterventionDays (Median)
Combination Therapy0.5
Oseltamivir Monotherapy0.5

[back to top]

28-day Mortality

Number of deaths (NCT01227967)
Timeframe: From treatment initiation to Day 28

Interventionparticipants (Number)
Combination Therapy0
Oseltamivir Monotherapy1

[back to top]

Percentage of Participants Who Required Hospitalization.

The percentage of participants hospitalized by 28 days was estimated from the Kaplan-Meier curves. (NCT01227967)
Timeframe: From treatment initiation to Day 28

Interventionpercentage of participants analyzed (Number)
Combination Therapy4.28
Oseltamivir Monotherapy0.98

[back to top]

Percentage of Participants Who Required New or Increased Use of Supplemental Oxygen

Percentage of participants who required new or increased use of supplemental oxygen (NCT01227967)
Timeframe: From treatment initiation to Day 28

Interventionpercentage of participants analyzed (Number)
Combination Therapy1.91
Oseltamivir Monotherapy1.6

[back to top]

Percentage of Participants With Clinical Failure at Day 5

Clinical failure at Day 5 is defined as the need for continued (non-study) antiviral use after Day 5. (NCT01227967)
Timeframe: From treatment initiation to Day 28

Interventionpercentage of participants analyzed (Number)
Combination Therapy7.0
Oseltamivir Monotherapy7.7

[back to top]

Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs

The central laboratory performed a qualitative PCR test on the NP sample from Day 0 in order to confirm influenza infection and to determine the influenza type and subtype. For participants with a positive influenza test result at Day 0 from this qualitative PCR testing, the laboratory then performed qPCR testing of subsequent samples to quantify viral shedding. (NCT01227967)
Timeframe: At Day 3

Interventionpercentage of participants analyzed (Number)
Combination Therapy40
Oseltamivir Monotherapy50

[back to top]

Time to Alleviation of Influenza Clinical Symptoms.

The assessed symptoms were cough, nasal obstruction (stuffy nose), sore throat, fatigue, headache, muscle aches, feverishness, rhinorrhea, nausea, vomiting, diarrhea. Duration of clinical symptoms is defined as the time from Day 0 to the first of two successive measurements at which all clinical symptoms are grade 0 (absent) or 1 (mild). A measurement is considered to be the 8AM or 8PM assessment during Days 0 to 7 (so two measurements are obtained per day) and then the daily assessment thereafter. Time will then be calculated in half-days through to Day 7. If a subject's first two assessments on (baseline assessment and first subsequent diary card assessment) satisfy this criterion, then the duration will be set to zero. For participants who did not have two successive records meeting this criterion, follow-up was censored for analysis purposes at the time of the last but one diary card record with symptoms evaluated. (NCT01227967)
Timeframe: From treatment initiation to Day 28

InterventionDays (Median)
Combination Therapy4.5
Oseltamivir Monotherapy4.0

[back to top]

Time to Feeling as Good as Before the Onset of the Influenza Illness

Time to feeling as good as before influenza is defined as time to the first of two successive 'yes' responses to the question of 'feeling as good as you did before you had the flu'.For participants who did not have two successive records meeting this criterion, follow-up was censored for analysis purposes at the time of the last but one diary card record with question answered. (NCT01227967)
Timeframe: From treatment initiation to Day 28

InterventionDays (Median)
Combination Therapy7.5
Oseltamivir Monotherapy6.5

[back to top]

Time to Resolution of All Symptoms AND Fever

The assessed symptoms were cough, nasal obstruction (stuffy nose), sore throat, fatigue, headache, muscle aches, feverishness, rhinorrhea, nausea, vomiting, diarrhea. Fever was considered present based on the diary cards if a subject reported a maximal temperature ≥38.0°C (for the period since the diary card was previously completed) or reported having taken an antipyretic drug (also for the period since the diary card was previously completed). Time to resolution of all clinical symptoms and fever is defined as the time from Day 0 to the first of two successive measurements at which all clinical symptoms are grade 0 (absent) or 1(mild) and no fever >=38.0 C or antipyretic drug is reported. For participants who did not have two successive records meeting this criterion, follow-up was censored for analysis purposes at the time of the last but one diary card record with symptoms and fever evaluated. (NCT01227967)
Timeframe: From treatment initiation to Day 28

InterventionDays (Median)
Combination Therapy4.5
Oseltamivir Monotherapy4.5

[back to top]

Change in Total Objective Score (III, IV) of the UDysRS From Baseline to Week 8

UDysRS Part III measures objective impairment (dyskinesia severity, anatomic distribution, and type, based on 4 observed activities); and Part IV measures objective disability based on Part III activities. The scores for the 2 Parts combined range from 0-44; a higher score represents more severe dyskinesia. (NCT01397422)
Timeframe: Baseline (Day 1) and Week 8

Interventionunits on a scale (Least Squares Mean)
Placebo-1.9
ADS-5102 (260 mg)-4.4
ADS-5102 (340 mg)-7.1
ADS-5102 (420 mg)-8.3

[back to top]

Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score From Baseline to Week 8

The UDysRS is a dyskinesia rating scale from 0-104, and it evaluates involuntary movements associated with PD. A higher score indicates more severe PD. The last observation carried forward (LOCF) method was used for analysis. Participants were summarized according to the actual treatment received. (NCT01397422)
Timeframe: Baseline (Day 1) and Week 8

Interventionunits on a scale (Least Squares Mean)
Placebo-6.7
ADS-5102 (260 mg)-12.3
ADS-5102 (340 mg)-17.9
ADS-5102 (420 mg)-16.7

[back to top]

Change in the Fatigue Severity Score (FSS) From Baseline to Week 8

The FSS is a 9-item self-reported scale, rating subject experience of fatigue during the previous 7 days. The total score, on a scale from 1-7, is represented by the mean of all answered items. The higher the score, the greater the fatigue severity. (NCT01397422)
Timeframe: Baseline (Day 1) and Week 8

Interventionunits on a scale (Least Squares Mean)
Placebo-0.25
ADS-5102 (260 mg)-0.06
ADS-5102 (340 mg)-0.55
ADS-5102 (420 mg)0.00

[back to top]

Change in ON Time Without Troublesome Dyskinesia (ON Without Dyskinesia Plus ON With Non-troublesome Dyskinesia) From Baseline to Week 8; Based on a Standardized PD Home Diary

A PD home diary was used to score 5 different conditions in 30-minute time intervals: ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia. The results were based on 2 consecutive 24-hour diaries taken prior to the day of randomization and prior to the Week 8 visit. (NCT01397422)
Timeframe: Baseline (Day 1) and Week 8

Interventionhours (Least Squares Mean)
Placebo0.9
ADS-5102 (260 mg)4.1
ADS-5102 (340 mg)3.8
ADS-5102 (420 mg)3.6

[back to top]

Change in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Combined Scores (Parts I, II, III) From Baseline to Week 8

The MDS-UPDRS Parts I, II, and III examined non-motor experiences of daily living, motor experiences of daily living, and motor examination, respectively. Each part had sub scales ranging from normal = 0 to severe = 4. (NCT01397422)
Timeframe: Baseline (Day 1) and Week 8

Interventionunits on a scale (Least Squares Mean)
Placebo-1.2
ADS-5102 (260 mg)0.0
ADS-5102 (340 mg)-3.4
ADS-5102 (420 mg)0.5

[back to top]

Parkinson's Disease Questionnaire-39 (PDQ-39)

The Parkinson's Disease Questionnaire-39 (PDQ39) is a copyrighted instrument to assess symptoms of Parkinson's disease (PD) with 39 questions relating to mobility, activities of daily living, emotional well-being, social support, cognition, communication and bodily discomfort. The test asks subjects to rate each question regarding their Parkinson's disease symptoms over the past month. (range 0 to 100, lower scores reflect better quality of life) (NCT01652534)
Timeframe: Baseline, week 4

Interventionscore on a scale (Mean)
Baseline
Amantadine38

[back to top]

Timed Up and Go (TUG) - OFF Usual Medication

This is a walking assessment. The subject will begin in the seated position, stand up, walk 7 meters, turn around, and sit back down. The entire process from leaving the chair to returning to the chair will be timed. Also, the Timed Up and Go (TUG) will be done both in the ON and OFF states. (NCT01652534)
Timeframe: Baseline, change at 4 weeks

,
Interventionseconds (Median)
BaselineChange at 4 weeks
Amantadine23-3.5
Placebo19.58.6

[back to top]

Timed Up and Go (TUG) - ON Usual Medication

This is a walking assessment. The subject will begin in the seated position, stand up, walk 7 meters, turn around, and sit back down. The entire process from leaving the chair to returning to the chair will be timed. Also, the Timed Up and Go (TUG) will be done both in the ON and OFF states. (NCT01652534)
Timeframe: Baseline, change at 4 weeks

Interventionseconds (Median)
Baseline
Placebo17.4

[back to top]

Timed Up and Go (TUG) - ON Usual Medication

This is a walking assessment. The subject will begin in the seated position, stand up, walk 7 meters, turn around, and sit back down. The entire process from leaving the chair to returning to the chair will be timed. Also, the Timed Up and Go (TUG) will be done both in the ON and OFF states. (NCT01652534)
Timeframe: Baseline, change at 4 weeks

Interventionseconds (Median)
BaselineChange at 4 weeks
Amantadine16.70.04

[back to top]

Clinical Global Impression (CGI)

"Global Improvement is the second scale in the clinical global impression (CGI). Total overall improvement is judged by whether or not, in the judgment of the assessor, the improvement is entirely due to the drug treatment. It is also a 1-7 point weighted scale, going from very much improved (1) to very much worse (7). A zero score is assigned if the score is not assessed." (NCT01652534)
Timeframe: 4 weeks

Interventionscore on a scale (Median)
Amantadine2
Placebo4.5

[back to top]

Number of Participants With Drug Safety Reports

Analyzing the safety of the medication, Amantadine. Data regarding the medication will be collected from the patient on each visit including any adverse events since the last visit, frequency and severity of falls. This is done in order to determine the safety of Amantadine. (NCT01652534)
Timeframe: Week 4

InterventionParticipants (Count of Participants)
Amantadine0
Placebo0

[back to top]

Number Who Completed Medication as Randomized

Tolerability analysis as determined by the number of subjects completing each arm of the study. (NCT01652534)
Timeframe: week 4

InterventionParticipants (Count of Participants)
Amantadine3
Placebo2

[back to top]

Analysis of Motor Functioning Using the Parkinson's Home Diaries

"Subject will record motor activity as OFF, ON (mobility improved) or asleep on the diary every half hour for two days. Subjects further define ON time according to dyskinesia categories none, non-troublesome or troublesome. The home diaries are used as an evaluation measure of the intervention by assessing the change in off time and change in on time with troublesome dyskinesia. The difference in time experiencing dyskinesia while ON meds relative to the time OFF meds at baseline and at 4 weeks is compared." (NCT01652534)
Timeframe: Baseline, change in 4 weeks

Interventionminutes (Median)
Baseline
Amantadine90

[back to top]

Analysis of Motor Functioning Using the Parkinson's Home Diaries

"Subject will record motor activity as OFF, ON (mobility improved) or asleep on the diary every half hour for two days. Subjects further define ON time according to dyskinesia categories none, non-troublesome or troublesome. The home diaries are used as an evaluation measure of the intervention by assessing the change in off time and change in on time with troublesome dyskinesia. The difference in time experiencing dyskinesia while ON meds relative to the time OFF meds at baseline and at 4 weeks is compared." (NCT01652534)
Timeframe: Baseline, change in 4 weeks

Interventionminutes (Median)
BaselineChange at 4 weeks
Placebo150450

[back to top]

Fatigue Severity Scale (FSS)

A questionnaire used to discriminate between Parkinson Disease (PD) patients with fatigue and those without fatigue. Range 9 to 63, higher scores indicate greater fatigue severity. (NCT01652534)
Timeframe: Baseline, change in 4 weeks

,
Interventionscore on a scale (Mean)
Baselinechange in 4 weeks
Amantadine271.5
Placebo26-5

[back to top]

Freezing of Gait Questionnaire

"A questionnaire that is used to assess the likelihood of the subject freezing in a number of different scenarios.~0=No freezing of gait to 24=severe freezing of gait" (NCT01652534)
Timeframe: Baseline, change in 4 weeks

,
Interventionscore on a scale (Median)
BaselineChange at 4 weeks
Amantadine10-2
Placebo151

[back to top]

Modified Timed Up and Go (mTUG)

The subject sits in the chair approximately 3 1/2 meters away from doorway with the door closed. Subject then stands up and walks one meter to a 40cm X 40cm box taped on the floor. Within the box the patient turns clockwise (360 degrees), then turns counterclockwise (360 degrees). Walk to open the door and walk through the doorway, turn around and return to the chair. Modified Timed Up and Go (mTUG) completed in three components including walking the course without additional tasks, carrying a tray with a cup of water, and counting backwards from 100, in both ON and OFF state. (NCT01652534)
Timeframe: Baseline, change in 4 weeks

,
Interventionseconds (Mean)
Baseline - ONchange in 4 weeks - ONBaseline - OFFchange in 4 weeks - OFF
Amantadine141162
Placebo16-1201

[back to top]

The Unified Dyskinesia Rating Scale (UDysRS)

The Unified Dyskinesia Rating Scale (UDysRS) will be the primary outcome measure for this study. This choice is based on the outcome of the Validation of Dyskinesia Rating Scales study. In this study, the UDysRS was identified as the most sensitive scale to detect change in dyskinesia in an 8-week, double-blind, placebo-controlled trial of amatadine. The UDysRS utilizes rater information, patient self-report and objective measures of dyskinesia to provide assessments of impairment and disability due to dyskinesia. Score ranges are 0-108 with higher scores representing more severe impairment. (NCT01789047)
Timeframe: Change from baseline to week 14 (end of study) on the Unified Dyskinesia Rating Scale

Interventionunits on a scale (Mean)
Topiramate4.00
Placebo (Sugar Pill)1.67

[back to top]

Intensity of Adverse Event

"If an adverse event occurred, the intensity was also indicated. The intensity of an adverse event was determined using a scale from 1-5 with 5 being the worst. The purpose of the study is to examine safety of rTMS combined with AMA relative to rTMS Alone and AMA alone. Results are not reported per arm rather, the arms are combined so as to compare the outcome when the interventions are provided separately (i.e., rTMS alone and amantadine alone) vs interventions are combined (rTMS +Amantadine alone)." (NCT02025439)
Timeframe: "30 days after treatment alone and an additional 30 days after treatment combined (i.e., 60 days)"

Interventionscore on a scale (Mean)
rTMS Alone0.5
rTMS+AMA0.98
AMA Alone0.33

[back to top]

Change in the Standardized PD Home Diary (ON Time Without Troublesome Dyskinesia, ON Time With Troublesome Dyskinesia, OFF Time)

A PD home diary was used to score 5 different conditions in 30-minute intervals: ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia. The results were based on 2 consecutive 24-hour diaries taken prior to the day of randomization and prior to the Week 2, 8, 12, 18, and 24 visits. (NCT02136914)
Timeframe: Baseline (BL) to Week 12 (W12) and Week 24 (W24)

,
Interventionhours (Least Squares Mean)
Change in ON time w/o troublesome dyskinesia (W12)Change in ON time w/o troublesome dyskinesia (W24)Change in OFF time (W12)Change in OFF time (W24)Change in ON time w/ troublesome dyskinesia (W12)Change in ON time w/ troublesome dyskinesia (W24)
ADS-5102 (340 mg)3.563.59-0.59-0.58-3.12-3.31
Placebo0.821.370.320.22-1.58-1.86

[back to top]

Change in the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Combined Score (Parts I, II, and III)

The MDS-UPDRS Parts I, II, and III examined non-motor experiences of daily living, motor experiences of daily living, and motor examination, respectively. Each Part contains items or questions that were each rated on a scale from 0 (normal) to 4 (severe). The Combined Parts I, II, and III (representing the sum of the individual scores from Parts I, II, and III) has a scale range of 0-236. Higher scores, whether for individual Parts or the sum of the combined Parts, indicate more severe PD. (NCT02136914)
Timeframe: Baseline (BL) to Week 12 (W12) and Week 24 (W24)

,
Interventionunits on a scale (Least Squares Mean)
Change from BL at Week 12Change from BL at Week 24
ADS-5102 (340 mg)-5.2-1.3
Placebo-4.0-3.5

[back to top]

Change From Baseline in the Unified Dyskinesia Rating Scale (UDysRS) Score at Week 24

The UDysRS is a dyskinesia rating scale from 0-104; it evaluates involuntary movements associated with PD. A higher score indicates more severe PD. The UDysRS was measured at Baseline and Weeks 2, 8, 12, 18, and 24. (NCT02136914)
Timeframe: Baseline to Week 24

Interventionunits on a scale (Least Squares Mean)
Placebo-6.3
ADS-5102 (340 mg)-15.6

[back to top]

Change From Baseline in the Unified Dyskinesia Rating Scale (UDysRS) Score at Week 12

The UDysRS is a dyskinesia rating scale from 0-104; it evaluates involuntary movements associated with PD. A higher score indicates more severe PD. The UDysRS was measured at Baseline and Weeks 2, 8, 12, 18, and 24. (NCT02136914)
Timeframe: Baseline to Week 12

Interventionunits on a scale (Least Squares Mean)
Placebo-8.0
ADS-5102 (340 mg)-15.9

[back to top]

Clinician's Global Impression of Change (CGI-C) in Overall PD Symptoms

The CGI-C consisted of a single question that assessed the investigator's global impression of the subject's change from Baseline in overall PD symptoms, including but not limited to LID. The CGI-C required that the investigator rate the extent to which the subject's PD had improved or worsened (from marked worsening to marked improvement). The CGI-C was assessed at Baseline and Weeks 2, 8, 12, 18, and 24. (NCT02136914)
Timeframe: Baseline to Week 12 and Week 24

InterventionParticipants (Count of Participants)
Week 1271965983Week 1271965984Week 2471965984Week 2471965983
Moderate ImprovementMinimal ImprovementNo ChangeMinimal WorseningModerate WorseningMarked WorseningMarked Improvement
Placebo2
ADS-5102 (340 mg)18
Placebo9
ADS-5102 (340 mg)20
Placebo10
ADS-5102 (340 mg)13
Placebo25
ADS-5102 (340 mg)9
ADS-5102 (340 mg)2
ADS-5102 (340 mg)0
Placebo0
ADS-5102 (340 mg)1
Placebo5
ADS-5102 (340 mg)14
ADS-5102 (340 mg)17
Placebo12
ADS-5102 (340 mg)12
Placebo17
ADS-5102 (340 mg)7
Placebo6
ADS-5102 (340 mg)5
Placebo4

[back to top]

Unified Dyskinesia Rating Scale

The Unified Dyskinesia Rating Scale is a validated tool for assessment of dyskinesia (involuntary movements) in Parkinson's Disease patients. Rating consists of the change from baseline to Day 98 of the sum of the 26 questions comprising the questionnaire. Each question in the questionnaire is rated on a 5 point scale from 0-4 where 0 is a better outcome. Questions assess: over the past week total hours with dyskinesia and total hours without dyskinesia; problems with speech, chewing and swallowing, eating, dressing, hygiene, handwriting, hobbies, balance, socializing, emotions, spasm or cramps, pain without dystonia and pain from dystonia. The minimum (better) value is 0 and the maximum (worse) value is 130. (NCT02153632)
Timeframe: Change from baseline to Day 98

,,
Interventionscore on a scale (Mean)
Visit 2 (Baseline)Visit 7 (Day 98)/Stable Dose LOCF [1]Mean Change from Baseline (SD)
240mg Amantadine HCl ER Tablets41.341.3-15.2
320mg Amantadine HCl ER Tablets36.336.3-13.7
Placebo Tablets for Amantadine40.740.7-9.0

[back to top]

Mobility State Self-Assessment - Subject Diary Cards

"hange from baseline in the number of awake hours without troublesome dyskinesia (involuntary movements). Every half hour the subject will indicate in the diary if the medication has (ON) or has not (OFF) produced benefits in terms of mobility, slowness and rigidity. Valid diaries of the 3 consecutive days prior to each visit will be averaged with respect to the number of awake hours without troublesome dyskinesia. The change from baseline in the number of waking hours that subjects report being ON without troublesome dyskinesias will be analyzed at analysis visits Day 14 and Day 98 of treatment. Higher scores mean a better outcome and the maximum value is 24 hours." (NCT02153632)
Timeframe: Day 14 and Day 98 of treatment

,,
InterventionHours (Mean)
Visit 2 (Baseline)Visit 7 (Day 98)/Stable Dose LOCF [1]Mean Change in Hours from Baseline (SD)
240mg Amantadine HCl ER Tablets10.412.72.3
320mg Amantadine HCl ER Tablets9.813.33.6
Placebo Tablets for Amantadine9.111.11.6

[back to top]

Unified Dyskinesia Rating Scale

The Unified Dyskinesia Rating Scale is a validated tool for assessment of dyskinesia (involuntary movements) in Parkinson's Disease patients. Rating consists of the change from baseline to Day 98 of the sum of the 26 questions comprising the questionnaire. Each question in the questionnaire is rated on a 5 point scale from 0-4 where 0 is a better outcome. Questions assess: over the past week total hours with dyskinesia and total hours without dyskinesia; problems with speech, chewing and swallowing, eating, dressing, hygiene, handwriting, hobbies, balance, socializing, emotions, spasm or cramps, pain without dystonia (spasm or cramps) and pain from dystonia, the degree of impairment for each of 7 body parts, and the degree of disability in communication, drinking from a cup, dressing and ambulation. The minimum score is 0 (better) and the maximum score is 130 (worse). (NCT02153645)
Timeframe: From baseline to Day 98

,,
Interventionscore on a scale (Mean)
Visit 2 (Baseline)Visit 7 (Day 98)/Stable Dose LOCF [1]Change from Baseline (SD)
240 mg Amantadine HCl ER Tablets46.227.5-18.8
320 mg Amantadine HCl ER Tablets39.226.4-13.3
Placebo Amantadine HCl ER Tablets38.728.7-9.6

[back to top]

Mobility State Self-Assessment - Subject Diary Cards

"Change from baseline in the number of awake hours without troublesome dyskinesia (involuntary movements). Every half hour the subject will indicate in the diary if the medication has (ON) or has not (OFF) produced benefits in terms of mobility, slowness and rigidity. Valid diaries of the 3 consecutive days prior to each visit will be averaged with respect to the number of awake hours without troublesome dyskinesia. The change from baseline in the number of waking hours that subjects report being ON without troublesome dyskinesias will be analyzed at analysis visits Day 14 and Day 98 of treatment. Higher scores mean a better outcome and the maximum value is 24 hours." (NCT02153645)
Timeframe: Day 14 and Day 98 of treatment

,,
Interventionscore on a scale (Mean)
Visit 2 (Baseline)Visit 7 (Day 98)/Stable Dose LOCF [1]Change from Baseline (SD)
240 mg Amantadine HCl ER Tablets3.54.10.8
320 mg Amantadine HCl ER Tablets3.32.8-0.5
Placebo Amantadine HCl ER Tablets4.33.80.1

[back to top]

Change From Baseline in Movement Disorder's Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) (Parts I-III Combined Scores)

"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.~Part I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).~Total range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.~Parts I, II, and III are summed to make the total score." (NCT02202551)
Timeframe: Up to 101 weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).

,,,
Interventionunits on a scale (Mean)
BaselineChange from Baseline at Week 8Change from Baseline at Week 16Change from Baseline at Week 28Change from Baseline at Week 40Change from Baseline at Week 52Change from Baseline at Week 64Change from Baseline at Week 76Change from Baseline at Week 88Change from Baseline at Week 100
ADS-5102 1A41.81.21.64.87.513.28.811.711.311.4
ADS-5102 Group 1P45.6-2.8-1.41.5-0.42.62.67.33.73.7
ADS-5102 Group 252.80.85.76.51.66.16.19.46.46.5
ADS-5102 Group 352.4-5.3-5.2-5.3-4.8-4.6-4.6-4.90.94.1

[back to top]

Change From Baseline in Movement Disorder's Society - Unified Parkinson's Disease Rating Scale MDS-UPDRS (Part IV - Motor Complications)

"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.~Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24" (NCT02202551)
Timeframe: 100 Weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).

,,,
Interventionunits on a scale (Mean)
BaselineChange in Baseline from Week 8Change in Baseline from Week 16Change from Baseline at Week 28Change from Baseline at Week 40Change from Baseline at Week 52Change from Baseline at Week 64Change from Baseline at Week 76Change from Baseline at Week 88Change from Baseline at Week 100
Group 1a6.5-0.2-0.8-0.30.00.20.40.90.40.4
Group 1P9.6-3.4-3.2-3.3-2.8-2.9-3.3-2.9-2.8-2.4
Group 29.8-3.6-1.1-1.4-2.9-2.5-1.9-2.7-3.7-3.6
Group 310.4-4.0-3.9-4.4-4.7-3.6-2.5-3.7-4.3-3.6

[back to top] [back to top]

Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score

The UDysRS is a dyskinesia rating scale from 0-104; it evaluates involuntary movements associated with PD. A higher score indicates more severe PD. The UDysRS was measured at Baseline and Weeks 2, 4, 8, and 12. (NCT02274766)
Timeframe: Baseline to Week 12

Interventionunits on a scale (Least Squares Mean)
Placebo-6.3
ADS-5102 (Amantadine HCl Extended Release)-20.7

[back to top]

Change in the Standardized PD Home Diary (ON Time Without Dyskinesia, ON Time With Troublesome Dyskinesia, OFF Time)

A PD home diary was used to score 5 different conditions in 30-minute intervals: ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia. The results were based on 2 consecutive 24-hour diaries taken prior to the day of randomization and prior to the Week 2, 4, 8, and 12 visits. (NCT02274766)
Timeframe: Baseline to Week 12

,
Interventionhours (Least Squares Mean)
Change in ON time without troublesome dyskinesiaChange in ON time with troublesome dyskinesiaChange in OFF time
ADS-5102 (Amantadine HCl Extended Release)3.95-3.61-0.49
Placebo2.05-2.470.61

[back to top]

Rate of Awakening (Number of Patients Who Are Able to Follow Commands)

"Defined as the ability to follow commands (i.e. wiggle your toes open your eyes squeeze my fingers. This corresponds to a Full Outline of Unresponsiveness motor score of 4. FOUR (full outline of unresponsiveness) measures the following: Eye Response, Motor Response, Brainstem Reflexes, and Respirations." (NCT02486211)
Timeframe: up to 28 days

InterventionParticipants (Count of Participants)
Amantadine2
Placebo2

[back to top]

Seizures (Number of Patients Who Experience Seizures as Detected by EEG Monitoring With or Without Clinical Correlate)

detected by EEG monitoring with or without clinical correlate (NCT02486211)
Timeframe: during study drug administration (7 days)

InterventionParticipants (Count of Participants)
Amantadine0
Placebo2

[back to top]

Time to Awakening

Defined as the time from enrollment to awakening (NCT02486211)
Timeframe: up to 28 days

Interventiondays (Median)
Amantadine4
Placebo8

[back to top]

Nausea or Vomiting

nausea requiring antiemetic medications or clinical vomiting (NCT02486211)
Timeframe: during study drug administration (7 days)

InterventionParticipants (Count of Participants)
Amantadine0
Placebo0

[back to top]

Number of Participants With Severe or Intracranial Bleeding

Bleeding that does not stop with direct pressure, requires transfusion, or occurs in the intracranial vault (NCT02486211)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Amantadine0
Placebo0

[back to top]

Acceptability of Treatment as Assessed by a Single Question Questionnaire

"Participants will answer yes or no to this question: Taken into consideration the possible benefits and/or disadvantages of this medication, would you choose it, going forward to treat your MS fatigue?. The number of participants who answered Yes to this question is reported here." (NCT03185065)
Timeframe: Week 5 of each treatment period

InterventionParticipants (Count of Participants)
Placebo39
Amantadine41
Modafinil55
Methylphenidate55

[back to top]

Epworth Sleepiness Scale (ESS) Score

ESS score during the fifth week of treatment period. The ESS score can range from 0 to 24. The higher the score, the higher that person's average sleep propensity in daily life, or their 'daytime sleepiness'. (NCT03185065)
Timeframe: Week 5 of each treatment period

Interventionscore on a scale (Least Squares Mean)
Placebo9.4
Amantadine9.3
Modafinil8.3
Methylphenidate8.8

[back to top]

Modified Fatigue Impact Scale (MFIS) Score

MFIS score during the fifth week of treatment period. The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period

Interventionscore on a scale (Least Squares Mean)
Placebo40.6
Amantadine41.3
Modafinil39.0
Methylphenidate38.6

[back to top]

Quality of Life in Neurological Disorders (Neuro-QoL) Item Bank - Fatigue Score

Neuro-QoL Item Bank - Fatigue T score during the fifth week of treatment period. T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Higher T-scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period

Interventionscore on a scale (Least Squares Mean)
Placebo53.1
Amantadine53.0
Modafinil52.5
Methylphenidate52.0

[back to top]

2-Minute Walk Test (2MWT): Change From Baseline at Week 16

The 2MWT is a measure of lower extremity function. The subject is instructed to walk as far as possible in 2 minutes, and the distance is measured in meters. Improvement is indicated by positive change scores. (NCT03436199)
Timeframe: 16 weeks

Interventionmeters (Least Squares Mean)
ADS-5102 137 mg6.306
ADS-5102 274 mg5.692
Placebo2.163

[back to top]

Timed 25 Foot Walk (T25FW, Feet/Second): the Proportion of Subjects With a ≥ 20% Increase in Walking Speed (Measured by T25FW) From Baseline at Week 16 (Responder Analysis)

The T25FW is a measure of lower extremity function. The subject is directed to a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the subject walk back the same distance. For this outcome measure, the result is reported as speed (feet per second). Improvement is indicated by an increase in speed. (NCT03436199)
Timeframe: 16 weeks

Interventionproportion of responders (Number)
ADS-5102 137 mg0.176
ADS-5102 274 mg0.211
Placebo0.113

[back to top]

Timed 25 Foot Walk: Change From Baseline at Week 16

The T25FW is a measure of lower extremity function. The subject is directed to a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the subject walk back the same distance. For this outcome measure, the result is reported as or speed (feet per second). Improvement is indicated by an increase in speed. (NCT03436199)
Timeframe: 16 weeks

Interventionfeet/second (Least Squares Mean)
ADS-5102 137 mg0.19
ADS-5102 274 mg0.19
Placebo0.07

[back to top]

Timed Up and Go (TUG): Change From Baseline at Week 16

The TUG is a measure of lower extremity strength, balance, and coordination. The subject stands up from a chair, walks 3 meters then turns around and walks back to the chair to sit down. The result is reported in seconds. Improvement is indicated by negative change scores. (NCT03436199)
Timeframe: 16 weeks

Interventionseconds (Least Squares Mean)
ADS-5102 137 mg-1.35
ADS-5102 274 mg-0.60
Placebo-0.56

[back to top]

2-Minute Walk Test (Week 52 Value)

The 2-Minute Walk test is a measure of lower extremity function. The subject is instructed to walk as far as possible in 2 minutes, and the distance is measured in meters. Improvement is indicated by positive change scores. (NCT03567057)
Timeframe: 52 weeks

Interventionmeters (Mean)
Placebo/274 mg ADS-510277.45
137 mg ADS-5102/274 mg ADS-510289.18
274 mg ADS-5102/274 mg ADS-510289.14

[back to top]

Number of Patients With Adverse Events

The incidence of treatment-emergent adverse events was used as the measure for long-term safety and tolerability of ADS-5102. (NCT03567057)
Timeframe: Through study completion, an average of 1 year.

InterventionParticipants (Count of Participants)
Placebo/274 mg ADS-5102122
137 mg ADS-5102/274 mg ADS-5102116
274 mg ADS-5102/274 mg ADS-510286

[back to top]

Timed 25-Foot Walk (Feet/Second) (Baseline Value)

The timed 25-foot walk is a measure of lower extremity function. The subject is directed to a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the subject walk back the same distance. The result is reported as speed (feet per second). Improvement is indicated by an increase in speed. (NCT03567057)
Timeframe: Baseline

Interventionfeet/second (Mean)
Placebo/274 mg ADS-51022.43
137 mg ADS-5102/274 mg ADS-51022.68
274 mg ADS-5102/274 mg ADS-51022.66

[back to top]

Timed up and go (Baseline Value)

"The timed up and go is a measure of lower extremity strength, balance, and coordination. The subject stands up from a chair, walks 3 meters then turns around and walks back to the chair to sit down. The result is reported in seconds. Improvement is indicated by negative change scores." (NCT03567057)
Timeframe: Baseline

Interventionseconds (Mean)
Placebo/274 mg ADS-510217.60
137 mg ADS-5102/274 mg ADS-510216.89
274 mg ADS-5102/274 mg ADS-510216.80

[back to top]

Timed up and go (Week 24 Value)

"The timed up and go is a measure of lower extremity strength, balance, and coordination. The subject stands up from a chair, walks 3 meters then turns around and walks back to the chair to sit down. The result is reported in seconds. Improvement is indicated by negative change scores." (NCT03567057)
Timeframe: 24 weeks

Interventionseconds (Mean)
Placebo/274 mg ADS-510217.39
137 mg ADS-5102/274 mg ADS-510215.36
274 mg ADS-5102/274 mg ADS-510216.89

[back to top]

Timed up and go (Week 52 Value)

"The timed up and go is a measure of lower extremity strength, balance, and coordination. The subject stands up from a chair, walks 3 meters then turns around and walks back to the chair to sit down. The result is reported in seconds. Improvement is indicated by negative change scores." (NCT03567057)
Timeframe: 52 weeks

Interventionseconds (Mean)
Placebo/274 mg ADS-510218.68
137 mg ADS-5102/274 mg ADS-510215.92
274 mg ADS-5102/274 mg ADS-510217.37

[back to top]

2-Minute Walk Test (Baseline Value)

The 2-Minute Walk test is a measure of lower extremity function. The subject is instructed to walk as far as possible in 2 minutes, and the distance is measured in meters. Improvement is indicated by positive change scores. (NCT03567057)
Timeframe: Baseline

Interventionmeters (Mean)
Placebo/274 mg ADS-510280.26
137 mg ADS-5102/274 mg ADS-510289.99
274 mg ADS-5102/274 mg ADS-510287.31

[back to top]

2-Minute Walk Test (Week 24 Value)

The 2-Minute Walk test is a measure of lower extremity function. The subject is instructed to walk as far as possible in 2 minutes, and the distance is measured in meters. Improvement is indicated by positive change scores. (NCT03567057)
Timeframe: 24 weeks

Interventionmeters (Mean)
Placebo/274 mg ADS-510281.48
137 mg ADS-5102/274 mg ADS-510287.99
274 mg ADS-5102/274 mg ADS-510292.03

[back to top]

Timed 25-Foot Walk (Feet/Second) (Week 52 Value)

The timed 25-foot walk is a measure of lower extremity function. The subject is directed to a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the subject walk back the same distance. The result is reported as speed (feet per second). Improvement is indicated by an increase in speed. (NCT03567057)
Timeframe: 52 weeks

Interventionfeet/second (Mean)
Placebo/274 mg ADS-51022.35
137 mg ADS-5102/274 mg ADS-51022.68
274 mg ADS-5102/274 mg ADS-51022.65

[back to top]

Timed 25-Foot Walk (Feet/Second) (Week 24 Value)

The timed 25-foot walk is a measure of lower extremity function. The subject is directed to a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the subject walk back the same distance. The result is reported as speed (feet per second). Improvement is indicated by an increase in speed. (NCT03567057)
Timeframe: 24 weeks

Interventionfeet/second (Mean)
Placebo/274 mg ADS-51022.50
137 mg ADS-5102/274 mg ADS-51022.72
274 mg ADS-5102/274 mg ADS-51022.71

[back to top]

Mean PHQ-9 Score

"The Patient Health Questionnaire (PHQ-9) is a self-administered, nine-item depression scale of the patient health questionnaire. The nine items of the PHQ-9 are based directly on the nine diagnostic criteria for major depressive disorder in the DSM-IV.~The PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as 0 (not at all) to 3 (nearly every day). Total scores can range from 0 to 27.~A total score of 0-4 indicates minimal depression severity, 5-9 indicates mild depression severity, 10-14 indicates moderate depression severity, 15-19 indicates moderately severe, 20-27 indicates severe depression severity. Therefore, a high score indicates a worse outcome.~Outcome measures will be assessing a change in scores pre- and post- prescription of Amantadine." (NCT04273737)
Timeframe: 3 weeks

Interventionscore on a scale (Mean)
Amantadine3.14

[back to top]

Mean Brief-A Score

The BRIEF-A is a standardized measure that captures views of an adult's executive functions or self-regulation in his or her everyday environment. Both a self-report and an informant report are used. The BRIEF-A includes 75 items within nine non-overlapping theoretically and empirically derived clinical scales: Inhibit, Self-Monitor, Plan/Organize, Shift, Initiate, Task Monitor, Emotional Control, Working Memory, and Organization of Materials. All 75 items are rated in terms of frequency on a 3-point scale: 1 (never), 2 (sometimes), 3 (often). Raw scores for each scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Composite scores are calculated and are scored from a range of 75 (better outcome) to 225. (NCT04273737)
Timeframe: 3 weeks

InterventionT-score (Mean)
Amantadine55.2

[back to top]

Mean Brief-A Score

The BRIEF-A is a standardized measure that captures views of an adult's executive functions or self-regulation in his or her everyday environment. Both a self-report and an informant report are used. The BRIEF-A includes 75 items within nine non-overlapping theoretically and empirically derived clinical scales: Inhibit, Self-Monitor, Plan/Organize, Shift, Initiate, Task Monitor, Emotional Control, Working Memory, and Organization of Materials. All 75 items are rated in terms of frequency on a 3-point scale: 1 (never), 2 (sometimes), 3 (often). Raw scores for each scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Composite scores are calculated and are scored from a range of 75 (better outcome) to 225. (NCT04273737)
Timeframe: 6 weeks

InterventionT-score (Mean)
Amantadine60.2

[back to top]

Mean PHQ-9 Score

"The Patient Health Questionnaire (PHQ-9) is a self-administered, nine-item depression scale of the patient health questionnaire. The nine items of the PHQ-9 are based directly on the nine diagnostic criteria for major depressive disorder in the DSM-IV.~The PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as 0 (not at all) to 3 (nearly every day). Total scores can range from 0 to 27.~A total score of 0-4 indicates minimal depression severity, 5-9 indicates mild depression severity, 10-14 indicates moderate depression severity, 15-19 indicates moderately severe, 20-27 indicates severe depression severity. Therefore, a high score indicates a worse outcome.~Outcome measures will be assessing a change in scores pre- and post- prescription of Amantadine." (NCT04273737)
Timeframe: Baseline

Interventionscore on a scale (Mean)
Amantadine4.667

[back to top]

Mean Brief-A Score

The BRIEF-A is a standardized measure that captures views of an adult's executive functions or self-regulation in his or her everyday environment. Both a self-report and an informant report are used. The BRIEF-A includes 75 items within nine non-overlapping theoretically and empirically derived clinical scales: Inhibit, Self-Monitor, Plan/Organize, Shift, Initiate, Task Monitor, Emotional Control, Working Memory, and Organization of Materials. All 75 items are rated in terms of frequency on a 3-point scale: 1 (never), 2 (sometimes), 3 (often). Raw scores for each scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Composite scores are calculated and are scored from a range of 75 (better outcome) to 225. (NCT04273737)
Timeframe: Baseline

InterventionT-score (Mean)
Amantadine57.4285

[back to top]

Mean PHQ-9 Score

"The Patient Health Questionnaire (PHQ-9) is a self-administered, nine-item depression scale of the patient health questionnaire. The nine items of the PHQ-9 are based directly on the nine diagnostic criteria for major depressive disorder in the DSM-IV.~The PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as 0 (not at all) to 3 (nearly every day). Total scores can range from 0 to 27.~A total score of 0-4 indicates minimal depression severity, 5-9 indicates mild depression severity, 10-14 indicates moderate depression severity, 15-19 indicates moderately severe, 20-27 indicates severe depression severity. Therefore, a high score indicates a worse outcome.~Outcome measures will be assessing a change in scores pre- and post- prescription of Amantadine." (NCT04273737)
Timeframe: 6 weeks

Interventionscore on a scale (Mean)
Amantadine6.429

[back to top]